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Abstract
Reversal of aberrant epigenetic silencing by small molecule inhibitors is of high
interest in the fields of chemical biology and drug discovery. Full understanding of
these processes is crucial for the development of truly epigenetic therapies. Histone
lysine methyltransferases (HKMTs), including G9a and EZH2, are the key players
in epigenetic regulation, and are involved in many diseases such as cancer. In 2009,
the first substrate competitive G9a inhibitor, BIX-01294, was reported by screening
a large chemical library, which paved the way for future HKMT drug discovery
research.
In our research, we aimed to develop a novel substrate competitive dual G9a
and EZH2 inhibitor using BIX-01294 as a prototype. Initially, the refinement of the
side chain modification of BIX-01294 allowed us to understand essential Structure
Activity Relationships (SAR) of the active compounds in a cell-based assay and an
enzymatic assay (Chapter 2). Furthermore, the replacement of the quinazoline ring
of BIX-01294 by other heteroaromatic rings was investigated (Chapter 3). While
maintaining similar side chains as thosed use within the active compounds, new
analogues including thieno-pyrimidine, furo-pyrimidine, purine and quinolone rings,
were synthesised.
Together these e↵orts have resulted in new synthetic routes towards a range
of di-substituted heteroaromatic analogues as well as novel quinazoline derivatives
for biological assessment. Compound 35, 158, and 183 show inhibitory activities
against EZH2 in the enzymatic assay and promising SAR for further optimisation.
Quinoline 183 also inhibits G9a in the low nanomolar range. Several compounds
show promising data in the cell-based assay. Further biological evaluation of novel
heteroaromatic analogues is currently underway.
5
6
Acknowledgments
Over the last few years, I’ve had the privilege of working with many truly amazing
scientists. There are too many to name here, but first acknowledgement must go to
Dr. Matthew Fuchter who always gave me suggestions and guidance. “There is a
room for you to improve, Ken” he kindly said, when I was in the first year of my
PhD. Since that time, his word has encouraged me to grow as a scientist and I will
always fulfil this room for improving myself after graduation.
The second acknowledgement must go to Professor Bob Brown and Dr. Masoud
Vedadi for their splendid collaboration and support. Without them, my compounds
would have no meaning (biologically). Thanks go also to the enthusiastic EZH2
team, Joachim Caron, Sandeep Sundriyal, Fanny Cherblanc, Nadine Chapman-Rothe,
Elham Shamsaei, and Sarah Kandil. Moreover, I’d like to thank Peter Haycock for
the analytical services, as well as Jonathan Barton and Lisa Haigh.
Four years in an overseas country was so long, lonely, and cold, but thanks for
their warmth and kindness of people in the Ho↵man lab, especially Hu✏epu↵ Bay
residents, Nicole Trainor, Katie Anderson, Matt Penny, Luza dos Reis Cruz and the
traitor Peter Blencowe!! Indeed, I will not forget the past and present members of
the Fuchter and Barrett groups with whom I spent time.
Big hug for my first two foreigner friends, Thomas and Leo. We’ve shared the
great experiences during our both curricular and extra-curricular activities under
the ICB’s umbrella. Your friendship is truly invaluable, I would say.
‘Thai Smile’ could be ubiquitously found anywhere, even in London (5926 km
from my beloved country Thailand). Thanks to my Thai friends here, including
Chaipat, Achaya, Mason, Picha, Pirada, Veena and Nat who unconditionally give
me moral supports along with a wonderful dinner on Friday nights.
I would like to give my special thank to Matt, Nicole, Claire, Jochen and Sandeep
for proof-reading this thesis.
I also would like to express my gratitude to Thai government funding body,
National Center for Genetic Engineering and Biotechnology (Thailand), and Institute
of Chemical Biology (UK) for supporting my studentship.
Last but not least, I’ve had great support from Srimongkolpithak family and also
the one who has been carried on our long-distance relationship for few years. Thank
you so much for sheer entertainment and distraction when I was su↵ering. Thank
you so much for listening to me when I wanted to share my good times.
7
8
List of Abbreviations
Ac acyl
Aq. aqueous (phase)
Bn benzyl
CI chemical ionization
d doublet
DCM dichloromethane
dd doublet of doublets
DMF N,N -dimethylformamide
DMSO dimethylsulfoxide
dt doublet of triplets
EI electron impact
ES electrospray
EZH2 enhancer of zest homolog 2
Et ethyl
G9a histone-lysine N -methyltransferase
EHMT2
GLP histone-lysine N -methyltransferase
EHMT1, G9a like protein
H3K27me3 histone 3 lysine 27 tri-
methylated
HMKT histone lysine methyltransferase
HRMS high resolution mass spectro-
scopy
IR infra-red
J coupling constant
m multiplet/meta
Me methyl
MLL mixed lineage leukemia
mp. melting point
MS mass spectroscopy
m/z mass to charge
NMR nuclear magnetic resonance
org. organic (phase)
Ph Phenyl
ppm parts per million
q quartet
R any alkyl group
RT room temperature
s singlet
SAH s-adenosylhomocysteine
SAM s-adenosylmethionine
SAR structure-activity relationship
SET suvar 3-9, enhancer of zeste,
trithorax
SUV39 suppressor of variegation 3-9
t triplet
THF tetrahydrofuran
TLC thin layer chromatography
9
10
Contents
Contents 11
List of Figures 13
List of Tables 15
List of Schemes 17
1 Regulation of Gene Expression by Histone Modification and Small
Molecules 19
1.1 Chromosome and Histone Modification . . . . . . . . . . . . . . . . . 20
1.2 G9a/GLP, EZH2 and Their Inhibitors . . . . . . . . . . . . . . . . . 22
1.2.1 Biology of G9a/GLP . . . . . . . . . . . . . . . . . . . . . . . 22
1.2.2 G9a/GLP Inhibitors . . . . . . . . . . . . . . . . . . . . . . . 23
1.3 EZH2 and Its Inhibitors . . . . . . . . . . . . . . . . . . . . . . . . . 27
1.3.1 Biology of EZH2 . . . . . . . . . . . . . . . . . . . . . . . . . 27
1.3.2 EZH2 Inhibitors . . . . . . . . . . . . . . . . . . . . . . . . . 34
2 Design and Synthesis of Quinazoline Derivatives and Their Biolo-
gical Activities Against G9a and EZH2 41
2.1 Preliminary Data and Chemical Library Design . . . . . . . . . . . . 41
2.2 Synthesis, and Pharmacological Evaluation of Quinazoline Derivatives 45
2.2.1 Chemical Synthesis . . . . . . . . . . . . . . . . . . . . . . . . 45
2.2.2 Biological Results and SAR Discussion . . . . . . . . . . . . . 58
2.2.3 qRT-PCR Phenotypic Screening . . . . . . . . . . . . . . . . 71
2.3 Target and O↵-Target Identification of Hits . . . . . . . . . . . . . . 73
2.3.1 Activity-Based Protein Profiling (ABPP) . . . . . . . . . . . 74
2.3.2 Initial Studies for Design and Synthesise Photo-A nity Based
Probe . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 75
2.3.3 Chemoinformatic Tools for Identifying a Target Protein: Sim-
ilarity Ensemble Approach . . . . . . . . . . . . . . . . . . . . 81
11
2.3.4 Conclusion and Future Work . . . . . . . . . . . . . . . . . . 85
3 Identification of Novel HKMT Inhibitors Using Sca↵old Hopping 87
3.1 Chemical Synthesis . . . . . . . . . . . . . . . . . . . . . . . . . . . . 88
3.1.1 Synthesis of Furo[3,2d]pyrimidine Derivertives . . . . . . . . . 88
3.1.2 Synthesis of Thieno[2,3]pyrimidine and Thieno[3,2]pyrimidine
Derivatives . . . . . . . . . . . . . . . . . . . . . . . . . . . . 92
3.1.3 Synthesis of Purine Derivatives . . . . . . . . . . . . . . . . . 92
3.1.4 Synthesis of Quinoline Derivatives . . . . . . . . . . . . . . . 95
3.2 Biological Results and Discussions . . . . . . . . . . . . . . . . . . . 101
3.2.1 SAR and Evaluation of New Derivatives using SPA Assay . . 101
3.2.2 SAR and pKa Measurement . . . . . . . . . . . . . . . . . . . 103
3.2.3 Phenotypic Screening of New Derivatives . . . . . . . . . . . 107
3.3 Conclusion and Future Work . . . . . . . . . . . . . . . . . . . . . . 108
4 Experimental Section 111
4.1 Compound Characterisation and Analysis . . . . . . . . . . . . . . . 111
4.2 Assay Protocols and Conditions . . . . . . . . . . . . . . . . . . . . . 173
4.2.1 PRC2 Assay (preformed by SGC) . . . . . . . . . . . . . . . 173
4.2.2 Mechanism of PRC2 Inhibition Assay (MOA) (performed by
SGC) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 174
4.2.3 Selectivity Assay (preformed by SGC) . . . . . . . . . . . . . 174
4.2.4 qRT-PCR Measurements for Cell-based Screening (preformed
by Professor Brown’s group) . . . . . . . . . . . . . . . . . . 175
4.2.5 MTT Assay (preformed by Professor Brown’s group) . . . . . 175
Bibliography 177
12
List of Figures
1.1 Waddington’s classical epigenetic landscape . . . . . . . . . . . . . . 19
1.2 Chromatin and histone modifications . . . . . . . . . . . . . . . . . . 21
1.3 The crystal structure of GLP complex with SAH and BIX-01294 . . 22
1.4 The crystal structures of G9a-UNC0224 and G9a-A336 . . . . . . . . 25
1.5 Structures of UNC0965 and A-336 . . . . . . . . . . . . . . . . . . . 26
1.6 Structures of co-factor competitive inhibitors: BIX01388, BRD9539
and BRD4770 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26
1.7 Structures of EZH2 and PRC2 . . . . . . . . . . . . . . . . . . . . . 27
1.8 The cross-talk of EZH2 and other factors. . . . . . . . . . . . . . . . 29
1.9 PRC2 and G9a/GLP cross-talking and an example of its roles in
physiological function and diseases . . . . . . . . . . . . . . . . . . . 31
1.10 DZNep and its mechanism of action . . . . . . . . . . . . . . . . . . 35
1.11 Structures and inhibitory activity of UNC1999 and its derivatives. . 38
1.12 Structures and inhibitory activities of non-indole/indazole EZH2 in-
hibitors and their derivatives . . . . . . . . . . . . . . . . . . . . . . 39
2.1 The concept behind the development of a quinazoline-based library. 42
2.2 The structures of BIX-01294 (1), UNC0224 (2), hits 3–5 and the
representative negative compounds 6–8 against EZH2 in cell-based
assay . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 42
2.3 Preliminary biological data . . . . . . . . . . . . . . . . . . . . . . . 44
2.4 General plan for target molecules . . . . . . . . . . . . . . . . . . . . 45
2.5 The overlay of compound 3 and the corresponding side-chain switched
molecule . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 52
2.6 Design and synthesis of lysine-mimic analogues . . . . . . . . . . . . 56
2.7 IC50 determination for compounds 3–5 against EZH2 . . . . . . . . 59
2.8 MOA studies of compound 3 . . . . . . . . . . . . . . . . . . . . . . 61
2.9 The comparison SAR of G9a and EZH2 with their most potent inhib-
itors, compound 117 and 35, respectively. . . . . . . . . . . . . . . . 64
13
2.10 qRT-PCR results of four new hits. . . . . . . . . . . . . . . . . . . . 72
2.11 Af BP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 74
2.12 (A) The structure and IC50 of compound 137, UNC0638, and UNC0965.
(B) The docking of UNC0638 and G9a. . . . . . . . . . . . . . . . . . 80
2.13 A chemical structure similarity map. . . . . . . . . . . . . . . . . . . 83
2.14 The biological results . . . . . . . . . . . . . . . . . . . . . . . . . . . 84
3.1 The design of novel sca↵olds based on the interaction of BIX-01294
and G9a. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 88
3.2 The observation of two regiomers of 146 using 1H/15HMBC at 328 K. 92
3.3 The mechanisms of intramolecular cyclisation induced by base (A)
and Lewis acid (B). . . . . . . . . . . . . . . . . . . . . . . . . . . . . 98
3.4 Selectivity of compound 183 on SETD2 . . . . . . . . . . . . . . . . 105
3.5 pKa determination of BIX-01294 (A) and compound 138 (B) by three
independent UV-vis measurements . . . . . . . . . . . . . . . . . . . 106
3.6 Future work . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 109
14
List of Tables
1.1 Structures of G9a inhibitors and their inhibitory activities. . . . . . 23
1.2 Structures of EZH2 inhibitors and their inhibitory activities. . . . . 36
2.1 Demethylation procedures. . . . . . . . . . . . . . . . . . . . . . . . . 49
2.2 Optimised conditions for the secondary replacement of side-chain
switched derivatives with 4-amino-1-benzylpiperidine . . . . . . . . . 54
2.3 In vitro ADME studies of hits 3–5 and negatives 6–7. . . . . . . . . 60
2.4 The selectivities of hits 3–5 and negatives 6–7. . . . . . . . . . . . . 62
2.5 RT-PCR data for a single dose of a panel of HKMT inhibitor compounds. 63
2.6 SAR of 2-amino moiety. . . . . . . . . . . . . . . . . . . . . . . . . . 65
2.7 SAR of 4-amino moiety . . . . . . . . . . . . . . . . . . . . . . . . . 67
2.8 SAR of benzenoid derivatives . . . . . . . . . . . . . . . . . . . . . . 68
2.9 SAR of a pseudo-symmetry derivative and switched side-chain derivetives 69
2.10 SAR of lysine/norleucin-mimicking derivatives . . . . . . . . . . . . . 70
2.11 qRT-PCR, SPA, and MTT results eight positive compounds. . . . . 73
2.12 The inhibitory activity of R1, R2, and R3 modified quinazoline deriv-
atives against G9a and EZH2 in SPA. . . . . . . . . . . . . . . . . . 79
2.13 The results of phenotypic screening. . . . . . . . . . . . . . . . . . . 81
3.1 Chlorination of xanthine. . . . . . . . . . . . . . . . . . . . . . . . . 94
3.2 The conditions and yields of intramolecular cyclisation reactions of
179a-d. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 99
3.3 The conditions for reductive amination and comments. . . . . . . . . 100
3.4 SAR, biological results and calculated pKas* of the new derivatives . 102
3.5 Selectivity data of BIX-01294, 180 and 183. . . . . . . . . . . . . . 104
3.6 Experimental and calculated pKa of BIX-01294 and compound 138. 105
3.7 Phenotypic screening of new derivatives at 10 µM . . . . . . . . . . . 108
15
16
List of Schemes
2.1 Re-synthesis of hits 3–5 and their derivatives . . . . . . . . . . . . . 45
2.2 The comparison of nucleophilic displacements at positions 2 and 4 of
quinazoline. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 46
2.3 Synthesis of substituted-benzyl derivatives. . . . . . . . . . . . . . . 47
2.4 Synthesis of quinazoline derivatives by SAI Chemicals . . . . . . . . 48
2.5 Synthesis of new quinazoline cores . . . . . . . . . . . . . . . . . . . 50
2.6 Synthesis of modified benzeniod derivatives . . . . . . . . . . . . . . 52
2.7 Synthesis of pseudo-symmetric quinazoline derivatives and side-chain
switched derivatives . . . . . . . . . . . . . . . . . . . . . . . . . . . 53
2.8 Synthesis of lysine-mimic derivative 114 . . . . . . . . . . . . . . . . 56
2.9 Synthesis of lysine-mimic derivative 116–120 . . . . . . . . . . . . . 57
2.10 Synthesis of lysine-mimic derivatives 126–128 . . . . . . . . . . . . 58
2.11 Compound 3 and the initial design for ABPP derivatives . . . . . . 75
2.12 The unsuccessful synthetic route for the R1 modified derivatives . . 76
2.13 The synthesis route for the R1 modified derivatives . . . . . . . . . . 77
2.14 The synthetic route for the R2 modified derivatives . . . . . . . . . . 77
2.15 The possibility of R3 over-alkylation . . . . . . . . . . . . . . . . . . 77
2.16 The synthetic route of R3 modified analogues via an orthogonal pro-
tection method. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 78
2.17 The synthetic routes for the R3 modified derivatives . . . . . . . . . 78
2.18 The synthetic route of C021 . . . . . . . . . . . . . . . . . . . . . . . 84
3.1 The synthetic route of furoprimidine derivatives . . . . . . . . . . . . 89
3.2 Curtius rearrangement using DPPA. . . . . . . . . . . . . . . . . . . 89
3.3 Direct ortholithiation of protected 3-amino furan . . . . . . . . . . . 90
3.4 The cyclisation of the furopyrimidine core . . . . . . . . . . . . . . . 91
3.5 The synthetic route of thienopyrimidine derivatives. . . . . . . . . . 93
3.6 The synthetic route of purine derivatives. . . . . . . . . . . . . . . . 94
17
3.7 The unsuccessful synthetic route of quinoline derivatives via malonyl
chemistry. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 95
3.8 The one-pot reaction of 2,4-dichloroquinoline 172 . . . . . . . . . . . 95
3.9 The synthetic route of quinoline derivatives. . . . . . . . . . . . . . . 96
3.10 The unsuccessful synthetic route of acetamidinonitrile 178b . . . . . 97
3.11 The formations of imidate 177 and acetamidinonitrile 178b . . . . . 97
3.12 The unsuccessful synthetic route of aminoquinoline 179b via based-
induced cyclisation . . . . . . . . . . . . . . . . . . . . . . . . . . . . 98
3.13 Stepwise reductive amination. . . . . . . . . . . . . . . . . . . . . . . 100
18
Chapter 1
Regulation of Gene Expression
by Histone Modification and
Small Molecules
Figure 1.1: Waddington’s classical epi-
genetic landscape, reprinted from [1].
Five decades ago, the idea that genes could
be turned on and o↵ was revolutionary.
This concept originated from the observa-
tion of bacteria adaptation in the presence
of di↵erent components of their growth me-
dium. Within developmental biology, it
is known that gene expression and pheno-
type can be shaped by nature. One famous
example of such shaping is the metamorph-
osis of a caterpillar into a butterfly. The
genes of the caterpillar and butterfly are the
same; however, those genes are expressed
di↵erently depending on their stage of life.
The word “epigenetics” has been used
to describe phenomena that link between genotype and phenotype. In 1957, Conrad
Waddington, a British developmental biologist, presented his metaphorical epigenetic
landscape to represent the pathway of cell fate, which was still under development
(Figure 1.1) [1].
In his epigenetic landscape, a ball rests at the top of the hill, ready to roll down
the hill. The ball could roll into one of several channels towards the bottom of
the hill. Similarly, cells can take specific permitted pathways, resulting in di↵erent
types of cells. From Waddingtons interpretation, epigenetics goes above and beyond
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genetics, which controls cell fate and di↵erentiation. Modern biologists have further
refined epigenetics to mean heritable changes in gene expression that are not caused
by alteration to the DNA sequence [2].
Due to the tremendous intricacy of gene regulation in humans, controlling gene
expression provides a challenging opportunity to apply epigenetics in therapeutic
applications. The use of small molecules to selectively alter gene expression represents
a new area in drug discovery [3]. Epigenetic enzymes, including histone-modifying
enzymes and DNA methyltransferases, have been well-known drug targets in the
pharmaceutical industry for many years. Azatidine (Vidaza®) and Decitabine
(Dacogen®), both DNA methyltansferase inhibitors, have received US FDA approval
for the treatment of myelodysplastic syndromes. Vorinostat (Zolinza™), a histone
deacetylase inhibitor, was granted approval for the treatment of cutaneous T-cell
lymphoma. Recently, many histone methyltransferases (HKMTs) have emerged
as novel drug targets. In this chapter, the control of gene expression by histone
lysine methyltransferases is described. Subsequently, the development of inhibitors,
particularly the two key methyltransferases G9a/GLP and EZH2, is reviewed.
1.1 Chromosome and Histone Modification
Chromosomes within eukaryotic cell nuclei are packaged in complex structures called
nucleosome, which contain DNA and the histone octamer (Figure 1.2). The histone
octamer consists of eight main subunits (two copies each of H2A, H2B, H3, and
H4) to form an octamer. Histone proteins are wrapped in DNA, which is the
fundamental repeating unit of chromatin. Two conformations of chromatin control
the gene expression status: transcription on and transcription o↵. A condensed
structure (heterochromatin), in which the nucleosomes are packaged tightly together,
results in the repression of gene transcription. On the other hand, a loose structure
(euchromatin) allows gene transcription to occur easily [4].
Histone modifications play key roles in epigenetic regulation and are able to
regulate gene expression via their e↵ects on the structure of chromatin. More than a
hundred site-specific modifications have been identified on histone proteins, especially
on the unstructured N -terminal tail, such as acetylation, methylation, ubiquitination,
sumoylation, and citrullination (Figure 1.2) [5, 6]. Each modification requires di↵erent
enzymes and such marks often act in a combinational manner
Protein methyltransferases (PMTs) transfer the methyl group to the target
proteins, including histones (Figure 1.2). They are classified into three types: The
SET-domain lysine methyltransferases, non-SET-domain lysine methyltransferases
and arginine methyltransferases [7, 8]. The evolutionarily conserved SET domain
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occurs in several chromatin-associated proteins. The name originates from its
identification in the Drosophila genes Su(Var), E(z), and Trithorax [9]. The SET
domain is an important catalytic site for the transfer of a methyl group from SAM
to a lysine residue, resulting in SAH as a by-product. During methyl transfer, SAM
and lysine bind to opposite sides of the SET domain; their binding pocket sites are
joined by a channel through which the reactive methyl group is transferred. Most
protein methyltransferases use a typical molecular nucleophilic substitution (SN2)
methyl transfer mechanism (Figure 1.2) [10, 11]. Histone lysine methyltransferases
significantly alter the basicity and hydrophobicity of the histone protein, which can
be mono-, di-, or tri-methylated on the amino functional group of the lysine residue.
Histone methylation initially results in the recruitment of e↵ector proteins that re-
Figure 1.2: Chromatin and histone modifications. HKMT (Histone Lysine Methyl-
transferase), HDMT (Histone Demethylase), HAT Histone Acetylase, HDAC (Histone
Deacetylase), SAM: S-Adenosyl-L-methionine, SAH (S-Adenosyl-L-homocysteine),
and DNMT (DNA Methyltrasferase).
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cognise specific methylation marks on histones depending on the degree of methylation
and the presence or absence of specific neighbouring modified amino acids [12, 13]. In
transcriptional regulation, many methyl marks on histone lysines have been shown to
be related to the activation or repression of gene expression. For example, H3K4me3
(tri-methylation of histone 3, lysine 4) is associated with transcriptional activation,
while H3K9me2 and H3K27me3 are associated with transcriptional repression [14, 15].
To date, more than 200 proteins in the human genome have been identified as
known or putative methyltransferases, and 30% of such methyltransferases have been
linked to disease states [16]. In the following sections, methyltransferases G9a and
EZH2 and their current inhibitors are discussed as potential drug targets.
1.2 G9a/GLP, EZH2 and Their Inhibitors
1.2.1 Biology of G9a/GLP
Figure 1.3: The crystal structure of
GLP complex with SAH and BIX-
01294, (PDB:3FPD).
G9a (also known as EHMT2) and GLP
(EHMT1) catalyse the addition of one or
two methyl groups to lysine 9 of histone H3
(H3K9me1 and H3K9me2) within a chro-
matin environment. These two enzymes
share 80% homology in their SET domains
and can form a heterodimer [17]. The SET
domains of G9a and GLP bind and methyl-
ate H3K9me and H3K9me1, whereas the re-
peat ankyrin domains of G9a/GLP form a
methyl-lysine binding module, enabling them
to bind H3K9me1/2 marks separately from
their catalytic domain.
Due to their central role in epigenetic
control and their ubiquitous expression, G9a
and GLP are associated with many biological
pathways. In mouse development, G9a/GLP knockout leads to embryonic lethality
due to severe growth defects [17]. Additionally, G9a/GLP is aberrantly regulated in
several human diseases such as cancer [18, 19] and AIDS [20]. The overexpression of
G9a has been identified in many types of cancer such as ovarian cancer and cancer
stem cell. G9a is also associated with a poor prognosis [21, 22].
According to a genome-wide analysis of histone modifications, the mono-methyla-
tion of histone H3 (H3K9me1) is associated with permissive chromatin, while di- and
tri-methylation (H3K9me2/3) label a repressed chromatin state [18]. Furthermore,
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G9a has been reported to methylate a variety of non-histone targets, including the
chromatin-modifying factor Tip49a7, CDYL1 and p53 [23]. Currently, the biological
roles of these nonhistone methylations are not well understood.
1.2.2 G9a/GLP Inhibitors
In 2007, Kubicek et al. employed high-throughput screening to discover the first
two G9a/GLP inhibitors (BIX-01338 and BIX-01294) and found their inhibitory
activities to be in the micromolar range [24]. These inhibitors were also screened
against other methyltransferases such as PRMT1, SETD7, SETDB1 and SUV39H1.
BIX01338 (Figure 1.6) inhibited all the tested methyltransferases in the low mi-
cromolar range. Interestingly, BIX-01294, which contains a 2,4-diaminoquinazoline
sca↵old, selectively inhibited G9a (IC50 = 1.7 µM) and GLP (IC50 = 38 µM) (Table
1.1). Therefore, BIX-01294 has been recognised as the first G9a/GLP-selective
inhibitor. Mechanistically, BIX-01294 was confirmed by competitive assay to be a
substrate-competitive inhibitor [25]. In addition, the X-ray crystal structure of the
SET domain of GLP complexed with BIX-01294 and SAH illustrated that BIX-01294
binds to the substrate pocket of GLP (Figure 1.3) [26].
Table 1.1: Structures of G9a inhibitors and their inhibitory activities.
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In order to maximise the G9a inhibitory activity and selectivity of BIX-01294, Liu
et al. modified BIX-01294 based on the X-ray crystal structure of GLP-BIX-01294
(Table 1.1) [24]. First, they speculated that the benzyl group of the compound did
not interact with the enzyme; therefore, it was reasonable to remove this group.
Furthermore, the methoxy group of the compound was extended to mimic a lysine
residue in the catalytic site. Subsequently, the compound UNC0224 was obtained,
and its G9a inhibitory activity was found to increase dramatically (IC50 = 15 nM),
while its increase in GLP inhibitory activity was comparable (IC50= 20–58 nM).
E72 was rationally designed by adding three lysine mimic groups to the quinazoline
sca↵old (Table 1.1) [27]. It was shown to inhibit GLP/G9a and exhibit selectivity
over SUV39H. E72 was also observed to be less toxic than BIX-01294. Notably,
this compound contained three free amines, which can result in low cell membrane
permeability and inactivity in a cellular assay.
After obtaining the X-ray crystal structure of the G9a-UNC0224 complex (Figure
1.4.A1), Liu et al. also designed the new compound UNC0321 (Table 1.1), which
is slightly more selective for G9a (IC50 = 6–9 nM) than for GLP (IC50 = 15–23
nM) [28]. The researchers also evaluated the selectivities of compounds by testing
their inhibitory activities on various types of enzymes in the PKMT family, including
SET7/9, SET8/PreSET7, PRMT3 and JMJDSE. The results indicated that UNC0321
did not significantly inhibit any of these enzymes. However, the UNC0321 showed a
low potency in a cell-based assay due to the high polarity of the compound.
Subsequently, the discovery of UNC0638 and a co-crystal structure of the G9a-
UNC0638-SAH complex were reported in 2011 [29, 30]. This compound retained
its activity against G9a (IC50 = < 15 nM) and GLP (IC50 = 19 nM). In GPCR
screening (Ricerca Selectivity Panel), UNC0638 did not significantly inhibit 26 out
of 29 targets (< 30% inhibition at 1 µM), but it significantly inhibited muscarinic
M2, adrenergic ↵1A and adrenergic ↵1B (64%, 90% and 69% inhibition at 1 µM,
respectively). Fluorescence immunostaining experiments indicated that UNC0638
significantly reduced global H3K9me2 at 100 nM in MDA-MB231 cells, and no
significant cellular toxicity was found. The low cell membrane permeability issue was
solved by designing the new compound to be less polar by, for example, replacing a
homopiperazine side chain of UNC0321 with a cyclohexane ring (Table 1.1). The
results demonstrated that the modified compound was active in mouse embryonic
stem cells and acted by silencing retroviral reporters and reactivating endogenous
genes. Next, UNC0642, a G9a/GLP inhibitor with improved PK properties relative
to UNC0638, was reported recently. UNC0642 exhibited consistent inhibitory activity
in vitro against G9a and GLP (both IC50 < 2.5 nM). It also selectively inhibited
G9a/GLP over 13 other HMTs, 50 selected kinases, 44 GPCRs, ion channels, and
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other epigenetic proteins. In MDA MB231 cells, UNC0642 at 106 nM was able to
reduce H3K9me2 by 50% with low cell toxicity.
In order to develop new chemical tools to explore the localisation of G9a on
chromatin, UNC0965 was designed and synthesised as a new G9a probe (Figure
1.5) [31]. As a functionalised chemical tool for chromatin precipitation, the use of
UNC0965 has some advantages over traditional antibodies, including less batch-to-
batch variation, cell permeability and a well-defined mode of binding. UNC0965
retained inhibitory activity against G9a in a biochemical assay (IC50 = < 2.5 nM)
and was cell-penetrant despite being a large and polar molecule. UNC0965 was able
to selectively precipitate G9a from the cell lysate; however, its activity against GLP
was not reported.
Apart from the aforementioned quinazoline derivatives, Sweis at al. discovered
Figure 1.4: The crystal structures of G9a-UNC0224 (PDB code: 3K5K, Figure A1)
and G9a-A336 (PDB code: 4NVQ, Figure B1). The binding between the respective
inhibitors and G9a (FigureA2 and B2). These images were generated by Pymol and
Postview software, respectively.
25
Figure 1.5: Structures of UNC0965 and A-336
A-366, which contains a spiro(cyclobutane-1,3-indol)-2-amine core and inhibits G9a
(IC50 = 3.3 nM) and GLP (IC50 = 38nM), in 2014 (Figure 1.5) [32]. Moreover, A-366
selectively inhibited these enzymes over other methyltransferase such as SUV39H2,
SUV420H1, SUV420H2, MLL1, SETDB1, SETD7, SETD8, PRMTs (1, 3, 5, 6 and
8), SMYD2 and SMYD3, EZH1, EZH2, and DMT. The mechanism of action of A-366
was revealed to be substrate competition. In addition, the X-ray crystal structure
confirmed the binding mode of A-366 in the substrate pocket of G9a (Figure 1.4).
Unlike previous substrate-competitive inhibitors, BRD9539 was discovered as
a co-factor competitive inhibitor by designing a 2-substituted benzimidazole using
BIX01338 as a prototype (Figure 1.6) [33]. BRD3539 showed inhibitory activity
against G9a in a biochemical assay at low micromolar concentrations (IC50 = 6.3 µM).
It inhibited G9a selectively over SUV39H1 and DNMT1, while it showed the same
inhibitory activity against PRC2 and NSD1. Unfortunately, BRD9539 was inactive
in a cell assay.
BRD4770, the methyl ester analogue of BRD9539, was assumed to be the prodrug
of BRD9539 and was further investigated [33]. In cells, BRD4770 reduced H3K9me2
and H3K9me3 significantly but increased H3K9me. However, the cellular level of
H3K27me3, which is a target of PRC, was not decreased in the same experiment.
These results indicated that BRD4770 did not inhibit PRC2 in cells. This compound
Figure 1.6: Structures of co-factor competitive inhibitors: BIX01388, BRD9539 and
BRD4770
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also induced senescence in the pancreatic cancer cell line PANC-1 without inducing
apoptosis.
1.3 EZH2 and Its Inhibitors
1.3.1 Biology of EZH2
EZH2 (enhancer of zest polycomb repressive complex 2) catalyses the addition of
one, two and three methyl groups to H3K27 within a chromatin environment. It is
one of the polycomb proteins that form Polycomb Repressive Complex 2 (PRC2).
PCR2 has been identified as an epigenetic gene silencer in eukaryotic cells. EZH2
has a homologue, EZH1, with 96% sequence identity in its SET domain; however,
EZH1 is a component of a noncanonical PRC2 [34].
PRC2, which has been purified and characterised from human cells, comprises a
catalytic subunit (EZH2), embryonic ectoderm development (EED), a suppressor of
zeste-12 [Su(z)12], and the histone-binding proteins RbAp46/RbAp48 (Figure 1.7.B) [35,
36]. EZH2 lacks catalytic function on its own and requires at least two additional
components, EED and SUZ12, to be stable [37, 38]. In addition, many other proteins
have been identified as PRC2 partners, such as polycomblink protein PHF1 and
Jarid2 [39, 40]
Various isoforms of PRC2 have been discovered in human cells [41]. These
Figure 1.7: Structures of EZH2 and PRC2. (A) The crystal structure of the EZH2
SET domain (PDB: 4MI5). The crystal structure contains two N-terminal zinc
binding domains, each of which binds three zinc molecules. The C-terminus folds
back into the the substrate pocket. (B) Polycomb Repressive Complex 2 (PRC2)
and its possible isoforms
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isoforms are produced from multiple gene copies, and four possible components can
be substituted in other isoforms (Figure 1.7.B). In addition, four EED isoforms can
also a↵ect the activity of PRC2. RbAp48 can be substituted by RbAP46, and EZH2
and PHF can be replaced by EZH1 and MTF2/PCL3, respectively [42]. Surprisingly,
PRC2, which contains EED2, is expressed in cancer and undi↵erentiated embryonic
stem cells, but it cannot be detected in normal and di↵erentiated embryonic stem
cells [43].
The SET domain of EZH2 is comprised of 121 amino acids and the structure of
the EZH2 SET domain was determined to consist of four highly conserved signature
sequences [44]. Unfortunately, the recently reported 2.00 A˚ X-ray crystal structure
of the EZH2 SET domain (PDB: 4MI5) showed that the C-terminus folds back
into the substrate site, blocking the histone lysine tail. In addition, SAM is absent
in the co-factor site. Due to the reported closed conformation of the EZH2 SET
domain, it is di cult to utilise this X-ray crystal structure data for drug design and
computational modelling.
The high-resolution (1.82 A˚) crystal structure of EED complexed with a 30-
residue peptide (residues 39-68) from EZH2 was reported. This is the only available
crystal structure of the EED-binding domain (EBD) in EZH2 [45]. Although this
crystal structure could not be used to design a direct EZH2 inhibitor, it was useful
to design an inhibitor of protein-protein interaction [46].
The overexpression of EZH2 has been associated with many types of cancer,
including prostate [47], breast [48], lymphoma [49], myeloma [50], and ovarian cancer
stem cells [15, 51]. In fact, EZH2 has been identified as a prognosis indicator for
clinical outcomes in patients su↵ering from such diseases. Interest has also been
shown in its role in chemoresistance [52]; for example, loss of EZH2 function could
resensitise cisplatin-resistant ovarian cancer cells [53].
In 2010, researchers at Epizyme reported that somatic point mutations in Tyr641
increased the catalytic activity of EZH2 in non-Hodgkin’s lymphoma (NHL) [54]. This
mutant EZH2 was found in about 10–20 % of NHL cases. Wild-type EZH2 showed the
highest catalytic e ciency for the methylation of unmodified H3K27 to H3K27me1,
and the e ciency gradually decreased for subsequent methylations (H3K27me2 and
H3K27me3). Conversely, the catalytic e ciency of the Tyr641 enzyme was limited
for the first methylation but increased for the subsequent methylation. These results
suggested that WT and mutant EZH2 worked together in order to produce H3K27me3
in NHL cells [55, 56].
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EZH2 and G9a/GLP
Many studies have found that EZH2 not only functionally interacts with its partner
proteins, but also collaborates with other enzymes in the cellular environment.
Interestingly, although G9a and GLP have been previously described to catalyse
H3K9 methylation, they have also been reported to catalyse H3K27 methylation
both in vitro and in vivo [57, 58]. Notably, H3K9 and H3K27 are embedded within
a similar ARKS peptide motif, resulting in an opportunity for methylation by both
G9a and EZH2. Moreover, G9a/GLP and PRC2 were shown to regulate common
genes that encode developmental regulators, and the recruitment of PRC2 to some
of its target genes is dependent on the enzymatic activity of G9a (Figure 1.8) [59].
The histone methyltransferases G9a and GLP have important roles when they act in
collaboration with EZH2, especially when that action is synergic.
A recent work by Mozzetta and colleagues demonstrated crosstalk between
G9a/GLP and EZH2 (Figure 1.8)[59]. First, they found that SUZ12, EED and EZH2
interact with G9a/GLP in HeLa cells and mouse embryonic stem (ES) cells, and
the in vitro binding study suggested that G9a/GLP interact with PRC2 through
EZH2. Second, G9a/GLP and PRC2 were found to regulate common genes that
encode developmental regulators. The authors generated the mRNA expression data
of G9a-/- and GLP-/- ES cells along with EZH2/G9a-/- and EED/G9a-/- ES cells. A
total of 487 genes were up-regulated when G9a/GLP and EZH2/EED were absent.
These genes encoded proteins involved in cell di↵erentiation and development. In
addition, the ChIP experiment and following sequencing experiment revealed that 958
genes were related to G9a and PRC2; 207 of these 958 genes were up-regulated in the
absence of either G9a or GLP. Third, the researchers revealed that the recruitment of
EZH2 to its several targets was aberrant when G9a/GLP were absent. This occurred
accompanied by a decrease in H3K27me3. G9a assisted in the recruitment of EZH2
to an artificial promoter re-expressed EZH2 target genes in G9a-/- ES cells. Therefore,
G9a can recruit PCR2 to specific target genes to enable H3K27me3.
The mechanism by which G9a/GLP and PRC2 are recruited to their target sites
remains elusive because G9a/GLP and PRC2 do not have DNA binding domains.
This might imply that both reply on other partner proteins (chromatin-binding
molecules and transcriptional factors) and non-coding RNA (Figure 1.9). Interaction
between EZH2 and G9a/GLP through partner proteins and non-coding RNA was
previously reviewed by Mozzetta et al. [60].
The roles of G9a/GLP and PRC2 in silencing specific genes in ES and adult
stem cells have been reported (Figure 1.9). Collaboration between G9a/GLP and
PRC2 is observed in normal physiological conditions. The loss of pluripotency
and di↵erentiation of ES cells can be induced by either G9a or PRC2 [61, 62].
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Figure 1.9: PRC2 and G9a/GLP cross-talking and an example of its roles in physiolo-
gical function and diseases, modified from [60].
G9a and EZH2 have been implicated in Nanog and Oct3/4 silencing in mouse ES
cells [40, 63, 64]. Moreover, recent evidence indicated that G9a/GLP and PRC2
play important roles in tissue-specific stem cells such as neural, hematopoietic and
muscle stem cells [60]. Notably, the inactivation of PRC2 in these studies focused
on individual members such as EZH2 in neural and muscle stem cells [65, 66], EED
in hematopoietic stem cells [67] and SUZ12 in ES cells [68]. Therefore, EZH2 is
dispensable for regulating self-renewal and di↵erentiation in some cases.
Epigenetic mechanisms result in the heritable silencing of genes without a change
in their coding sequence. Disruption of the EZH2/G9a results in pathologies such as
cancer, retardation, inflammation, and syndromes related to chromosomal instabil-
ity [69]. PRC2, especially the EZH2 subunit, has been linked to many kinds of cancer,
including several hematopoietic malignancies [47, 48, 49], similar to G9a/GLP [18, 19]
as previously mentioned. Moreover, the global methylation levels of H3K9 and H3K27
are significantly related in some cancer cells [70]. Moreover, recent studies revealed
the mechanism of G9a- and EZH2-mediated histone methylation as COX-2 epigenetic
silencer in idiopathic pulmonary fibrosis (IPF) [71].
In summary, the crosstalk between G9a/GLP and PRC2 is very sophisticated;
however, several reports implied that the dual inhibition of G9a and PRC2 might
be a novel strategy for epigenetic therapy. G9a/GLP and PRC2 share some target
genes along with some partner proteins. PRC2 inhibition may not be su cient to
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reactivate the target genes probably because of either the compensation of G9a/GLP
in methylation processes or their crosstalk.
EZH2 and other epigenetic enzymes
Previous research indicated that EZH2 and DNA methyltransferases (DNMTs) are
mechanistically synergistic in vivo, which was a new model in epigenetics. The results
of chromatin immunoprecipitation experiments and bisulphite genomic sequencing
demonstrated that DNA methylation might be required for EZH2 activity [72].
Another study suggested that unlike in normal cells, PCR2 resulted in the recruitment
of DNMTs for de novo methylation in cancer cells [73].
Histone deacetylases (HDACs) are enzymes that remove acetyl groups from a
N-acetyl lysine amino acid on a histone tail (Figure 1.2). HDAC and PRC2 are
physically and functionally related (Figure 1.8). PCR2 is sterically hindered by
acetylated H3K27 (H3k27ac). H3K27ac is acetylated by CBP acetyltransferases and
deacetylated by HDACs to provide an available "-amino group for methylation by
PCR2. This process is the same for other histone lysine residues such as H3K9,
H3K14, and H4K8 [51, 74, 75]. In addition, H3K27ac functionally opposes PCR2
silencing in mammalian cell lines. Even though the mechanism of this opposition is
not clear, some evidence suggests that the histone deacetylase inhibitor panabinostat
reactivates the expression of genes repressed by H3K27me3 in human multiple
myeloma cell lines [50, 76, 77].
JMJD3 and UTX are H3K27me3 demethylases [78] (Figure 1.8) that contain
highly homologous JmjC domains at their C-termini. JMJD3 specifically reduces
H3K27me3 and has no e↵ect on H3K27me1/2 or methylation on H3K4 and H3K9 [79].
On the other hand, UTX specifically demethylates H3K27me2/3, not H3K27me.
As a member of mixed-lineage leukemia (MLL) 2/3 complexes, the recruitment of
the UTX complex to the PRC2 target genes causes the demethylation of H3K27
and the concomitant methylation of H3K4 by an MLL methyltransferase. One
study indicated that UTX may be a linker between the demethylation of H3K27
and MLL2/3 and methylation of H3K4 [13]. Therefore, JMJD3 and UTX act in a
competitive manner with EZH2.
EZH2 and nonH3K27-chromatin modifications
It is not only H3K27me3 that controls the expression status of PRC2 target genes;
other histone modifications also a↵ect gene regulation. This section describes other
histone modifications that are indirectly related to PRC2 silencing, such as non-K27
methylation and phosphorylation (Figure 1.8) [12].
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H3K4me3 and H3K36me2/3 are active marks of gene expression, unlike H3K27me3.
The tails of H3K4me3 and H3K36me3 allosterically inhibit PRC2 when attached to
the same histone tail [80]. Likewise, cell-based experiments show that H3K27me3
rarely co-exists with H3K36me2/3 on the same histone H3 polypeptide [81]. These
findings indicate that PRC2 is sensitive to the modification state of the histone. MLL
and ASH1L, which methylate H3K4 and H3K27, may function to inhibit the activity
of PRC2 [80].
Serine28 on the tail of Histone3 (H3S28) is located next to H3K27, which is a
well-known position of MSK1 phosphorylation during interphase and mitosis [82].
Not only can H3S28 phosphorylation (H3S28phos) displace PRC2 binding via steric
hindrance, it also induces a methyl-acetylation switch on the adjacent K27 residue.
These results indicate that H3K28phos and H3K27ac synergistically oppose PRC2
silencing and turn chromatin into an active state [83].
EZH2 and its post-translational modifications
Apart from the antagonistic histone modifications, EZH2 post-translational modifica-
tions and the expression of EZH2 also indirectly a↵ect EZH2 activity, altering EZH2
target gene expression.
The modulation of PRC2 activity by the cell cycle machinery was recently
elucidated. The phosphorylation of EZH2 at Thr350 by cyclin-dependent kinase 1
(CDK1) and cyclin-dependent kinase 2 (CDK2) was found to be essential for the
recruitment of EZH2 (Figure 1.8) [84]. If this phosphorylation process is blocked,
the overall e↵ect of EZH2 on gene silencing decreases along with EZH2-mediated
cell migration and proliferation. However, the phosphorylation seems to enhance
PRC2 recruitment instead of increasing intrinsic EZH2 activity [84, 85]. In contrast,
the phosphorylation of Thr487 by CDK1 decreased EZH2 activity, resulting in the
inhibition of cancer cell invasion [86]. This phosphorylation at Thr487 disrupted
EZH2 binding with SUZ12 and EED. Nevertheless, another study in mouse models
showed that mimicking phosphorylation at 345 and 487 residues have no e↵ect on
the assembly of the PRC2 complex [85]. These results suggest that CDKs may play
an important role in EZH2 regulation linked to the cell-cycle.
Phosphoinositide 3-kinase-Akt (PI3K-Akt) signalling is involved in many cel-
lular processes such as cell survival, proliferation and metabolism [87]. The Akt-
phosphorylated serine21 of EZH2 was observed to suppress EZH2 activity by impeding
EZH2 binding to H3 (Figure 1.8). Subsequently, a decrease in H3K27me3 and the
depression of silencing genes were observed. Cells that contain a high level of activ-
ated Akt often have low levels of H3K27me3. A previous study also showed that
insulin-like growth factors (IGF) are able to induce the activation of Akt followed
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by the reduction of H3K27 trimethylation. On the other hand, either knocking
out Akt expression with siRNA or blocking PI3K with specific inhibitors increased
the H3K27me3 mark [88]. Two recent studies showed that xenoestrogen activates
PI3K-Akt signalling, resulting in a decrease in H3K27me3 (Figure 1.8) [89, 90]
EZH2 and its expression
The greater the amount of EZH2 in cells, the higher the EZH2 methyltransferase
activity. Three examples of factors that contribute to EZH2 expression (vascular
endothelial growth factor (VEGF), p53, and microRNAs) are shown below (Figure
1.8).
A recent report on the regulation of tumour angiogenesis by EZH2 indicated
that VEGF increases the level of EZH2 via a paracrine circuit. On the other hand,
using siRNA for EZH2 silencing resulted in significant growth inhibition of tumour-
associated endothelial cells [91]. The study showed that VEGF is able to directly
raise the level of EZH2 in endothelial cells via E2F1and E2F3 transcription factors.
As a result, EZH2 promotes angiogenesis by methylating and silencing vasohibin1,
which is a known EZH2 target gene.
The role of p53 has been intensely studied from the prospective of protecting
cells from cancer [92]. Two recent studies revealed that EZH2 gene expression can
be repressed by p53 through the suppression of the EZH2 gene promoter in senescent
cells [93, 94]. The proposed mechanism involved the inactivation of RB/E2F pathways
by p53 transcriptional target p21Waf1. Interestingly, the function of E2F via the
p53 pathway is opposite that via the VEGF pathway.
MicroRNAs (miRNAs) are post-transcriptional regulators that bind comple-
mentarily to target mRNAs, resulting in translational repression and gene silencing.
Recent studies have shown that the over-expression of miR-261 in human lung cancer
cells significantly inhibits cell proliferation, metastasis, and G1/S phase transition
and induces apoptosis [95, 96]. In addition, the expression of the EZH2 target gene
decreases due to the high expression of miR-26a. There is some evidence that the
MYC oncogene, which normally induces proliferation and apoptosis, decreases the
level of miR-26a, resulting in the up-regulation of EZH2 [95].
1.3.2 EZH2 Inhibitors
In 1995, 3-deazaneplanocin A (DZNep, cyclopentenyl analogue of 3-deazaadenosine)
was discovered as a powerful modulator of cellular processes and as an anti-HIV1
agent [97]. DZNep was demonstrated to have inhibitory activity against S-adenosyl-
L-homocyteine hydrolase, which hydrolyses S-adenosylhomocysteine (SAH) (Fig-
ure 1.10) [98, 99]. However, DZNep was also suggested to be a novel chromatin-
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Figure 1.10: DZNep and its mechanism of action
remodelling compound and reverse PRC2-mediated gene repression. The mechanism
by which DNZep inhibits the activity of PRC2 is involves the cellular accumulation
of SAH, which inhibits the formation of by-product SAM-dependent enzymes such
as dihydrofolate reductase and SAM synthase [100]. Also SAH itself is the inhibitor
of HKMTs. As a result, the decreased level of SAM is not su cient to supply methyl
groups to PRC2 and other enzymes [101]. However, SAM, a methyl donor, plays a
physiological role in human metabolic reactions. Therefore, the use of DNZep as a
drug should be considered carefully because it may lead to side e↵ects from SAM
reduction.
Researchers from Epizyme, GSK and Novartis recently employed high-throughput
screening campaigns to search for EZH2 inhibitors. Optimisation of the lead hits
resulted in the discovery of novel EZH2 inhibitors based on indole/indazole sca↵olds
such as EPZ005687, GSK126 and EI1 (Table 1.2). Non-indole/indazole derivatives
such as EPZ6438, EPZ011989, CPI-905 and Tanshindiol C were subsequently reported
(Figure 1.12).
The indazole derivative EPZ005687 (Table 1.2) exhibited inhibitory activity
against EZH2 (IC50 = 54 nM) [102], and was a SAM-competitive inhibitor. It
was also 500-fold selective over 15 other protein methyltransferases, even 50-fold
selective over the homologues enzyme EZH1. The inhibitor was able to reduce H3K27
methylation in many kinds of lymphoma cell lines. Interestingly, EPZ005687 induced
apoptosis in Tyr641 and other EZH2 mutant cells but showed little e↵ect on the
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Table 1.2: Structures of EZH2 inhibitors and their inhibitory activities.
proliferation of wild-type cells. These results implied that a mutant EZH2 might play
an important role in determining sensitivity to EZH2 inhibition in cancer, especially
in the aforementioned NHL. Selective mutant EZH2 inhibitors also have the potential
to be used in further clinical research.
The indole derivative GSK126 (Table 1.2) was subsequently discovered in 2012
after the discovery of GSK343 and GSK936 from the GSK research group [34, 103].
GSK343 and GSK936 were tested against purified EZH2 and found to exhibit inhibit-
ory activities (IC50 = 4 and 20 nM, respectively). In addition, they are over 1000-fold
selective for other HMTs with the exception of EZH1 (60-fold selectivity). These led
to the further discovery of GSK126, a potent SAM-competitive inhibitor (IC50 =
0.5 nM, Kiapp = 0.3–5 nM, both in wild-type and mutant EZH2). The selectivity of
GSK129 is better than that of EPZ005687; it inhibits over 20 other methyltransferases
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with 1000-fold selectivity and inhibits EZH1 with 150-fold selectivity. GSK129 did
not significantly inhibit other chromatin-modifying enzymes (HDAC1-11, JMJD2d,
JMJD3, LSD1), a broad panel of kinases, GPCRs, or ion channels. In a cellular
assay, GSK126 decreased global H3K27me3 levels and also reactivated silenced PRC2
target genes. The compound decreased the proliferation of Tyr641 EZH2 mutant in
the di↵use large B-cell lymphoma (DLBCL) cell line and DLBCL xenografts in mice.
The Tyr641 residue is the most often mutated residue and comprises more than
20% of the germinal centre in DLBCL cells. Recently, GSK2816126, the indazole
derivative of GSK126 (Figure 1.2), has been investigated in phase 1 clinical trials for
safety, pharmacokinetics, pharmacodynamics and clinical activity in subjects with
relapsed/refractory DLBCL and transformed follicular lymphoma (ClinicalTrials.gov
Identifier: NCT02082977).
Also in 2012, a Novartis research team reported the indole derivative EI1 (Table
1.2) as a selective EZH2 inhibitor with inhibitory activity against WT and Tyr641
mutant EZH2 (IC50 = 15 and 13 nM, respectively). Not surprisingly, EI1 is a
SAM-competitive inhibitor that exhibited 10000-fold EZH2 selectivity over 10 other
methyltransferases and 90-fold selectivity over EZH1. Like the previously mentioned
EZH2 inhibitors, the treatment of cells with EI1 results in the genome-wide loss
of H3K27 methylation, especially H3K27me2 and H3K27me3, and the activation
of PRC2-silencing genes. The researchers further investigated the pharmacological
activity of EI1 in DLBCL against mutant EZH2 and revealed that EI1 induced
apoptosis and cell cycle arrest and decreased cancer cell proliferation.
In 2013, UNC1999 was reported as an orally bioavailable chemical probe of
EZH1 and EZH2 (Table 1.11) [104]. It was optimised via EZH2 homology modelling
based on the GLP X-ray crystal structure. Although the indazole sca↵old was
retained, some critical changes in its medicinal chemistry properties were observed.
The docking model of EPZ005687 and the EZH2 homology model revealed that
the morpholinomethyl group pointed outwards towards the solvent site and did
not interact with EZH2. On the other hand, several moieties formed hydrophobic
interactions and hydrogen bonds in the co-factor pocket, including a hydrogen
bond between the amide adjacent to the indazole core and Asn688 along with
hydrogen bonds between the pyridine moiety and His689. Therefore, the SAR of
the morpholinomethyl side chain was studied and comparing with those of other
EZH2 inhibitors, resulting in the discovery of UNC1999, which possessed better
physical properties (cLogP) for oral administration. UNC1999 inhibited EZH2 with
high potency (IC50 = 10 nM). Furthermore, UNC2400, the N-caping derivative of
UNC1999, was used as a negative control for subsequent experiments (Figure 1.11).
In terms of selectivity, UNC1999 is more than 10000-fold selective over 15 other
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Figure 1.11: Structures and inhibitory activity of UNC1999 and its derivatives.
histone and DNA methyltransferases, and no significant inhibition was found in
a broad panel of kinases, GPCRs, ion channels, and transporters. Unfortunately,
UNC1999 inhibited EZH1 (IC50 = 45 nM). Compared to the aforementioned EZH2
inhibitors, UNC1999 inhibited both EZH1 and EZH2. In a cellular assay, UNC1999
decreased the H3K27me3 level in MCF10A and showed low cellular and animal
toxicities. The researcher claimed that these might be a benefit for the pan EZH1
and EZH2 inhibition because the loss of PRC2-EZH2 function is compensated by
the activity of PRC2-EZH1. Therefore PRC2-EZH1 can still methylate H3K27.
Moreover, the UNC research team developed UNC2399 and UNC2239 as chemical
tools for pull-down assay and live cell imaging, respectively (Figure 1.11) [104].
UNC2399, a biotinylated derivative of UNC1999, showed inhibitory activity in a
biochemical assay (IC50 = 17 nM) and was able to pull down EZH2 from the cell
lysate. UNC2238, a dye-conjugated derivative, inhibited EZH2 (IC50 = 21 nM) and
was able to visualise EZH2 in the living cell co-localisation studies.
In addition to the indazole/indole-based EZH2 inhibitors, Epizyme, Constellation
and Korean research groups have reported EZH2 inhibitors containing di↵erent
cores (Figure 1.12). First, Epizyme reported EPZ6438, which inhibited EZH2 in
EZH2 highly-expressed tumour cell lines [105]. EPZ6438 was developed using the
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observed SAR data from EPZ005687 studies. EPZ6438 showed higher potency and
better pharmacokinetic properties than EPZ005687. Mechanistically, the compound
acted as a SAM-competitive inhibitor in a competitive assay and displayed 35-fold
EZH2 selectivity over EZH1 and more than 4,500-fold selectivity over 14 other
histone methyltransferases. In SMARCB1-deficient cells, EPZ6438 reduced global
H3K27me1, H3K27me2, and H3K27me3 levels and did not a↵ect other chromatin
modifications, including H3K4me3, H3K9me3, H3K36me2, H3K79me2 and H3K27ac.
In animal studies, the compound prevented tumour regrowth after dosing cessation.
In collaboration with Eisai, Epizyme has investigated EPZ6438 as a single agent
in subjects with advanced solid tumours or with B-cell lymphomas in phase 1/2
clinical trials (clinicaltrial.gov identifier: NCT02082977). In 2015, Epizyme also
reported EZP011989, which was discovered by modifying the pyran substituent in
EPZ-6438. A trans-N,N -dimethylcyclohexylamine group was able to maintain its
activity in biochemical assay. Unfortunately, if combined with a morpholine side-
chain, its activity in cells decreases because of the dibasic functional group. Therefore,
researchers designed and synthesised the following compounds by attenuating the
pKa of the amine group and balancing the physiochemical properties with their
inhibitory activity. This resulted in the addition of a methoxyethyl group to the
cyclohexylamine. Moreover, the replacement of the benzene group with an acetylene
linker with the adjacent morpholine reduced the pKa to within the desired range.
EPZ011989 inhibited mutant and wild-type EZH2 equally (Ki < 3 nM). It inhibited
EZH2 over EZH with >15-fold selectivity and more than 20 other HMTs with >3000-
Figure 1.12: Structures and inhibitory activities of non-indole/indazole EZH2 inhib-
itors and their derivatives
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fold selectivity. This compound provided desired pharmacokinetic properties and less
cytotoxicity. Oral administration of EPZ011989 inhibited tumour growth significantly
in a mouse xenograft model of human B-cell lymphoma. Thus, EPZ011989 is a good
EZH2 probe for in vivo and for animal studies.
Second, a novel tetramethylpiperidinyl benzamide derivative CPI compound 3
(Figure 1.12) was discovered by Constellation via high-throughput screening [106].
This compound showed inhibitory activity against wild-type EZH2 and Try641
mutant EZH2 in vitro— (IC50 = 21 and 197 nM, respectively). It was also shown to
be SAM-competitive. The compound selectively inhibited EZH2 over G9a, SET7D,
SETD8, WHSC1, and DOT1L, but it was only 10-fold selective for EZH2 over EZH1.
In HeLa cells, wild-type and EZH2 mutant cells, CPI-905 reduced global H3K27me2
and H3K27me3 levels but did not a↵ect H3K27me1. Notably, the compound did
not exhibit a proliferation e↵ect in prostate cancer cells; however, it reduced global
H3K27 methylation levels, and EZH2 is known as a prostate cancer biomarker.
Third, the natural product Tanshindiol C inhibited EZH2 in biochemical assay
(IC50 = 0.55 µM) [107]. It significantly inhibited the growth of the Pfei↵er cell line, a
di↵use large B-cell lymphoma harbouring EZH2 A677G activating mutation. Further
investigation of the treatment of Pfei↵er cells with Tanshindiol indicated a decrease in
H3K27me3 in Western blot analysis and histone methylation ELISA. An investigation
into the mechanism of action using enzyme kinetics and docking studies found that
Tanshundiol is a SAM-competitive inhibitor.
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Chapter 2
Design and Synthesis of
Quinazoline Derivatives and
Their Biological Activities
Against G9a and EZH2
2.1 Preliminary Data and Chemical Library Design
BIX-01294 (1) was reported as the first substrate-competitive inhibitor against the
methyltransferases G9a/GLP in 2007 (Figure 2.1) [25]. It also served as a prototype
for the development of selective G9a/GLP inhibitors such as UNC0224 (2) (Figure
2.2). Moreover, BIX-01294 was observed to inhibit other chromatin-modifying
enzymes such as histone demethylases and DNA methyltransferase [108, 109]. As
compounds derived from BIX-01294 (1) have been chemically modified to generate
substrate-competitive inhibitors of G9a and GLP [25], we suggested that BIX-01294
derivatives could lead to novel substrate-competitive inhibitors against other HKMTs,
especially EZH2 which previously showed the histone cross-talk activities with G9a.
[59, 60]. Therefore, BIX-01294 was used as a starting point for the development of a
quinazoline-based chemical library.
In collaboration with the groups of Prof. Jim Snyder (Emory University) and
Prof. Robert Brown (Imperial College), three prospective hits (3–5) against HKMTs
have already been developed at the start of these e↵orts (Figure 2.2). In previous
research in our laboratory, when EZH2 was knocked out, we observed the reversal of
the epigenetic silencing process, as indicated by the decrease in methylation mark
H3K27me3 and increase in the expression of EZH2 target genes KRT17 and FBXO32
in breast cancer cell lines. Histone methylation, as opposed to DNA methylation and
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Figure 2.1: The concept behind the development of a quinazoline-based library.
histone deacetylation, seems to be the key mechanism responsible for the silencing of
these genes [100]. Moreover, these target genes were previously accepted to be related
to cancer [94, 110, 111]. For example, EZH2 depletion results in the induction of
FBXO32, which is normally directly suppressed by EZH2 in multiple human cancer
cells [100, 111]. Furthermore, KRT17 is more than 100-fold down regulated in several
metastatic cancers [112]. Based on these findings, cell-assay phenotypic screening
was carried out in the MDA-MB-231 cell line.
Our laboratory has identified small molecule inhibitors that are able to re-express
EZH2 target genes, which have been shown to be involved in the silencing process
Figure 2.2: The structures of BIX-01294 (1), UNC0224 (2), hits 3–5 and the
representative negative compounds 6–8 against EZH2 in cell-based assay
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via the methylation mark H3K27me3. Using a cell-based assay (MDA-MB-231)
and a small library of 40 quinazoline derivatives, we previously identified three hit
compounds 3, 4 and 5 that up-regulate DNA unmethylated EZH2 target genes
(KRT17 and FBXO32) but fail to up-regulate a DNA methylated EZH2 target
gene (RUNX3) (Figure 2.3.A). On the other hand, BIX-01294, UNC0224, and the
negative compounds 6–8 were not able to reactivate gene expression, although their
structures are similar. All three hits showed a clear decrease in repressive chromatin
marks (H3K27me3, H3K9me3) at both genes (Figure 2.3.B). Compound 5 showed a
concomitant increase in all permissive chromatin marks and JMJD3 binding, while
compounds 3 and 4 showed increases in most permissive marks. The responses
of di↵erent breast cancer cell lines to compound treatment relates to their level of
EZH2 protein expression (Figure 2.3.C). The results suggest that cancer cells are
more vulnerable than normal cells (MCF10a). Interestingly, the most sensitive cell
line (BT474) has the lowest expression of EZH2 protein levels, as determined by
Western analysis. In summary, we have identified three novel small molecules that
induce gene re-expression, reverse H3K27me3-mediated gene silencing and induce
the inhibition of tumour cell growth. The details of these preliminary studies can be
found in our recent publication [113].
Our current research focuses on expanding the quinazoline-based chemical library
to understand the structure-activity relationships (SARs) and mechanism of action of
our three hits (3–5). Compounds 3, 4, and 5 were re-synthesised on a large scale to
facilitate further experiments. Using the same synthetic method, we also synthesised
quinazoline derivatives to expand our chemical library.
In order to study SARs of our current hits, we designed novel quinazoline
derivatives, as shown in Figure 2.4. Initially, we focused on modifications at the
following positions:
• Position 2: The size of the ring and the heteroatom presence/positioning in the
ring were varied. In addition, the substituent attached to the nitrogen atom
was replaced by a variety of functional groups.
• Position 4: An electron-donating or electron-withdrawing group was added to
the benzyl group. Also, the piperidine ring was slightly modified.
• Positions 2 and 4: The corresponding side-chain at these two positions were
switched. Also the pseudo symmetric quinazoline analogues, bearing the same
side-chain were synthesised.
• Positions 6 and 7: The dimethoxy group was removed, connected, or replaced
with a benzyloxy group. The lysine/norleucin-mimic group was introduced at
position 7.
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Figure 2.3: Preliminary biological data. (A) RT-PCR data for single concentration
10 µM dose of compounds. RNA levels for target genes are normalised against the
concentration of the housekeeping gene GAPDH in the mock treated sample. (B)
Sybr green real-time measurements of the FBXO32 and KRT17 promoter regions
following chromatin immunoprecipitation. MDA-MB-231 cells treated with the three
selected compounds at 5 µmol dm 3 for 72 h. (C) MTT cell viability assay results
for breast cancer cells lines and Western blot analysis for untreated breast cancer
cell lines for endogenous EZH2 along with the H3K27me3 protein level [113].
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Figure 2.4: General plan for target molecules
2.2 Synthesis, and Pharmacological Evaluation of Quinazoline
Derivatives
2.2.1 Chemical Synthesis
Re-synthesis of hits 3–5 and their derivatives
We modified the quinazoline compounds at positions 2 and 4 using the general
procedure reported by Liu with some modifications (Scheme 2.1) [24]. Initially,
quinazolinedione 9 was converted to dichloride 10 by treat with POCl3 in the
presence of N,N -diethylaniline as a base, resulting in the product 6 with a yield of
up to 83%.
Scheme 2.1: Re-synthesis of hits 3–5 and their derivatives. (i) POCl3, PhNEt2,
MeCN, reflux 4.5 h. (ii) 4-Amino-1-benzylpiperidine, DIEA, THF, overnight. (iii)
NHR, toluene, reflux, 24–72 h, or NRH (excess), neat, microwave, 185  C, 30 min.
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Scheme 2.2: The comparison of nucleophilic displacements at positions 2 and 4 of
quinazoline.
The displacement of the more reactive chloride at position 4 with 1.5 equivalents
of 4-benzyl amino-piperidine and 2 equivalents of DIEA in THF at room temperature
a↵orded 11 in a good yield (70%). We then synthesised 3–5 in gram quantities, and
the yield was lower than small-scale production. Mechanistically, the di↵erence in
reactivity between the 2-position and 4-position of dichloroquinazolines in nucleophilic
displacements is due to the stability of the resonance forms a and b in the transition
state of the 4-isomer as compared with c and d in the 2-isomer (Scheme 2.2).
Therefore, nucleophilic substitution at position 4 is more likely than at position 2.
The contribution from d is lower due to the stability of the 6⇧ benzene ring.
The displacement of the secondary chloride required harsher conditions. Thus,
the reactions were refluxed in toluene for 36–72 hours with excess amines (1-methyl
piperazine, piperidine and 1-(2-pyridyl)piperazine) to a↵ord compounds 3–5. The
starting material (11) was still observed after the reaction and this led to di culties
in the purification process. Alternatively, the reaction was heated in a microwave
reactor with excess amine at 185  C for 30 min. This reaction was faster, but
reaction scale was limited by the capacity of the microwave reactor. The purification
process was optimised by gradient column chromatography (ammonia, methanol in
dichloromethane). The final compounds were purified multiple times until the purity
was greater than 95% by LCMS-UV.
Compound 3 was further prepared in an HCl salt form (20 gram scale) to increase
the kinetic solubility in water for biological testing, especially for pharmacokinetic
studies in mice. We found that the kinetic solubility in water was improved (>15 µM);
however, as the compound is slightly hydroscopic, it must be kept in an air-tight
container.
Using the same route, we generated compounds 12–16 bearing quinazoline
sca↵olds with variations at position 2 (Scheme 2.1). In general the secondary
displacement reactions were carried using a microwave reactor with the exceptions of
compounds 12 and 13 which were synthesised by refluxing in toluene. Compounds 12
and 13 were prepared in toluene because insoluble products were observed when the
reactions were carried out in the microwave reactor. This result may be attributed to
the degradation of azetidine and pyrolidine. The yields of the final products 12-16
were moderate to excellent (70–98%).
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Synthesis of substituted benzyl-piperidine quinazoline derivatives
Focusing on position 4, various substituted benzyl-piperidine derivatives were pre-
pared (Figure 2.4). An electron-donating ( methoxy group) or electron-withdrawing
group (fluorine atom) was added to the benzyl group by replacing the hydrogen
atom in order to observe the electronegativity e↵ect on the benzene ring. Moreover,
fluorine-hydrogen isosterism has been explained in medicinal chemistry [114]. From
the steric point of view, the fluorine atom is much smaller than the rest of the halogen
atoms; therefore fluorine resembles the hydrogen atom when compared to chlorine
and iodine. On the other hand, fluorine is the most electronegative of the halogens
and forms particularly stable bonds with carbon atoms. This chemical property
explain why fluoro-derivatives are more resistant to metabolic degradation, especially
when in vivo para-hydroxylation of the benzene ring occurs.
Fluorine substituents were previously prepared at the ortho, meta, and para
positions, while a methoxy substituent was prepared only at the meta position. The
starting material 17a-d was previously synthesised by Dr. Joachim Caron [115] and
17a-d was used for the secondary displacement with amine at 185  C for 30 minutes.
Compounds 18–23 were obtained as final products in good yields (70–96%).
Scheme 2.3: Synthesis of substituted-benzyl derivatives.
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In order to accelerate the library generation, an external company (SAI Chemicals)
provided 52 additional compounds 25-76 that contained a diversity of amines at
positions 2 and 4 (Scheme 2.4).
Scheme 2.4: Synthesis of quinazoline derivatives by SAI Chemicals. (i) NH2R, DIEA,
DMF, rt, 17 h. (ii) NHR, IPA, 4 M HCl, dioxane, 130  C, 16 h or NHR, t-BuOH,
130  C, 16 h.
Synthesis of modified benzenoid quinazoline derivatives
As a strategy to replace the benzenoid ring of the quinazoline sca↵old, a number
of derivatives were prepared. The dimethoxy functionality was either modified
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Table 2.1: Demethylation procedures.
Entry s.m. conditions results
1* 9 BBr3, DCM, rt no reaction
2* 9 NaSEt, DMF, 150  C product** (38%) + s.m.
3* 9 LiCl, DMF, 150  C product** (34%) + s.m.
4* 9 MsOH, Methionine, 50  C product** (39%)
5 10 BBr3, DCM, -78 - rt, 18 hr no reaction
6 10 HBr, 140  C, 12 hr decomposed
7 10 pyridine.HCl, 205  C (microwave) decomposed
8 3 pyridine.HCl, 205  C (microwave) s.m. + unknowns
*Results from Thomas Moss Final Report. **Monodemethylated of 9.
or removed (Figure 2.4). The dimethyl group does not specifically interact with
G9a; however, it anchors to the adjacent the lysine channel (Figure 1.4). Not
only is the dimethoxy functionality thought to be important to study the SARs,
this functional group is also important in metabolism, including the demethylated
metabolites 6-hydroxy-, 7-hydroxy- and 6,7-dihydroxy metabolites [116]. Therefore,
the understanding of SAR of benzenoid moiety is interesting.
Our group previously tried to develop demethylation methods using quinazoline-
dione 9 as a starting material (Table 2.1, Entry 1–4) to modify the dimethoxy
group. These procedures (Entries 2-4) were successful in producing 6-hydroxy, 7-
methoxy quinazolinedione, but the yields were low (34–39%). Other starting materials
including dichloroquinazoline 10 and compound 3 were used due to their better
solubilities in organic solvents. Unfortunately, the new procedures were still not
successful. Using BBr3 to demethylate dimethoxy quinazoline was ine↵ective; no
reaction occurred. Other harsh procedures also were applied, but provided very polar
compounds that were di cult to purify and identify using NMR.
As the demethylation did not provide su cient material to carry forward, the
alternative strategy to prepare four new quinazoline cores 83a-d was successfully
employed with varying benzene substituents (Scheme 2.5). Six synthetic steps were
required to achieve 83a-d. The details of each step are discussed in the following
paragraphs.
First of all, to access derivatives with variation at either position 6 or position 7 of
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the quinazoline sca↵old, the synthetic route for the protected quinazoline cores must
be robust. The benzylation method developed by Liu et al. [24] was slightly modified
(Scheme 2.5).The protections of commercially available phenols 77a and 77b with
benzyl bromide in DMF were successful, resulting in 78a and 78b in excellent yields
(quantitative yield and 83%, respectively).
Secondly, the nitration of protected 78a, 78b and commercially available 78c
with nitric acid in acetic anhydride a↵orded nitro compounds 79a-c in excellent
yields (95, 91 and 76%, respectively) as single regioisomers via electrophilic aromatic
substitution. The nature of the electrophile operating in nitric acid and acetic
anhydride systems has been discussed; acetyl nitrate, protonated acetyl nitrate,
dinitrogen pentoxide and nitronium ion have been advocated [117]. The presence of
each species depends on the concentration of nitric acid in acetic anhydride. In our
reaction, the concentration of nitric acid is less than 20 mole%; thus, acetyl nitrate
is likely to be major nitrating agent. Both small- and large-scale reactions were
performed (25–55 mmol), and the overall yields were satisfactory and consistency.
The reduction of the nitro group was initially suggested by Liu et al. to proceed
with iron dust [24]; however, the purification process was unsuccessful due to iron con-
tamination, particularly during large-scale purification by silica gel chromatography.
Alternatively, a method using sodium dithionite (sodium hydrosulfite, Na2S2O4) was
found to be more convenient and a↵orded aniline 80a-c as a cleaner product without
Scheme 2.5: Synthesis of new quinazoline cores. (i) BnBr, K2CO3, DMF. (ii) HNO3,
Ac2O. (iii) Na2S2O4Bu4NBr, DCM/H2O. (iv) ClCOOCH3, DIEA, DMA/DCM. v)
H2O2, NaOH, EtOH, room temperature. (vi) POCl3, PhNEt2, reflux.
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the need for column chromatography [118]. In our reaction, the crude product was
cleaned by acid/base extraction to a↵ord a variety of yields (66, 5, and 40% for
80a-c, respectively) (Scheme 2.5). Notably, the yield of 80b was very low because
the reaction was quenched too early. Since, the amount of 80b was su cient for
further experiments, this procedure was not further optimised.
Next, using methyl chloroformate in 2:1, DMA:DCM, the acylation of anilines 80a-
c led to the formation of carbamate compounds 81a-c in excellent yield (quantitative
yield for 81a and 81b and 69% for 81c, Scheme 2.5). Consequently, the carbamates
81a-c spontaneously cyclised in the presence of sodium hydroxide and hydrogen
peroxide to a↵ord the quinazolinedione compounds 82a-c in good yields (70%, 63%
and 61%, respectively). Notably, from the benzylation up to this step, no column
chromatography was required.
The chlorination of quinazolidinedione 82a-c and commercially available 82d
with excess phosphoryl chloride gave the dichloro compound 83a, 83c and 83d in
good yields (90%, 80% and 82%, respectively). Without column chromatography,
each crude product was su ciently clean for further experiments, except compound
83b which was purified by column chromatography to a↵ord the clean product in a
moderate yield (35%).
Finally, the dichloroquinazolines 83a-d were substituted using the method de-
scribed in Scheme 2.1. The reaction time of first displacement in each reaction
was 24 hours, providing intermediates 84b-d in quantitatively yield. However, the
intermediate 84a was obtained in moderate yield (43%) because the reaction was
not complete within 24 hours and the reaction was stopped early. All intermediates
84a-d were then conjugated with amines to a↵ord the final compounds 85–100
(Scheme 2.6).
Synthesis of pseudo-symmetrical and side-chain switched quinazoline ana-
logues
Due to the flat and nearly symmetrical shape of the quinazoline core, it is possible
that the binding modes of the hits 3–5 and the target molecule can be inverted.
As shown in Figure 2.5, the nitrogen atoms of both side chains of compound 3
(green molecule) are located near the flipped molecule (purple molecule). Even
this model assumes that the quinazoline core overlaps perfectly, which it does not
need to, the quaternary nitrogens of both side chains were close to each other
(2.1–2.8 A˚). This might imply that in the solution, where the compound is more
dynamic, the compound would possibly flip in the pocket site. Therefore, we designed
and synthesised pseudo-symmetrical quinazoline analogues and side-chain switched
analogues.
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Scheme 2.6: Synthesis of modified benzeniod derivatives. (i) 4-Amino-1-
benzylpiperidine, DIEA, THF, 24 h. (ii) RNH (neat), microwave, 185  C, 30
min.
Figure 2.5: The overlay of compound 3 (green) and the corresponding side-chain
switched molecule (purple), Chem3D CambridgeSoft.
To obtain the psuedo-symmetric quinazoline analogues, compound 10 was doubly
substitued with di↵erent amines in one pot using a microwave reactor at 185  C for
30 min (Scheme 2.7). On the other hand, the starting material 10 was coupled with a
variety of amines including methylpiperidine, piperidine, 1-(2-pyridyl)piperazine and
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1-(2-furoyl)piperazine to provide 101, 102, 103 and 104, respectively. In general,
conversion was high, but the overall yields were low (15–59%) due to the complicated
purification process, which required multiple chromatographic steps.
To obtain side-chain switched compounds, two displacements of dichloroquinazoline
10 were carried out sequentially (Scheme 2.7). Following the previous publica-
tion [119], the first displacement of 10 was done by adding excess cyclic amine
Scheme 2.7: Synthesis of pseudo-symmetric quinazoline derivatives and side-chain
switched derivatives. (i) NHR (excess), 185  C, 30 min. (ii) NHR, methanol, room
temperature. (iii) NH2R, 155
 C, microwave, DIEA in toluene, 14–20 h.
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including 1-methyl piperazine, piperidine, 1-(2-pyridinyl)piperazine and morpholine
in methanol which provided four corresponding compounds 105a-d in moderate to
good yield (21–81%). To optimise the reaction conditions for the second displacement
with 4-amino benzylpiperidine, many conditions were explored (Table 2.2). Likewise,
the conditions of the second displacement of hits, the initial reaction (Entries 1 and
2) was carried out in harsh conditions and short period in a microwave, but the
resulting mixtures were dirty and unable to be separated. The multiple products
were observed by TLC chromatography. The reaction was also carried out under
lower-temperature conditions both with and without the microwave reactor (Entries
3 and 4); however, these conditions were not su cient to drive the reaction for-
ward. Increasing the duration of the reaction using a microwave reactor (Entries
5 and 6) was able to provide a satisfactory amount of products. In the secondary
displacement of the quinazoline reaction, a temperature of 155  C was recommend,
and the reaction was monitored by TLC. The reaction also was carried out without
starting material (Entry 7), and multiple spots were identified by TLC. This might
indicate that 4-amino-1-benzylpiperidine was not stable under these conditions.
Using the our finding conditions, 105a-d were conjugated with secondary amines
including 4-amino-1-benzylpiperidine, 3-amino-1-benzylpiperidine and 1-benzyl-3-
aminopyrrolidine. However, only compounds 106–110 were su ciently pure for
biological testing (> 95% LCMS pure).
Table 2.2: Optimised conditions for the secondary replacement of side-chain switched
derivatives with 4-amino-1-benzylpiperidine
Entry s.m. Condition Result
1 105a 185  C, 30 min, microwave, neat dirty reaction
2 105b 185  C, 30 min, microwave, neat dirty reaction
3 105a 150  C, 100 min, microwave,
DIEA, in 2-propanol
no reaction
4 105a 125  C, 12 h in toluene small conversion + s.m.
5 105a 155  C, 15 h, microwave, DIEA in
toluene
product + s.m. + side products
6 105b 155  C, 14 h, microwave, DIEA in
toluene
product + s.m + side products
7 - amine, 155  C, 14 h, microwave,
DIEA in toluene
multiple spots in TLC
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Design and synthesis of lysine-mimic analogue
To improve the potency of the hits, the concept of adding a lysine-mimicking
functionality was introduced [24, 27, 120]. Evidence to support this hypothesis is
provided by the X-ray crystal structures of GLP-E72 and GLP-monomethylated
H3K9 peptide, which shown that the lysine-mimic molecules can bind the lysine-
binding channel of GLP (Figure 2.6.A). Liu and his colleagues previously showed
that the potency against G9a of the lysine mimic UNC0224 (IC50 = 15 nM, Table
1.1), significantly increased from the potency of the parental compound (IC50 =
330 nM) [24]. This lysine-mimic strategy has been e↵ectively shown in the G9a
study, but not in the EZH2 study yet [120]. Therefore, the biological evaluation of
lysine-mimic analogues against EZH2 would be interesting.
According to this concept, the displacement of the O-7-methoxy groups of the
hits with lysine-mimic substituents are expected to extend into the active site of
EZH2 (Figure 2.4). In addition, norleucine-mimicking analogues were synthesised
along with way for observing the SAR of the nitrogen atom. Therefore, we expect
that the lysine-mimic analogues are able to bind the SET domain more tightly. They
might show more inhibitory activities against all PKMTs, including EZH2, GLP,
G9a, and so on. However, their selectivity among all PKMTs might decrease because
such enzymes contain a lysine-binding channel. In this experiment, compound 3
and BIX-01294 were selected and synthesised as prototype lysine-mimic molecules
against G9a and EZH2.
Following the previous report [121], using benzyl-protected compound 84, the
benzyl-protective group was cleaved to a↵ord phenolic compound 111 in moderate
yield (58%, Scheme 2.8). The debenzylation of the benzyl piperidine moiety was
slowly observed via TLC monitoring, and the product was separated by column
chromatography. In order to mimic a lysine molecule, the phenol 111 was alkylated
with 5-bromo-pentanenitrile, a↵ording nitrile 112 in good yield (83%). The secondary
displacement of nitrile compound 112 was carried out to give compound 113 in good
yield (87%). Finally, the nitrile group was reduced with LiAlH4 to a↵ord lysine-mimic
molecule 114. In comparison with compound 3, the lysine-mimic molecule is more
polar and basic. Therefore, the purification in the final step provided 114 in low
yield (26%).
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Figure 2.6: Design and synthesis of lysine-mimic analogues. (A1) The lysine-binding
channel cavities in the X-ray crystal structures of GLP and E72. (A2) Interaction of
GLP-E72. (B1) and (B2) The docking of compound 3 (blue) and its lysine-mimic
molecule (brown) in the homology modelling of EZH2 [121].
Scheme 2.8: Synthesis of lysine-mimic derivative 114. (i) Pd, H2, EtOH, EtOAc. (ii)
5-Bromo-pentanenitrile, K2CO3, TBAB, acetone, 50
 C, (iii) 1-Methyl piperazine,
toluene, reflux, 48 h. (iv) LiAlH4, THF, 0
 C.
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In order to investigate the lysine-mimic derivatives, more derivatives mimicking
methylated lysine and norleucine were synthesised (Scheme 2.9). Using phenolic
compound 111 as a starting material, the Misunobu and alkylation reactions were per-
formed. For the former reaction, compound 111 was treated with 3-dimethylamino-
1-propanol, DIAD and PPh3 in THF, giving the alkylated product 115a in a good
yield (78%). For the latter reaction, compound 111 was treated with 1-bromo-octane,
potassium carbonate, catalytic TBAB in acetone, giving the alkylated product 115b
in a good yield (76%). This reaction proceeded at slightly high temperature (50
 C), and pleasingly no alkylation of the the quinazoline core was observed. Each
intermediate 115a-b was subsequently coupled with the co-responding amine to
a↵ord the final compounds 116–120 in moderate yields (41–72%), with the exception
of the product of the coupling between 115a and 3-(dimethylamino)-1-propylamine,
which could not be purified.
In addition, aniline 121, which obtained from Dr. Jochim Caron [115], was used
as the starting material. The intermediate 125 was obtained in four steps (20% yield,
Scheme 2.10). The intermediate 125 then was coupled with three di↵erent amines
to a↵ord compounds 126–128 in decent yields (55%, 17% and 53%, respectively).
Scheme 2.9: Synthesis of lysine-mimic derivative 116–120. (i) 3-Dimethylamino-1-
propanol, PPh3, DIAD, THF. (ii) 1-Bromo-octane, K2CO3, TBAB, ccetone, 50
 C.
(iii) Methylpiperazine, toluene, reflux, 48 h. (iv) LiAlH4, THF, 0
 C.
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Scheme 2.10: Synthesis of lysine-mimic derivatives 126–128. (i) ClCOOCH3, DIEA,
DMA/DCM. (ii) H2O2, NaOH, EtOH, room temperature. (iii) POCl3, PhNEt2,
reflux. (iv) Amine, DIEA, THF, room temperature. (v) Amine (neat), microwave,
185  C, 30–60 min
2.2.2 Biological Results and SAR Discussion
Hit validation, ADME studies, MOA and selectivity profiling.
The enzymatic assay. With our collaboration with the Structural Genomic
Consortium (SGC), a PRC2 enzymatic assay was carried out to measure the inhibitory
activities of three initial hits 3–5. This revealed that 3–5 biochemically inhibited the
activity of EZH2 in the low to moderate micromolar range (IC50 = 24 , 16 and, 12 µM,
Figure 2.7). The IC50 value was generated using a scintillation proximity assay (SPA).
This assay qualitatively investigated the activity of EZH2 in the transfer of a tritium-
labelled methyl group from [3H]S-adenosyl-L-methionine (SAM) to a biotinylated-H3
peptide substrate mediated by a trimeric PRC2 complex (EZH2:EED:SUZ12). In
contrast to our preliminary cell-based assay, BIX-01294 and the negative compounds
6 and 7 also showed comparable biochemical inhibitory activities against EZH2 (IC50
= 15 , 6 and, 35 µM).
Indeed, the results of this enzymatic PRC2 assay should be considered carefully
because the short peptide substrates in this assay might be poor models for the
complex chromatin environment in cells. In addition, only the minimal number of
PRC2 members, which are required for enzymatically active EZH2, were used in
this assay. Furthermore, a possible functionality or chemical feature in the negative
compounds might render them inactive due to a non-specific cellular e↵ect such as
cellular permeability and drug e✏ux. Therefore, the ADME study and physical
properties are investigated and discussed in the following paragraph. Finally, there
may be a yet-to-be-determined and functionally important o↵-target. The studies
carried out to identify the underlying mechanism along with o↵-target studies are
discussed in the following section.
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Figure 2.7: IC50 determination for compounds 3–5 against EZH2. These results
were generated by the SGC and the assay condition can be found in the experimental
section
ADME studies. ADME experiments were carried out to investigate the possib-
ility of non-pharmacological specific cellular e↵ects and to evaluate in vitro data.
These ADME experiments, including solubility, Caco-2 permeability and logD, were
performed by Cyprotex, an external company (Table 2.3). Aqueous solubility was
measured using a high-throughput turbidimetric assay. The results showed that
compounds 3, 4, 6 and 7 had high solubilities (> 100 µM), while compound 5
had lower solubility (< 20 µM). Therefore, the precipitation of the negatives in our
cell-based assay is unlikely. For the Caco-2 permeability assay to predict human
intestinal permeability and to investigate drug e✏ux, all hits 3–5 exhibited mid-range
permeability in the apical to bilateral (A-B) direction and higher permeability in
the bilateral to apical (B-A) direction. This resulted in e✏ux ratios (permeability
coe cient of B-A/A-B) of 8.4, 9.6 and 13.6 for compounds 3, 4, and5, respectively,
while the negatives 6 and 7 showed lower e✏ux ratios (1.0 and 4.6, respectively). In
general, an e✏ux ratio greater than 2 in this assay indicates that e✏ux transport-
ers are possibly involved, warranting follow-up transporter substrate identification
studies. Therefore, the e✏ux e↵ects of the negatives are not likely to explain any
non-specific cellular e↵ectd. Lastly, the logD value was measured for each compound.
In general, the optimal range of logD values tends to be between 0 and 3 [122].
Within this rage, a compound is likely to have a good balance between solubility
and permeability. This range also tends to be optimal for cell membrane permeation.
The results showed that the logD values of compound 3 and negative compounds
6–7 were in the optimal range, while those of compounds 4 and 5 were slightly above
the optimal range. On the other hand, negatives 6 and 7 are more polar than hits.
Based on these acceptable logD values, the less lipophilic properties of the negatives
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Table 2.3: In vitro ADME studies of hits 3–5 and negatives 6–7.
Compound Solubility Caco-2 Log D Protein binding Metabolism t1/2
(µM) (e✏ux ratio) (%) (mice:human, hr)
3 > 100 8.4 2.60 34 2:3.5
4 > 100 9.6 3.29 89 0.17:0.63
5 < 20 13.6 3.43 95 0.2:0.5
6 > 100 1.0 0.35 41 2.1:3.5
7 > 100 4.6 0.37 40 0.38:3.4
These data were generated by Cyprotex
is not likely to become a problem. Therefore, according on these ADME experiments,
there did not seem to be an obvious feature or physical property of the negative
compounds that would render them inactive due to a non-specific cellular e↵ect.
Additional experiments included protein binding and in vitro metabolism studies
(Table 2.3). These revealed that compound 3 exhibited a relatively better ADME
profile compared to compounds 4 and 5, including good solubility, low protein binding
(34%) and half-lives in mouse and human liver microsomes of t1/2= 32 and 3.5 h,
respectively. Moreover 4 and 5 had shorter half-lives both in mouse and human liver
microsomes (less than 0.7 h). Therefore, compound 3 was the best representative for
further pharmacokinetic and animal studies.
MOA. Next our collaborator, the SGC, studied the MOA of PRC2 inhibition
by compound 3 via varying the concentrations of the substrate (H3 peptide) and
the cofactor (SAM). As described by the Lineweaver-Burke plot (Figure 2.8.A),
Vmax did not change because Vmax was a function of all EZH2 uniting with the
peptide substrate (H3-21-44). On the other hand, Km changed with changes in the
concentration of compound 3 because it required a higher concentration of the peptide
substrate due to the direct competition of compound 3. MOA was also confirmed
using the competitive assay against SAM (Figure 2.8.B). As shown in the plot, Vmax
changed, while Km did not because Km is constant regardless of the compound 3
concentration. Hence, according to our design rationale and MOA studies, compound
3 was revealed as a unique peptide substrate-competitive inhibitor, unlike the known
EZH2 inhibitors [46, 103, 106, 105].
Selectivity. Next, we determined the selectivities of compound 3-7 over 17 other
methyltransferases (Table 2.4). The e↵ects of compound 3-7 on the methyltransferase
activity of G9a, GLP, MLL1, SETD7, DNMT1, DOT1L, PRMT5, SETD2, PRMT5,
SETD2, PRMT1, SMYD2, WHSC1, PRMT3, SETD8, SUV420H1, SUV420H2
60
Figure 2.8: MOA studies of compound 3. (A) The competitive assay against
peptide substrate (H3 21-44). (B) The competitive assay against SAM shown in the
Lineweaver-Burke plot. These data were generated by the SGC and the assay details
can be found in the experimental section.
and SETDB1 were assessed by monitoring the incorporation of the tritium-labelled
methyl group in the lysine or arginine residues of peptide substrates using scintillation
proximity assay (see experimental section). Since our compounds were derived from
BIX-01294, a G9a/GLP inhibitor, they still retained inhibitory activities against G9a
and GLP in the low-molar range. No significant inhibition was observed for all other
enzymes, with the exception of the slight inhibition of SETD2, PRMT1 and SMYD2
by compound 6. These data suggested that our hits also inhibited G9a/GLP along
with EZH2.
Finally, all three hits 3–5 and negatives 7-8 were re-evaluated using our phen-
otypic assay along with BIX-01294, UNC0638 and GSK343. The hits still showed
activities for up-regulating KRT17and FBXO32 mRNA levels at doses of 10 µM
(Table 2.5). The reported G9a-specific inhibitors BIX-01294 and UNC0638 revealed
di↵erent e↵ects on the expression of the target gene, even though they were struc-
turally closely related to our hits 3–5. BIX-01294 did not up-regulate KRT17 but
up-regulated FBXO32. These results were consistent with previous reports [123]
showing that many mechanisms and factors can regulate FBXO32. At concentrations
up to 10 µM, the selective EZH2 inhibitor GSK343 had no e↵ect on all the target
genes when examined up to 72 h following treatment.
This evidence combined with prior works in the group suggests that we have
identified the EZH2 inhibitors with G9a inhibitory activities (i.e., the so-called dual
EZH2 and G9a inhibitors). The specific G9a inhibitor UNC0638 or the specific
EZH2 inhibitor GSK343 could not reactivate EZH2 target genes in the cell line.
More importantly, these hits represent the uniquely targeting EZH2 substrate pocket.
This demonstrated our concept for designing known substrate-competitive HKMT
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Table 2.4: The selectivities of hits 3–5 and negatives 6–7.
Protein
IC50 µM
3 4 5 6 7
G9a 0.101±0.010 0.47±0.017 3.190±0.080 8±2 23±5
GLP 3±0.5 >100 3±0.5 0.4±0.03 0.7±0.04
MLL NI NI NI NI NI
SETD7 NI NI NI NI NI
SUV39H2 NI NI NI NI NI
DNMT1 NI NI NI NI NI
DOL1L NI NI NI NI NI
PRMT5 NI NI NI NI NI
SETD2 NI NI NI >50 NI
PRMT1 NI NI NI 50±12 NI
SMYD2 NI NI NI >25 NI
WHSC1 NI NI NI NI NI
PRMT3 NI NI NI NI NI
SETD8 NI NI NI NI NI
SUV420H1 NI NI NI NI NI
SUV420H2 NI NI NI NI NI
SETDB1 NI NI NI NI NI
These data were generated by the SGC and the assay details can be found in the experimental
section. NI = no inhibition (>1000 µM)
inhibitors targeting other HKMTs (Figure 2.2.B), although our selective data revealed
EZH2 and G9a/GLP to be the sole HKMT targets of our hits. Interestingly, the
small changes in the chemical structure of the prototype BIX-01294 allow our hits
to function as dual inhibitors. Indeed, the significant EZH2 inhibitory activities of
known the specific G9a inhibitors including UNC0638 and UNC0642 have not been
reported [29, 30].
Screening of new quinazoline derivatives
The new quinazoline analogues were screened using in vitro and in vivo assays carried
out by the SGC and Professor Brown’s group, respectively. IC50 was determined for
the top ranked compounds and those for which the percentages of enzyme activity
were below 28% and 50% for G9a and EZH2, respectively. Herein, the biological
results are reported and discussed according to the structures of the new derivatives:
(1) cyclic amine at position 2; (2) amino-benzyl piperazine at position 4; (3) pseudo-
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Table 2.5: RT-PCR data for a single dose of a panel of HKMT inhibitor compounds.
Compound KRT17 FBXO32 JMJD3 EZH2 Comment
3 4.05 3.65 3.12 0.63 Hit
4 4.23 39.4 11.56 0.21 Hit
5 6.95 33.25 6.25 0.22 Hit
6 0.66 1.12 1.57 0.86 Negative
7 1.32 1.06 0.9 1.38 Negative
8 0.78 0.93 0.87 0.13 Negative
BIX-01294 1.06 3.34 2.7 0.87 G9a/GLP inhibitor
UNC0638* 1.1 5.5 3.4 0.4 G9a/GLP inhibitor
GSK343 0.9 1.2 1.0 1.0 EZH2 inhibitor
These data were generated by Brown group. RNA levels for target genes are normalised against
the housekeeping gene GAPDH. The fold increase compared to the mock treated sample is shown.
*UNC0638 treatment at 7.5 µM; all other compounds are given at 10 µM [113]
symmetric quinazoline derivatives and side-chain switched derivatives; (4) modified
benzenoidderivatives at positions 6 and 7; and (5) lysine- and norleucin-mimic
derivatives.
SAR and biological results for modified cyclic amine at position 2 (R1).
The 2-amino moiety of the quinazoline sca↵old was explored first (Table 2.6). 1-
Methyhomopierazine BIX-01294 and para-N pyridyl piperazine 35 exhibited the
highest potencies against G9a and EZH2, respectively. 1-Methylhomopiperazine
could be replaced with the methylpiperazine 3 without significant potency loss for
both G9a and EZH2. Replacing methylhomopiperazine 1 with piperidine 4 and
pyridyl piperazine 5 led to a slight loss of inhibitory activity against G9a but not
against EZH2.
When the nitrogen atom of 1-methyl piperazine 3 was replaced with a carbon
atom 25, the inhibitory activities against both G9a and EZH2 significantly decreased.
In term of G9a, this is because the nitrogen atom of piperazine ring is important for
establishing the salt bridge with Asp1074 (Figure 2.9). Likewise, the introduction of
dimethyl piperidine 36 dramatically decreased the inhibitory activities against both
G9a and EZH2.
A small series of amines were synthesised to explore the SARs of cyclic amines
containing 4-, 5-, 6- and 7-membered rings (12, 13, 4, and 15, respectively). With
the exception of azetidine 12, which significantly lost its activities against EZH2 and
G9a, the ring-size modifications to the 2-amino region were well tolerated on G9a
and EZH2.
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Figure 2.9: The comparison SAR of G9a and EZH2 with their most potent inhibitors,
compound 117 and 35, respectively.
The pyridine nitrogen positions (ortho-, meta- and, para- in compounds 5, 34
and 35, respectively), a↵ected the inhibitory activities against both G9a and EZH2.
Among these compounds, para-N pyridine 35 showed the greatest inhibitory activities
against G9a and EZH2. Removing the nitrogen in the pyridine ring, phenyl piperazine
17 significantly lost its inhibitory activity against EZH2 but not against G9a.
A variety of functional groups were introduced to piperazine at the 2 position. For
example, methyl-carboxylate- 29, dimethylamino- 30, acetyl- 31, cyclopropyl- 32,
and benzoyl-piperazine all led to losses in potency against both G9a and EZH2. In
addition, Boc piperazine 16 and 3,5-dimethylpiperidine 36 exhibited lower potencies
than our hits against G9a; however, their inhibitory activities against EZH2 were
not evaluated.
In summary, the nitrogen atom in the piperazine ring was important for maintain-
ing the inhibitory activity against G9a, but not against EZH2. In general, the SAR
on G9a was in agreement with the previous literature [24]. Furthermore, variation in
the size of the piperazine ring from five to seven members was well tolerated by both
enzymes. The preferable positions for the nitrogen atom in the pyridine ring in terms
of activity against both G9a and EZH2 were para, ortho, and meta (Figure 2.9).
SAR and biological results of modified benzyl piperazine at position 4
(R1). The selected derivatives containing 1-methyl piperazine at the 2 position
and a variety of substituted amines at the 4 position are presented in (Table 2.7).
Benzylpiperidne 3 showed the highest inhibitory activities against G9a and EZH2.
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Table 2.6: SAR of 2-amino moiety.
G9a EZH2 G9a EZH2 IC50 (EZH2/G9a)
BIX-01294 (1) 6 25 0.067±0.003 15 224
3 5 53 0.101±0.010 24±2 238
4 7 48 0.472±0.017 16±1 34
5 15 50 3.190±0.080 12±0.5 4
12 27 60 0.489 ND ND
13 7 22 0.166 17 102
14 5 44 0.332 28 84
15 18 62 ND ND ND
16 30 75 0.11 ND ND
25 7 77 1.326 ND ND*
29 11 90 ND ND ND
30 5 43 0.506 24 47
31 10 90 ND ND ND
32 8 45 ND 59 ND*
33 18 86 ND ND ND
34 12 91 ND ND ND
35 6 33 0.338 8 24
36 22 100 ND ND ND
Selectivityat 50 µM
Enzyme Activity (%)
Compound
IC50 (µM)
N
N
N
N
N
N
N N
N
N
N
N
NBoc
N
N
N
N
O
O
N
N
N
O
N
N
O
N
N N
N
N
N
N
R1
N
N
NH
R1O
O
NPh
ND = not determined, * cannot be calculated. These data were generated by the SGC and the
assay details can be found in the experimental section
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Replacing the benzyl group of piperidine with the para, metha, and ortho fluorine-
substituted deivatives (18, 21, and 23, respectively) resulted in no potency loss for
both G9a and EZH2. In the same fashion, the meta-methoxy analogues 24 showed
similar inhibitory activities against both G9a and EZH2. This result for G9a was
consistent with the X-ray crystal structure of the GLP-BIX-01294 complex (PDB:
3FPD, Figure 1.3); the benzyl group of BIX-01294 was outside of the substrate
pocket, and no interaction was found.
Replacing the benzyl group of 3 with acetyl 43 and methoxypropanoyl 67 groups
resulted in slight losses in potency against G9a and dramatic losses against EZH2.
The relocation of N -benzyl 51 and ring contraction to pyrrolidine 60 also caused the
slight losses in inhibitory activity. Finally, replacing benzylpiperidine with benzene
37 led to the complete loss of inhibitory activities against both G9a and EZH2 and
this might stem from the e↵ect of hydrogen atom of secondary nitrogen at position 4
(Figure 2.9).
In short, slight modifications to the benzyl piperidine side chain were well tolerated
in terms of the inhibition of G9a and EZH2. The piperidine ring was also important,
and slight alterations in the size of the ring and the location of the N -benzyl group
were tolerated. The general SAR of G9a and 4-amino quinoline was consistent with
a previous report [24]. In addition, we showed that the SAR of EZH2 and 4-amino
quinoline followed the same trend.
SAR and biological results of modified benzenoid derivatives. The modi-
fied benzenoid derivatives were evaluated for their inhibitory activities against G9a
and EZH2 (Table 2.8). 7-Benzyloxy 85-88, 6,7-dibenzyloxy 89–92, dioxol 93–96
and desmethoxy 97-100 were found to be far less active against G9a and EZH2.
The loss of potency against G9a was in agreement with a recent report on related
analogues [109].
A number of theoretical and experimental studies have shown that ortho- dimeth-
oxybenzenes prefer to adopt co-planar conformations with the sp2 oxygen lone pairs
projecting towards each other and the corresponding methyl groups angled away
from each other. Indeed, such a conformation is apparent in the inhibitor-G9a/GLP
crystal structures (such as PDB 3FPD (Figure 1.3), 3K5K (Figure 1.4.A1), and
4NVQ (Figure Figure 1.4.B1)). Thus, in dioxols 93–96 (Table 2.8), the oxygen lone
pairs were forced to point in the opposite direction. Interestingly, these derivatives
were found to be largely devoid of G9a inhibitory activity, suggesting that the con-
formational preference of the dimethoxy functionality is important for G9a and EZH2
activities.
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Table 2.7: SAR of 4-amino moiety
G9a EZH2 G9a EZH2 IC50 (EZH2/G9a)
3 6 53 0.101±0.010 24±2 238
18 6 52 0.112 ND ND*
21 5 50 0.132 51 386
23 6 61 0.116 ND ND*
24 7 57 0.128 ND ND*
37 79 87 ND ND ND
43 13 97 ND ND ND
51 7 79 ND ND ND
60 6 50 0.344 78 227
67 10 78 ND ND ND
SelectivityCompound
Enzyme Activity (%)
IC50 (µM)
at 50 µM
N
N
F
N
F
N
F
N
O
N
N
Ph
N
O
O
NO
R2
N
N
NHR2
NO
O
N
ND = not determined, * cannot be calculated.
These data were generated by the SGC and the assay details
can be found in the experimental section.
SAR and biological results of pseudo-symmetric and switched side-chain
derivatives. The pseudo-symmetric 103 and the switched side-chain 106, 107,
109 and, 110 were screened at 50 µM against G9a and EZH2 (Table 2.9). The double
pyridyl piperazine 103 completely lost its inhibitory activities against G9a and EZH2
compared to the parental 5. On the other hand, the potency of 106 against G9a was
significantly reduced, while that against EZH2 was slightly decreased (63% activity)
compared to the parental 4. In addition, pyrrolidine 107 exhibited lower potency
against both G9a and EZH2 compared to piperidine 106. Likewise, pyridylpiperzine
109 and 110 lost their potencies for both G9a and EZH2.
These results showed that the binding mode of quinazoline derivatives and G9a
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Table 2.8: SAR of benzenoid derivatives
 moeity G9a EZH2 G9a EZH2
85 42 95 ND ND
86 92 91 ND ND
87 77 105 ND ND
88 98 112 ND ND
89 94 88 ND ND
90 102 93 ND ND
91 68 91 ND ND
92 103 90 ND ND
93 63 76 ND ND
94 78 93 ND ND
95 109 96 ND ND
96 94 99 ND ND
97 27 77 ND ND
98 72 60 ND ND
99 97 82 ND ND
100 18 39 ND 54
Compound
Enzyme Activity (%)
Benzenoid at 50 µM
IC50 (µM)
BnO
O
N
N
N
N
N N
N
O
N
N
N
N
N N
N
O
N
N
N
N
N N
N
O
N
N
N
N
N N
N
N
BnO
BnO
O
O
R
1
N
N
NH
NPh
R1
Benzenoid
moeity
ND = not determined. These data were generated by the SGC
and the assay details can be found in the experimental section
was restricted on G9a. In particular, the NH group at position 4 was important for
maintaining the inhibitory activity against G9a, which is in agreement with previous
studies [24, 104]. On the other hand, it was di cult to reach the same conclusion
about the SAR of EZh2 due to the limited analogues and the low potencies of our
inhibitors.
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Table 2.9: SAR of a pseudo-symmetry derivative and switched side-chain derivetives
G9a EZH2 G9a EZH2
103 88 91 ND ND
106  39 63 ND ND
107 67 78 ND ND
109 44 63 ND ND
110 49 90 ND ND
Compound
Enzyme Activity (%)
Structure at 50 µM
IC50 (µM)
N
NO
O
N
N
N
N
N
N
N
N
O
O
N
H
N
N Ph
N
N
O
O
N
H
N
N
Ph
N
N
O
O
N
H
N
N
N
Ph
N
N
N
O
O
N
N
H
N N Ph
N
ND = not determined. These data were generated by the SGC
and the assay details can be found in the experimental section
SAR and biological results of lysine and norleucin derivatives. Lysine-
mimic derivatives 116–117 and norleucin-mimic derivatives 118–120 and 126–128
were evaluated for their inhibitory activities against G9a and GLP but not EZH2
(Table 2.10). As expected, the lysine-mimic derivatives 116 and 117 showed better
potency for the inhibition of G9a and GLP than the parental compounds (1 and 3).
Compound 117 with methylhomopiperazine as R1 exhibited the highest inhibitory
activity. In contrast, the norleucine derivatives 118–120 and 126–128 significantly
loss both G9a and GLP inhibitory activities, compared to the the parental compounds
(1 and 3). Among the norleucine derivatives, hexoxy 126–128 was more potent than
octoxy 118-120. These compounds are likely equipotent in the inhibitions of G9a
and GLP.
The SAR studies of lysine-mimiclimg analogues on the inhibition of both G9a
and GLP have been reported [24, 30, 27]. The reported X-ray crystal structures
of GLP and E72 indicated the presence of lysine-binding channel cavities (Table
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2.6). Replacing the aminoalkyl (lysine) moiety with alkyl (norleucine) resulted in
the loss of a hydrogen bound between an amino group and the corresponding serine
(Leu1086 for G9a and Ser1141 for GLP). Therefore, the loss of potency in norleucin
analogues 118–120 and 126–128 was in agreement with the previous reported SAR
of G9a/GLP. Therefore, moving forward, the evaluation of lysine and norleucin
analogues against EZH2 suggests the possibility of introducing lysine-mimic moieties
to our future analogues (Figure 2.9).
Table 2.10: SAR of lysine/norleucin-mimicking derivatives
Selectivity
G9a GLP IC50 (G9a/GLP)
BIX-01294 (1) Me 101±10 3000 0.04
3 Me 67±3 NA NA
116 8 11 0.73
117 <2.5 <2.5 ND
118 1018 1127 0.90
119 211 498 0.42
120 185 200 0.93
126 114 78 1.46
127 29 27 1.07
128 39 29 1.34
Compound
 
IC50 (nM)
N
NR2O
O
NH
NPh
R1
R2 R1
N
7
5
N
N
N
N
N
N
N
N
H
N
N
N
N
N
N
H
N
N
N
N
N
N
NA = not available, ND = not determined.
These data were generated by the SGC and the assay details
can be found in the experimental section
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2.2.3 qRT-PCR Phenotypic Screening
In light of the preliminary data, compound 3–5 showed inhibitory activity against
EZH2 via the re-expression of KRT17 and FBXO32 genes, which are known to be
silenced in an EZH2-dependent manner [100]. Our collaborator set up a phenotypic
screening assay using a 10 µM treatment of MDA-MB-231 to observe the ability of
our analoges to reactivate KRT17 and FBXO32 (The assay details can be found in
the experimental section). If toxicity was observed as judged by GADPH, the lower
doses (5 and 1 µM) were subsequently tested. The JDJM3 and EZH2 RNA levels
were also investigated, as for the previous hits. When compounds were classified as
positive (defined by the re-expression of KRT17 and FBXO32 genes without any
toxic e↵ect), they were repeatedly evaluated using qRT-PCR at five concentrations
(10, 7.5, 5, 2.5, and 1 µM) in order to confirm dose-dependency. They were also
tested using MTT assay to observe the toxicity in MDA-MB-231 cells; the details of
the screening protocol can be found in the experimental section.
In our screening, eight compounds that reactivated KRT17 and FBXO32 at 10
µM were identified as positive. Subsequently, their dose-dependent characteristics
were evaluated at various concentrations (Figure 2.10) followed by testing by MTT
assay (Table 2.11). All compounds showed toxicity in the intermediate micromolar
range (IC50 = 4.75–12.57 µM), although none exhibited toxicity. Compound 28
could not reactivate both EZH2 target genes. Compounds 36, 54, and 64 reactivated
FBXO32 but had no e↵ect on KRT17. Four compounds (51, 52, 60, and 61) showed
dose-dependent reactivation of KRT17 and FBXO32; therefore, we discovered four
new hits from the cell-based assay (Figure 2.10).
According to the cell-based assay data, the new hits 51, 60 and 61 showed that
the slight change to the benzyl piperidine ring (R2) was well-tolerated (Table 2.11).
The inhibitory activities against G9a of 51, 60 and 61 were still retained (%inhibition
at 50 µM = 7, 6, and 9%, respectively). On the other hand, only compound 60
exhibited the moderate inhibitor activity against EZH2 (IC50 = 78 µM).
Conclusion
The synthetic routes for quinazoline derivatives were straightforward and successful.
Previously reported methods were followed and optimised [24, 27, 104, 124]. The
preliminary hits 3–5 were re-synthesised on multi-gram scales. A total of 50 final
compounds were synthesised, and an additional 52 compounds were obtained from
SAI Chemical Ltd. Therefore, over 100 compounds were added into our focused
chemical library.
Our collaborator evaluated the quinazoline derivatives using an enzymatic assay.
The results revealed the e↵ects of SAR on inhibitory activities against G9a and EZH2.
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The importance of the 6,7-diomethoxy group and the tolerance of benzyl piperidine
on position 4 followed the same trend on both G9a and EZH2. The modification
of the benzenoid ring led to dramatic losses in EZH2 and G9a inhibitory activity
except for in the lysine-mimic compound 177, which showed enhanced inhibitory
activity. Notably, 177 has not yet been tested in the EZH2 assay. Furthermore, the
2-amino substituents showed the di↵erent SARs with EZH2 and G9a (Table 2.6).
The pocket of EZH2 might be larger than that of G9a, and the addition of para-N
pyridine (compound 35) slightly increased the inhibitory activity against EZH2 and
G9a. Moreover, the nitrogen of the piperazine ring is necessary to form electrostatic
bonds with Asp1074, but it is not important for EZH2 inhibitory activity.
In our phenotypic screening assay, four compounds (51, 52, 60, and 61) were
discovered as new hits. These compounds showed similar reactivation patterns for
KRT17 and FBXO32 RNA levels in a dose-dependent manner. They also exhibited
low toxicity profiles. The SARs of the new hits were not consistent with those from
the enzymatic assay. However, the pharmacokinetic properties of the hits need to
Figure 2.10: qRT-PCR results of four new hits.
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These data were generated by Prof Brown Group and the assay detail can be found in the
experimental section.
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Table 2.11: qRT-PCR, SPA, and MTT results eight positive compounds.
 Cell-based 
Screening
G9a EZH2 G9a EZH2 IC50 (µM)
28 NA NA NA NA 8.08 Not Hit
36 22 100 ND ND 6.63 Not Hit
51 7 93 ND ND 8.81 Hit
52 NA NA NA NA 8.14 Hit
54 10 65 ND ND 4.75 Not Hit
60 6 50 0.344 78 12.57 Hit
61 9 80 0.83 ND 9.15 Hit
64 7 77 ND ND 9.06 Not Hit
Compound
Enzyme Activity (%)
IC50 (µM)
at 50 µM
MTT
R2R1
N
NO
O
R1
NH
R2
N
N
N
O
NPh
NPh
NPh
N
N
N
Ph
N
PhN
N
N N
Ph
N
N
N
NPh
N
N
N
N
NA = not available and ND = not determined.
These data were generated by SGC and Prof Brown Group
and the assay detail can be found in the experimental section.
be characterised, and several factors in a cell-based assay might be involved such as
o↵-target e↵ects.
2.3 Target and O↵-Target Identification of Hits
Our preliminary results suggested that the three hit compounds 3–5 reactivate EZH2
target genes in our cell-based assays. However, in the enzymatic assay, both hits and
negatives showed inhibitory activities against EZH2 in the low-molar concentration
range. These results led us to question why the negative compounds 6–8 are negative
in the cell-based assay. Furthermore, the in vitro ADME studies did not provide a
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conclusive reason, such as poor cellular permeability or high metabolism, as to why
the negatives were inactive. These results might indicate the possibility of o↵-target
e↵ects for the hits in our cell-based assay. Therefore, in this section, we initiated
two techniques: chemo-informatics and chemical probes to attempt to identify the
o↵-target proteins.
2.3.1 Activity-Based Protein Profiling (ABPP)
ABPP has been introduced as a powerful chemical proteomic profiling method to
analyse the functional states of proteins in a complex proteome [125]. The general
design of activity-based probes (ABPs) consists of a binding group and an analytical
handle, which are connected by a linker. The binding group relies on irreversible
binding to the protein’s active site. The analytical handle, which may be a fluorophore
or biotin, is used for the visualisation and characterisation of the target protein,
respectively (Figure 2.11A).
Figure 2.11: AfBP. (A) Anatomy of AfBPs and initial design. (B) Workflow of
Af BPs.
74
The installation of a photo-active group is required to irreversibly bind the
protein targets because our hits lack the intrinsic reactivity to form covalent bonds
with proteins. Low solubility and low cell permeability are serious concerns for
probes in general as these characteristics limit applicability of the probe in profiling
proteins in living cells. These problems often stem from the bulky analytical handle.
Moreover, a bulky handle can disturb the interaction between the binding group
and the target protein. In order to avoid the abovementioned problems, in situ
proteome reactivity profiling via click chemistry, which disconnects the binding and
analytical handles, represents a powerful approach to identify a target proteome in
cell-based screening [125, 126, 127, 128]. This technique is known as a nity-based
probe profiling (AfBPs). In our initial design, the probe contains five parts: an
inhibitor, a photo-reactivity group, a clickable tag, a linker, and a functional handle
(Figure 2.11A).
In the AfBP technique (Figure 2.11B), cells are treated with clickable probes
without analytical handles, allowing target proteins to recognise the reversible
inhibitor. Subsequently, the photo-reactive group is activated by light and cross-links
with the protein. Finally, a clickable tag with the analytical handle is added to
generate azide-alkyne cyclo-addition followed by further analyses such as SDS-PAGE
and mass spectrometry. Recently, several studies have been published on the profiling
of epigenetic enzymes using AfBPs [129, 130, 131]. Based on our cell-based assay
and ADME data, compound 3 was chosen to develop an Af BP prototype.
2.3.2 Initial Studies for Design and Synthesise Photo-A nity Based
Probe
Scheme 2.11: Compound 3 and the initial design for ABPP derivatives
We planned to modify three side chains (R1, R2, R3) to explore the chemical
space in which a long alkyl chain and other Af BP moieties may be attached (Scheme
2.11). This would allow us to understand the site within our hits at which the
photo-reactive group could be attached. Although the SARs of G9a were explored as
described in the previous section, the SARs of EZH2 was still not fully understood.
Therefore, the modified compounds with the bulky group should still exhibit their
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inhibitory activity against G9a and EZH2 in the enzymatic assay and they should
be able to reactivate EZH2 target genes. From this experiment, the chemical space,
especially the solvent-exposed site, and the SAR might be explained by the variation
in the length, size and shape of R.
Synthesis of R1-modified derivatives
After designing the small chemical library based on compound 3 (Scheme 2.11), the
bulky R1-modified derivatives were synthesised. Initially, we planned to prepare a
piperazine quinazoline derivative 129 for the subsequent alkylation step (Scheme 2.12).
First, using the previous synthetic compound 15 (Scheme 2.1), the Boc-protecting
group was removed using TFA/DCM to obtain de-protected compound. However, the
final alkylation step at room temperature failed due to over-alkylation, as determined
by mass spectroscopy. We tried the reaction at lower temperatures (0  C) with a
1 : 1 equivalent of bromo-alkylating reagent and quinazoline derivative 16. However,
the over-alkylation still occurred, and the mono-alkylated and bi-alkylated products
were not separated.
Scheme 2.12: The unsuccessful synthetic route for the R1 modified derivatives
An alternative route would be to modify the R1 position of the piperazine
derivative prior to the alkylation of 2-chloro-quinazoline 11 (Scheme 2.13). First,
the modified amines were prepared from 1-Boc-piperazine. 1-Boc-piperazine was
alkylated with benzyl bromide and (6-chlorohexyl) benzene in the presence of Triton-
B followed by the removal of the Boc group with TFA, giving compounds 129a and
129b in low yields over two steps (27% and 10%, respectively). The low overall
yield was attributed to the alkylation step due to a purification issue despite the
completion of the reaction. Compounds 129a and 129b were then reacted with
quinazoline 11 under reflux in toluene for 36–48 h, yielding final compounds 130
and 131 (32% and 72%, respectively).
Synthesis of R2-modified derivatives
In an attempt to modify the R2 position (Scheme 2.14), the previously prepared
7-hydroxyquinazoline 111 was used as a staring point. Next, 111 was alkylated
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Scheme 2.13: The synthesis routes for the R1 modified derivatives. (i) Alkylating
agent, Triton-B. (ii) TFA, DCM. (iii) compound 11, toluene, reflux.
with 1-bromo-4-phenylbutane using potassium carbonate with TBAB as a catalytic
agent, giving compound 132 in moderate yield (41% yield). Compound 132 was
then conjugated to the methyl-piperazine under reflux in toluene, providing the final
compound 133 in good yield (75%).
Scheme 2.14: The synthetic routes for the R2 modified derivatives. (i) 1-Bromo-4-
phenylbutane, K2CO3, TBAB, ccetone, 50
 C. (ii) Methyl-piperazine, toluene, reflux,
36 h.
Synthesis of R3-modified derivatives
The synthesis of R3-modified analogues was first attempted by constructing a sec-
ondary amine piperidine quinazoline sca↵old and then alkylating piperidine with
di↵erent alkyl bromines to obtain R3 analogues. However, the over-alkylation of
the R1 position suggested that the same problem may also occur in these reactions
(Scheme 2.15).
To avoid over-alkylation, orthogonal protection of the amine starting material
was carried out (Scheme 2.16). Compound 3 contains a benzyl group, which can be
removed using Pd/H2. Hence, the other protecting group should be stable under
Scheme 2.15: The possibility of R3 over-alkylation
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Scheme 2.16: The synthetic route of R3 modified analogues via an orthogonal
protection method.
such conditions. Unfortunately, our preliminary results revealed that this strategy
was not successful. The protection of the secondary amine with the Boc group or
acetyl groups was unsuccessful, possibly due to a steric e↵ect in that region.
However, the alternative pathway involving the preparation of 4-aminopiperazine
derivatives did prove successful (Scheme 2.17). 4-Amino-1-benzylpiperidine was
treated with di-tert-butyl dicarbonate to give the Boc-intermidiate in moderate yield
(43%). The hydrogenolysis of the intermediate with catalytic Pd/C provided com-
pound 134 in good yield (91%). Subsequently, 134 was alkylated with either 1-bromo-
4-phenylbutane or 4-(bromomethyl)-benzophenone followed by Boc-deprotection to
a↵ord 135a and 135b in 32% and 63% yields, respectively. They were then reacted
with 2,4-dichloro-6,7-dimethoxyquinazoline 10 to give 136a and 136b in 49% and
60% yields, respectively. Subsequently, the compounds were conjugated to 1-methyl-
piperazine under reflux in toluene, providing the final compounds 137 and 138 in
moderate yields (55% and 56%, respectively).
Scheme 2.17: The synthetic routes for the R3 modified derivatives. (i) Boc2O, MeCN.
(ii) Pd, H2, methanol. (iii) alkylating agent, TEA, DCM. (iv) TFA, DCM. (v) 10,
DIEA, THF, room temperature. (vi) 1-Methyl piperazine, toluene, reflux.
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Table 2.12: The inhibitory activity of R1, R2, and R3 modified quinazoline derivatives
against G9a and EZH2 in SPA.
G9a EZH2 G9a EZH2
3 Me Me 5 53 0.101±0.010 24
17 Ph Me 30 75 0.11 ND
131 Me 19 77 ND ND
85 Me 42 95 ND ND
133 Me 43 73 ND ND
137 Me Me 6 42 0.071 49
138 Me Me 8 83 1.104 ND
IC50 (µM)
Compound  
Enzyme Activity (%)
at 50 µM
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N
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ND = not determined. These data were generated by SGC
and the assay details can be found in the experimental section
Biological results and discussion
The newly synthesised compounds along with the previously synthesised and related
compounds, including 3, 17, 85, 129-131, 133, and 137-138, were screened by
both SPA assay (Table 2.12) and phenotypic screening assays (Table 2.13) by our
collaborators SGC and Professor Brown’s group, respectively.
According to the SPA results, R3-modified compound 137 maintained inhibitory
activity against G9a (IC50 = 0.071 µM) but lost half of its activity against EZH2
(IC50 = 49 µM) compared to compound 3. In contrast, the other R3-modified
compound 138, which bears a benzoquinone moiety, maintained its activity against
G9a (IC50 = 1.104 µM) but completely lost its inhibitory activity against EZH2. The
rest of the bulky group conjugated compounds showed no strong inhibition towards
G9a and EZH2.
These results reveal that it is possible to install the handle group at the R3 position,
and that the modified compounds are likely to retain their inhibitory activity against
G9a. These results were supported by recent studies using a G9a/GLP chemical
probe, UNC0965 [31]. UNC0965 contained the bulky group at the 4 position of the
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quinazoline core and docking of UNC0965 in G9a showed that its bulky group was
exposed to the solvent site (Figure 2.12.B). However, the selectivity of UNC0965
towards EZH2 has not been reported, which might imply that UNC0965 cannot
inhibit EZH2 due to the selectivity profile of UNC0638 as a prototype (Figure
2.12.A) [29]. In summary, the R3 position should be a suitable position for installing
the handle group for Af BP studies because the inhibitory activities against G9a and
EZH2 are retained.
In comparison with the other ABP EZH2 probes, the indazole derivatives
UNC2239 and UNC2300 (Figure1.11) [104]. bind EZH2 in a co-factor pocket,
unlike the studied quinazoline analogues. Furthermore, the indazole EZH2 inhibitor
GSK343 did not reactivate EZH2 target genes in our phenotypic assay (see Chapter
2, Table 2.5). Therefore, the published EZH2 probe would not be able to identify
the underlying mechanism and the expected o↵-target protein.
The synthesised compounds were also evaluated in our phenotypic screening assay
(Table 2.13); the results showed that all compounds were negative. Most of them
showed a high GAPDH at 10 µM; the GAPDH then became negative upon reducing
the dosing. For example, compounds 137 and 138 were able to reactivate KRT17
and FBXO32, but the GAPDH range was not acceptable, possibly due to confounding
factors related to its toxicity at 10 µM. When the dosing was subsequently reduced
Figure 2.12: (A) The structure and IC50 of compound 137, UNC0638, and UNC0965.
(B) The docking of UNC0638 and G9a. Modified from [31].
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Table 2.13: The results of phenotypic screening.
Compound Conc. KRT17 FBXO32 JMJD3 EZH2 Comments
3 10 4.5 3.6 3.1 0.6 positive
17
10 2.88 7.97 5.72 0.40 high GAPDH
5 3.2 13.8 0.8 7.3 high GAPDH
1 1.2 1.0 24.1 0.5 negative
130 10 1.0 1.2 1.3 0.8 negative
131
10 - - - - toxic (undetechable)
5 1.2 1.1 34.2 0.5 negative
85
10 2.2 18.3 0.6 4.1 high GAPDH
5 1.4 1.1 3.3 0.5 negative
133
10 - - - - toxic (undetechable)
5 5.4 12.6 201.5 0.1 high GAPDH
1 1.9 1.6 1.1 1.3 negative
137
10 5.8 7.6 6.6 0.5 high GAPDH
5 3.5 1.4 35.7 0.3 negative
138
10 3.3 5.9 2.8 0.3 high GAPDH
5 1.7 1.0 14.6 0.5 negative
These data were generated by Professor Brown’s Group and the assay details can be found in the
experimental section.
to 5 µM, both compounds were not able to reactivate either FBXO32 or KRT17.
Notably, it has been reported that UNC2239 and UNC2300 lose more than half of
their EZH2 inhibitory activities against EZH2 based on the biochemical assay results
(Table 2.12). Hence, these compounds did not reactivate the EZH2 target genes at
the lower dose.
2.3.3 Chemoinformatic Tools for Identifying a Target Protein: Sim-
ilarity Ensemble Approach
In order to identify target molecules, we use Similarity Ensemble Approach (SEA), a
chemoinformatic search tool, to match our hit molecules with available bioactive mo-
lecules in the databases. ChEMBL, a 2D, open-access, bioactive database containing
the chemical structures, calculated physiochemical properties and biological activities
of over 700,000 small molecules, has been developed (https://www.ebi.ac.uk/chembldb).
This website is a tool that can be used to search for bioactive small molecules with
structures similar to the hit compounds. The compounds in this database are mostly
extracted from primary articles published in the field of drug discovery. In addition,
ChEMBL data can also be integrated with PubChem BioAssay data to increase the
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total amount of searched compounds.
ChEMBL used as a primary tool to identify possible o↵-target protein binding of
the hit molecules. The greater the similarity of our hits to molecules in the database,
the greater the possibility that the o↵-target proteins can be found. In our initial
search, the criteria for finding a molecule in the database similar to the hit compound
is a chemically similarity of more than 90%. In addition, the assay used to evaluate
the compounds in the database must be suitable for our study.
Searching o↵-targets inspired by ChEMBL
Initially, the structures of three hit molecules, 3, 4, and 5, were used as starting
points to search for compounds with well defined biological activities that share
>90% similarity with the hit molecules.
The resulting compounds were mapped based on their biological activities, and
representative compounds were selected from the primary literature for each category
(Figure 2.13). We found the following four interesting and suitable categories that
share similar structures and may a↵ect the gene-expression process: G9a, C-C
chemokine receptor type 4 (CCR4), transforming growth factor beta (TGF- ), and
adrenergic receptor inhibitors.
We also identified a few further clusters of bioactive molecules; however, these
groups were ignored because they kill Giardia lambila and a group of inactive Human
Flap endonuclease 1 inhibitors: compounds 3 and 4 were reported to be inactive
against human flap endonuclease 1 and polymerase Iota. Human flap endonuclease 1
and polymerase Iota classes are of lower priority than the other four classes.
In addition to the data obtained from the ChEMBL data base, a kinase inhibitor
group was included in our consideration. Although the structures of the kinase
inhibitors (Gefitinib) [132] and CDK2 inhibitors [133] are not highly similar to those
of the hit molecules, previous studies indicate that they have significant potential to
regulate the function of EZH2 [84, 85, 87].
To validate the computational results obtained, a number of experimental tests
were conducted.
G9a activity First of all, the G9a inhibitor UNC0638 optimised for cell permeab-
ility was evaluated in our cell-based assay. MDA-MB-231 cells were treated for 48
hours at a concentration of 1-10 µM. The mRNA levels of KRT17, FBXO32, EZH2
and JMJD3 were measured by RT-PCR. The resulting data were normalised against
the housekeeping gene GAPDH (Figure 2.14.A). UNC0638 could not reactivate
KRT17. Only FBXO32 was reactivated at a high dose of UNC0638 (i.e., above
EC50 (8.8 µM). This usually occurred when the toxicity of a compound induced the
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Figure 2.13: A chemical structure similarity map. The chemical structures of the
three hits 3–5 were matched with four classes of inhibitors, including G9a, CCR4,
TGF- , and adrenergic receptor inhibitors.
reactivation of FBXO32 and JMJD3 together. This interpretation was supported
by the results of a single-dose experiment, which indicated that UNC0638 could not
reactivate the EZH2 target genes (Table 2.5). On the other hand, our hits previously
showed inhibitory activity against G9a in the low micromolar range (Table 2.4).
Taken together, although the inhibition of G9a might be important for the cell based
e↵ects observed, targeting only the G9a pathway is not su cient to reactivate EZH2
target genes.
GPCR activity One function of CCR4, which is highly over-expressed in breast
cancer cell lines, is to promote tumour growth [134]. No published articles indicate a
CCR4 pathway related to gene reactivation or any epigenetic mechanism. Therefore,
based on the chemoinformatic results, we synthesised C021, a CCR4 inhibitor, to
evaluate its activity in our cell-based assay. C021 (compound 139) was synthesised
using the same route used to synthesize the hits (Scheme 2.18). C021 exhibited a
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Figure 2.14: The biological results by our collaborators and the assay detail can be
found in the experimental section. (A) RT-PCR results of UNC0638 and C021 at a
concentration of 1–10 µM. (B) MTT assay results of UNC0638, C021 and the three
hits. (C) The biochemical assay results of the three hits and positive control against
CDK1 and CDK2.
dose-dependent response in our RT-PCR assay (Figure 2.14.A). However, the JMJD3
RNA level increased dramatically at concentrations of 7.5 µM and 10 µM. Therefore,
the increases in KRT17 and FBXO32 expression likely stemmed from the toxicity
of C021 (EC50 = 3.75 µM). In addition, the enzymatic assay showed that C021
could weakly inhibit EZH2 (IC50 = 40 µM). Although it is likely that C021 cannot
reactivate the EZH2 target gene and has low inhibitory activity against EZH2 in
enzymatic studies, the further evaluation of hits against CCR4 is recommend to
confirm the relationship between the CCR4 pathway and epigenetic mechanisms.
Scheme 2.18: The synthetic route of C021. (i) 4-Amino-1-benzylpiperidine, DIEA,
THF, overnight. (ii) 1,4-Bipiperidine, toluene, reflux for 36 h.
The possible o↵-target e↵ects of BIX-01294 at the GPCR receptors have been
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considered, with a particular focus on the adrenergic receptors. At a concentration
of 1 mM, UNC0638 showed 64%, 90% and 69% inhibitions of muscarinic M2,
adrenergic ↵1A, and adrenergic ↵1B receptor, respectively [29]. At present, there
is no strong evidence to support the relationship between GPCR and epigenetic
silencing processes. Nevertheless, several ↵1 adrenergic inhibitors appear similar to
our leads [135].
Kinase activity The post-translational modifications of CDK1, CDK2 and Akt
can disturb EZH2 activities [85, 88]. All three hits were evaluated for their activities
against CDK1 and CDK2 using BS-194 as the positive control [136] (Figure 2.14.C).
All three hits 3–5 show no activity against CDK1 and CDK2 (IC50 > 100 µM).
Likewise, our hits were evaluated against Akt using Staurosporine as the positive
control compound [137, 138]. The three hits are also inactive against Akt (IC50 >
100 µM, data not shown). Therefore, the kinase pathways via CDK1, CDK2 and
Akt are not the o↵-target pathway for the post-translational modification of EZH2.
In our opinion, access to the recommend inhibitors (ALK5 and Prazosin) and
assays (GPCRs screening or TGF-  signalling assay) has been limited, and the
results have not yet been clarified. Therefore, the benefits of using ChEMBL remain
unclear. Moreover, when using ChEMBL data for analysis, the user should carefully
consider the type of data used to address the question of interest. We selected only
the appropriate target types with the understanding of these individual targets.
However, the 90% similarity of compound 3–5 might be too high, restricting the
possible protein targets. We were also aware of bias based on only ChEMBL data
set which was di↵erent form the commercial data base, such as MDL Drug Data
report and WOMBAT target. In addition, the use of ChEMBL and other bioactivity
databases can be limited by other factors including missing information regarding
stereochemistry and functional groups [139].
2.3.4 Conclusion and Future Work
We have initiated two approaches to search for a possible o↵-target protein. Based
on the initial results, the similarity ensemble approach using ChEMBL allowed us to
rule out some o↵-target proteins (e.g., the two-kinase pathway involving CDK1/2
and Akt). However, o↵-target proteins have not yet been confrimed and still requires
further investigation. For example, we are keen to observe the biological e↵ects of
selective TGF-  inhibitors such as ALK5 in our cell-based assay. The investigation of
the reactivation of EZH2 gene by Prazosin, a selective adrenergic receptor inhibitor,
is also recommended. Alternatively, all hits and negatives should been tested for
activity towards GPCR receptors.
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Many factors will be involved in the design of a new probe to verify o↵-target
proteins using Af BPs. First of all, the probe must reactivate EZH2 target genes in
our phenotypic assay. Second, the probe must be potent so that the lowest probe
concentration as possible can be used, resulting in the probe binding fewer target
proteins. On the basis of our initial result, we recommend for the clickable tag and
photo-reactive group to be added at the R3 position. The linker should be long
enough so as not to disturb the inhibitory activity of the new probe. The example in
which benzyl piperidine and benzophenone were combined resulted in a dramatic
reduction in EZH2 inhibition. In light of the uncertainty regarding suitable ABP
design, the planed target identification studies were not further pursued in this
project.
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Chapter 3
Identification of Novel HKMT
Inhibitors Using Sca↵old
Hopping
Whilst the prior studies, particularly those of Jin and co-workers, established im-
portant G9a SARs with respect to the side chains of the quinazoline core [31, 24,
28, 29, 30, 104], the pharmacophoric features of the central heterocycle have yet
to be determined for the inhibition of G9a and EZH2. Thus, we set out to better
define the important features of the central inhibitor sca↵old while maintaining the
aforementioned interactions within the substrate pocket of the enzyme.
Sca↵old hopping is a useful method to discover compounds with novel structures
starting from biologically active molecules by changing the molecular backbone of the
template. Such new chemical sca↵olds may speed up the lead optimisation process
by exploring the SAR of a new sca↵old. Furthermore, the new sca↵old might convey
physiochemical properties that are di↵erent from those of quinazoline analogues.
Finally, diversifying our chemical library allows us to establish new intellectual
property related to quinazoline patents [140]. Many methods have been developed to
assist medicinal chemists in the search for new sca↵olds; these methods include shape
matching, pharmacophore searching, fragment replacement, and similar searching.
BIX-01294 and its optimised analogues are composed of quinazoline heterocyclic
cores with substitutions at positions 2 and 4 (Figure 3.1). The complexes between
BIX-02194 and its quinazoline analogues with G9a reveal important interactions
between the inhibitor and the substrate pocket of G9a. The first key binding
interaction is a salt bridge between N-1 of the quinazoline core, which is expected
to be protonated at physiological pH [141, 142, 143], and Asp1088. The second
interaction is a hydrogen bond (Hb) between the C-4 NH functionality and Asp1083.
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Figure 3.1: The design of novel sca↵olds based on the interaction of BIX-01294 and
G9a.
In order to design novel cores, these two interactions will be retained in the new
derivatives. Therefore, we decided to synthesise the fused pyrimidine analogues and
quinoline analogues bearing the same side chains as BIX-01294 and our initial hits
(compound 3-6). Notably, sca↵old hopping studies require a large amount of SAR
or QSAR data to design sca↵olds. Thus, the results are more reliable and precise,
allowing a variety of novel sca↵olds to be obtained. However, in the beginning of
our studies, the structural diversity of the hits and SAR data were limited, and we
simply designed novel sca↵olds based on previous reports and the compounds that
were synthetically accessible. Therefore, the synthesis of the quinoline and fused
pyrimidine analogues are described below.
3.1 Chemical Synthesis
3.1.1 Synthesis of Furo[3,2d]pyrimidine Derivertives
The reported synthesis of the dichloro-furopyrimidine core (Scheme 3.1) was adapted
from Zhu’s work [144] for the preparation of dichloro-furopyrimidine 145. We then
used the previous method to synthesise quinoline derivatives. The intermediate 145
was then substituted with 4-amino-1-benzylpiperidine at C-4 to yield 146, which
was further heated with a variety of secondary amines to obtain the fully substituted
heterocyclic compounds 147-150. The details of each reaction are explained as
follows.
Curtius rearrangement is known to be a useful approach to convert carboxylic
acids to amines [145]. Diphenylphosphoryl azide (DPPA) is normally used in the
modified Curtius rearrangement, which can be carry out in a one-pot reaction to
provide Boc-protected amine. Mechanistically, the carboxylic acid reacts with DPPA
in the presence of a base such as triethylamine to give an acyl azide, which thermally
undergoes the Curtius rearrangement with the expulsion of nitrogen. The formed
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Scheme 3.1: The synthetic route of furopyrimidine derivatives. (i) DPPA, TEA,
t-BuOH, reflux, 18 h. (ii) n-BuLi (2.5 eq), TMEDA (2.5 eq), THF, methyl chloro-
formate, -40  C. (iii) TFA, DCM, room temperature, 3 h. (iv) ClO2SNCO, DCM,
-78  C to 0  C followed by reflux with 6 N HCl. (v) 2 N NaOH, MeOH, reflux, 1.5
h. (vi) POCl3, DIEA,110
 C, 3 days. (vii) 4-Amino benzylpiperidine, DIEA, room
temperature, overnight. (viii) NHR, 185  C (neat, microwave), 30 min.
isocyanate then reacts with tert-butanol to produce the carbamate (Scheme 3.2). In
our experiment, a carboxylic group of 3-furoic acid was first converted to an amino
group by modified Curtius rearrangement to give the crude Boc-protected amine
(Scheme 3.1). All starting material was consumed, and column chromatography was
employed to purify the crude product. The cleaned product 140 was obtained in a
good yield (68%).
Scheme 3.2: Curtius rearrangement using DPPA.
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In order to install the pyrimidine ring adjacent to the furan, ortho-functionalisation
via lithiation was perfomed. Not only is the proton at the 2 position of Boc-protected
3-amino furan the most acidic proton due to conjugation, the NHBoc group also acts
as a directing ortho-metallating group, amplifying this intrinsic acidity [146]. The
ability of the NH-Boc group to act as a directing ortho-metallating group for furan
derivatives and the method for furan lithiation have been previously reported [147]
In the first synthetic plan, the procedure reported by Zhu was followed [144]. We
attempted to introduce a methyl ester at the 2 position of the furan by lithiation
followed by quenching the reaction with dimethylcarbonate at -30  C. Unfortunately,
most of the starting material 140 was recovered at the end. This result might stem
from 140 not being converted to the lithiated species; alternatively, the lithiated
intermediate may have been formed but quenched during the aqueous workup. There-
fore, to investigate the formation of the lithiated intermediate, a small-scale modified
experiment was carried out using D2O instead of quenching with dimethylcarbonate.
As a result, the deuterated 140 was formed, which confirmed that the lithiation
process was successful. Therefore, the electrophile methyl chloroformate, which is
more reactive than dimethyl carbonate, was chosen as a new quenching reagent, and
the reaction was cooled to -40  C (Scheme 3.3). The intermediate methyl ester furan
141 was obtained as a yellow oil in moderate yield (42%). A side product was also
obtained (15%). The reported mass was consistent with that of 141, while the NMR
spectrum of the side product indicated that three protons in the furan ring were still
present, and the N-H proton was absent. Therefore, the structure of the side product
was determined to be methyl ester carbamate (Scheme 3.3).
The de-protection of the amino group of 141 was subsequently carried out by
stirring a solution of 141 in dichloromethane and TFA for 3 hours (Scheme 3.1). The
Boc-protected 141 was converted to the free amino 142 in a moderate yield (58%).
The slow addition of chlorosulfonyl isocyanate to 142 then allowed the inter-
mediate N -chlorosulfonylurea to accumulate; this reaction was monitored by TLC
until its completion (Scheme 3.4). Subsequently, the intermediate was hydrolysed in
Scheme 3.3: Direct ortholithiation of protected 3-amino furan
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acidic solution to obtain the primary urea 143 in a moderate yield (56%). Although
the yield of this method was not high, the reaction proceeded cleanly, and further
purification was not required. The urea 143 was intramolecularly cyclised under
basic conditions to provide furo[3,2-d]pyrimidine-2,4-dione 144 in quantitative yield.
The resulting furo[3,2-d]pyrimidione 144 was chlorinated using POCl3 to obtain
dichloro-furopyrimidine 145 (Scheme 3.1). The previously used method for the
chlorination of quinazoline (Scheme 2.1), which employed POCl3 with or without
DMF as a catalyst at reflux, resulted in degradation; therefore, we used POCl3 and
DIEA and heated to 110  C, which led successfully to 145 in a moderate yield (43%).
The failure of the standard conditions may have been attributed to the instability of
the furan-pyrimidine heteroaromatic compound. On the other hand, the addition of
DIEA could facilitate the reaction by trapping the HCl from the chlorination.
The substitution of the chloride at the 4 position of dichloro-furo[3,2-d]pyrimidine
145 with 4-amino benzyl-piperidine using DIEA at room temperature gave 146 in
good yield (74%). The regioselectivity of the reaction was resolved by 1H/15N HMBC
at 328 K; a signal of the long-length coupling of the NH proton of amino benzyl
piperidine and N in the pyrimidine ring was revealed in the spectrum (Figure 3.2.A).
This confirmed that the first displacement of chlorine occurred at the 4 position
of the furan-pyrimidine. If the amine had replaced the chlorine at the 2 position,
two signals would have been observed (Scheme 3.2.B). This evidence along with the
reported data for compound 146 were used to confirm the observed regiomer [144].
The intermediate 146 was conjugated with corresponding amines including
methylpiperazine, piperidine, 1-(2-pyridyl)piperazine and methylhomopiperazine at
185  C for 30 min in a microwave reactor to obtain the target molecules 147-150,
respectively, in moderate to excellent yields (Scheme 3.2).
Scheme 3.4: The cyclisation of the furopyrimidine core
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Figure 3.2: The observation of two regiomers of 146 using 1H/15HMBC at 328 K.
(A) The observed regiomer of compound 146. (B) The unobserved regiomer.
3.1.2 Synthesis of Thieno[2,3]pyrimidine and Thieno[3,2]pyrimidine
Derivatives
The equivalence between –CH = CH– and –S– has been well-known analogy between
benzene and thiophene [114]. Therefore, the synthesis of thienopyrimidine analogues
(Scheme 3.5) was suggested and a general approach to synthesis was followed [144, 148].
Initially, two commercially available amino esters (151a and 151b) were used in an
attempt to form urea intermediates using urea as a reagent in a microwave reactor
followed by cyclisation under basic conditions to give thienopyrimidinediones 152a
and 152b. Only 152a was successfully synthesised using this method (35%). The
preparation of thieno[3,2-d]pyrimidinedione 152b was unsuccessful because the urea
intermediate was not formed. An alternative approach in which chlorosulfonyl isocy-
anate was hydrolysed under reflux in acidic conditions to give the urea intermediate
followed by cyclisation in basic conditions successfully gave 152b in 52% yield [144].
Next, thienopyrimidinediones 152a-b were chlorinated to give the corresponding
dichloro compounds 153a-b in moderate yields (75% and 69%, respectively). Se-
quential substitution reactions at the 4 and 2 positions then gave 155-162, except
compound 161 was not pure enough (< 95% LCMS-UV)
3.1.3 Synthesis of Purine Derivatives
The chlorination of methylated xanthines with POCl3 or phosphorus pentachloride
(PCl5) has been successfully demonstrated [149]; however, the chlorination of un-
modified xanthine 164 with POCl3 had not been reported until the work of Erkang
and co-workers was published in 2011 [150]. In their work, the solvent-free, 188
gram-scale chlorination of xanthine with 1 equivalent of phosphorus oxychloride and
1 equivalent of pyridine at 180  C for 3 hours provided 165 in an excellent yield.
However, this approach was unsuccessful in our multi-gram-scale experiment, and
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Scheme 3.5: The synthetic route of thienopyrimidine derivatives. (i) Urea, 190  C,
microwave, 2.5 h, NaOH aq. (ii) ClSO2NC, DCM, aq HCl, aq NaOH. (iii) POCl3,
DMF, reflux. 6-8 h. (iv) 4-Amino benzylpiperine, DIEA, THF, room temperature,
overnight. (v) NHR, neat, microwave, 185  C, 30 min.
only starting material was recovered (Table 3.1, Entry 1).
The chlorination of xanthine was repeated using the same procedure employed
for chlorination of quinazoline-dione 8 in previous experiments (Table 3.1, Entry 2).
However, the reaction was not successful, and only the starting material was obtained
when the reaction was performed in the presence of excess POCl3 and diethylaniline
under reflux for one day. Furthermore, the addition of DMF to form the Vilsmeier
reagent led to decomposition (Table 3.1, Entry 3).
The chlorination of xanthine 163 was successfully achieved by using pyrophos-
phoryl chloride ((POCl2)2O) as the chlorinating agent at 165
 C in a sealed tube
(Table 3.1, Entry 4) [151]. Pyrophosphoryl chloride was prepared by the dropwise
addition of a half mole of water to POCl3 followed by heating the mixture to 100
 C for 2 hours to eliminate HCl. After cooling, only the upper layer was used for
chlorination. The overnight reaction was carried out on a small scale, resulting in a
low yield (23%) of 2,4-dichloropurine 164 (Table 3.1, Entry 4). When the multi-gram
scale reaction was carried out over 2 days, the reaction yield increased to 45% (Table
3.1, Entry 5). This indicated a longer reaction time was required to improve the yield
of the chlorination of xanthine using pyrophosphoryl chloride. In parallel, a control
experiment using POCl3 instead of pyrophosphoryl chloride was carried out under
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Scheme 3.6: The synthetic route of purine derivatives. (i) (POCl2)2O, reflux, 3 days.
(ii) 4-Aminobenzyl piperidine, TEA, butanol, 120  C, sealed tube. (iii) NHR, neat,
185  C, microwave.
the same conditions; however, no reaction occurred (Table 3.1, Entry 6). Xanthine
163 was not soluble in POCl3, even under reflux conditions.
After obtaining 2,4-dichloropurine 164, the subsequent chloride displacement
reaction was performed by heating with 4-aminobenzyl piperazine and triethylamine
in butanol at 120  C in a sealed tube (Scheme 3.6) [152]. Although 2,4-dichloropurine
164 was completely consumed in the overnight reaction, the purified 165 was obtained
in low yield (26%) due to the need for repeated column chromatography separations.
The second chloride displacement at the 2 position was carried out by heating 165
with the corresponding cyclic amines (NHR) at 185  C for 30 min in a microwave
reactor. However, only 167 and 169 were obtained in satisfactory purities (> 95%
purity, LCMS-UV); 166 and 168 could not be purified using column chromatography
and semi-preparative TLC.
Table 3.1: Chlorination of xanthine
Entry Conditions Comments
1 1 eq of POCl3, 1 eq of pyridine at 180
 C, 3 hr no reaction
2 excess POCl3, 2 eq of diethylaniline, reflux, 1 day no reaction
3 excess POCl3, 2 eq of diethylaniline, DMF(cat), reflux, 1 day decomposition
4 excess (POCl2)2O, 100
 C, overnight product (23%) + SM
5 excess (POCl2)2O, 100
 C, 2 days product (45%) + SM
6 excess POCl3, 100
 C, 2 days no reaction
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3.1.4 Synthesis of Quinoline Derivatives
The synthetic route of quinoline derivatives via malonyl chemistry
Initially, we attempted to synthesize quinoline analogues via the 2,4-dichloroquinoline
intermediate 172 (Scheme 3.7). In this synthetic route, 2,4-dichloroquinoline 172
was obtained by malonate cyclisation chemistry. However, malonic acid was not
su ciently reactive to react with 3,4-dimethoxy aniline 171; instead, it was converted
in situ to the corresponding acid chloride using POCl3 to form the chlorocarbonyl
ketene (Scheme 3.8) [153], which is more reactive than malonyl dichloride. This
reactive intermediate reacted with the aniline 171 to provide the malonyl heterocycle,
which was subsequently chlorinated by excess POCl3 under reflux conditions. This
one-pot reaction provided 2,4-dichloroquinoline 172 in a moderate yield (50%).
Scheme 3.7: The unsuccessful synthetic route of quinoline derivatives via malonyl
chemistry. (i) Malonic acid, POCl3, reflux. (ii) NHR, DIEA, dioxane, 140
 C, sealed
tube for 3 days. (iii) 4-Amino benzylpiperidine, 185  C for a few hours to several
days
Following a procedure from the literature [154], the first chloride displacement at
the 2 position by cyclic amines was carried out. This displacement required a higher
temperature and a longer reaction time than previously needed. 2,4-Dichloroquinoline
172 was heated with the corresponding amines, DIEA, and dioxane in a sealed tube
at 140  C for 3 days, resulting in the desired products 173 and 174 in low yields
(7-11%) [155]. Replacing dioxane with NMP or DMF and replacing DIEA with DBU
did increase the yield and led to additional side products.
Unfortunately, the second chloride displacement was unsuccessful. Using reaction
conditions reported in the literature [154], the second substitution was carried
out using hydrazine rather than another amine. In that report, hydrazine was
Scheme 3.8: The one-pot reaction of 2,4-dichloroquinoline 172
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heated with the 2-chloro,4-substituted quinoline, at 90  C for 2 hours, providing
their desired products. These conditions were replicated in our experiment using
4-amino benzylpiperidine instead of hydrazine; however, no reaction was observed.
As expected, the chloride displacement at the 4 position may require either higher
temperature or a longer reaction time. Thus, the temperature was increased to 185  C,
and the reaction time was varied from a few hours to several days. These conditions
caused many side products along with the degradation of 4-amino benzylpiperidine.
Therefore, this route was discontinued at the last synthetic step.
The synthetic route of quinoline derivatives via Lewis acid-induced in-
tramolecular cyclisation and reductive amination
The failure of the previous attempted synthesis of quinoline analogues was likely due
to the lack of reactivity of the two chlorines in the quinoline ring of 172. Therefore,
an alternative route was established to install the amines earlier in the synthesis.
The syntheses of the new quinoline derivatives 180-183 were successfully carried
out using a modified version of Campbell’s method (Scheme 3.9) [143] followed by
additional reductive amination.
Scheme 3.9: The synthetic route of quinoline derivatives. (i) HNO3, acetic anhydride,
room temperature, overnight. (ii) Na2S2O4, TBAF, DCM/H2O, room temperature
(iii) CH3C(OC2H5)3, 100
 C (neat). (iv) NHR, pTsOH, 100  C, 24–48 h. (v) ZnCl2,
DMA, reflux, 3–36 h. (vi) Step-wise reductive amination: N -benzyl piperidone,
acetic acid, toluene, reflux, 2-3 days, Dean-Stark, NaBH4 or STAB, acetic acid, THF,
reflux, 2 days
In order to obtain acetamidinobenzonitriles 178a-d using the commercially
available 3-4-dimethoxybenzonitrile as the starting material, the following four-step
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synthesis was required: nitration, reduction of the nitro group, imidate formation,
and aceamidinonitrile formation. The first two steps were previously optimised by
our group (Scheme 2.5), and 176 was a↵orded in moderate yield (56% over two
steps).
Initially, the syntheses of acetamidinonitriles 178a-d were attempted by treating
176 with imidinium chloride, which was prepared by exposing acetamide to POCl3 in
chloroform (Scheme 3.10) [143]. Acetamide 181 was previously prepared by stirring
piperidine with 4 equivalents of isopropenyl acetate at 60  C overnight, giving the
acetamides in a good yield [156]. However, the formations of acetamidinonitriles
178a-d were unsuccessful due to the insolubility of the starting material 176 in the
solvent. Replacing chloroform with other aprotic solvents such as toluene did not
increase the solubilities of the compounds.
Scheme 3.10: The unsuccessful synthetic route of acetamidinonitrile 178b
Alternatively, acetamidinonitrile formation via imidate as the intermediate was
successful. The starting material 176 and triethylorthoacetate were heated under
slightly reduced pressure via a water pump to remove ethanol from the system.
This gave the crude imidate 177 in quantitative yield (Scheme 3.11). Subsequently,
the imidate 177 was heated and stirred at 100  C with the piperidine resulting in
acetamidinonitriles 178b. We also observed the aniline 176 as a side product from
this reaction (Scheme 3.11). This method was implemented for other acetamidinoni-
trile formation with required amine (1-methylpiperazine, 1-2 pyridylpiperazine, or
1-methylhomopiperazine). This resulted in acetamidinonitriles 178a, 178c and 178d,
respectively, in moderate yields (40-58%).
Scheme 3.11: The formations of imidate 177 and acetamidinonitrile 178b
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Scheme 3.12: The unsuccessful synthetic route of aminoquinoline 179b via based-
induced cyclisation
Following a procedure from the literature[143], the base-induced cyclisation
approach was used for the cyclisation of acetamidinonitrile derivatives (Scheme 3.12).
A solution of 178b in dried THF was added dropwise to a stirred solution of LDA
at -78  C for 1 hour. The solution was then allowed to reach room temperature and
stirred overnight. However, the reaction failed and only the isolated starting material
was recovered.
Alternatively, the ring closures of acetamidinonitriles 178a-d were fully achieved
through treatment with zinc chloride, presumably via the enamine tautomer, which
was induced by a Lewis acid (Figure 3.3). Following the reported procedure [157],
acetamidinonitrile 178b was heated with 2 equivalents of zinc chloride in DMA
under reflux for 3 hours. The reaction mixture was worked up and purified to obtain
2-4-diaminoquinoline 179b in low yield (13%). The reaction was repeated using
6 equivalents of zinc chloride with heating under reflux overnight, resulting in an
increased yield (41%; Table 3.2, Entries 1 and 2). The cyclisations of the other
acetamidinonitriles (178a and 178d) were also carried out with 6 equivalents of zinc
chloride and longer reaction times to a↵ord quinoline 179a and 179d in moderate
yields (36% and 33%, respectively). We also tried to optimise the reaction by using
less ZnCl2 and a shorter reaction time for the reaction of 178c (Table 3.2, Entry 3),
giving 179c in moderate yield (43%).
The subsequent reductive aminations of the prepared amionquinolines 179a-d
were challenging due to the fact that no examples were available in the literature. In
addition, these quinoline amines are normally less reactive than the corresponding
alkyl amines. In general, the carbonyl compound (N -benzyl piperidone in this case)
can undergo the direct reductive amination with an amine (aminoquinoline) in the
Figure 3.3: The mechanisms of intramolecular cyclisation induced by base (A) and
Lewis acid (B).
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Table 3.2: The conditions and yields of intramolecular cyclisation reactions of 179a-d.
Entry SM. eq. of ZnCl2 Time (h) Yield (%)
1 178b 2 3 13
2 178b 6 24 41
3 178a 6 24 36
4 178c 3 8 43
5 178d 6 36 33
presence of a reducing agent. The reducing agent must be carefully chosen because
it must selectively reduce the iminium over the ketone.
Normally, reductive amination is carried in a one-pot reaction rather than a
stepwise reaction. However, in our experiment, the one-pot reactions of 179a
were not successful. Amine 179a, N -benzyl piperidone, acetic acid, and sodium
triacetoxyborohydride (STAB) were refluxed in THF for 4 days but TLC monitoring
did not indicate the product (Table 3.3, Entry 1). The acetic acid catalyst was
replaced with sulphuric acid, but this caused precipitation of N -benzyl piperidone
salt, and no reaction occurred (Table 3.3, Entry 2).
Due to the failure of the one-pot procedure, a stepwise reaction was attempted
(Scheme 3.13). The iminium formation step was modified using a Dean-Stark
apparatus with toluene as the solvent to remove water from the system. In the first
stepwise experiment, a mixture of amine 178a, N -benzyl piperidone, and acetic acid
in toluene was heated and stirred using the Dean-Stark apparatus. Due to the small
scale of the reaction, the water formed could not be observed in the Dean-Stark
apparatus. After the reaction was carried out for 4 days, a new spot, which was
positive in the ninhydrin drip test, was visible by TLC, but the starting material
179a and N -benzyl piperidone were both still present. The crude product was used
for the next step without purification. The toluene was replaced with THF, and
NaBH4 and a catalytic amount of acetic acid were then added. The reaction was
carried out overnight, and 180 was obtained in low yield (10%) after multiple silica
gel column chromatography purification steps (Table 3.3, Entry 3). A small amount
of the starting material 179a was also recovered (approximately 10%).
To modify the previous reductive amination procedure, NaBH4 was replaced
by STAB, and the stepwise procedure was carried out. STAB was used because it
does not reduce the remaining ketone left from the iminium formation step, which
might lead to a complete reductive amination. The modified procedure was used
for the remaining reactions; however, amioquinoline and N -benzyl piperidone still
remained, resulting in di culty in the purification step. The quinoline 183 was only
obtained in a low yield (13%; Table 3.3, Entry 6). Despite the implementation of
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Scheme 3.13: Stepwise reductive amination.
Table 3.3: The conditions for reductive amination and comments.
Entry SM. Method Conditions Comments
1 178a one-pot Ketone, AcOH, STAB, THF,
reflux 4 days
no reaction
2 178a one-pot Ketone, H2SO3, STAB, THF,
room temperature
no reaction
3 178a stepwise 1)Ketone, AcOH, toluene,
Dean-Stark. 2) AcOH,
NaBH4, THF, reflux
purified 180 (10%)
4 178b stepwise 1)Ketone, AcOH, toluene,
Dean-Stark. 2) AcOH, STAB,
THF, reflux
the mixture of SM and 181
5 178c stepwise 1)Ketone, AcOH, toluene,
Dean-Stark. 2) AcOH, STAB,
THF, reflux
the mixture of SM, unknown,
and 182
6 178d stepwise 1)Ketone, AcOH, toluene,
Dean-Stark. 2) AcOH, STAB,
THF, reflux
purified 183 (13%)
many purification techniques such as re-crystallisation, aluminium oxide and silica
column chromatography, aluminium oxide and silica preparative TLC, and semi-prep
LC-MS, compounds 181 and 182 were of insu cient purity (less than 95% purity,
LCMS-UV). The mixture of starting amines, desired product and unknown could
not be separated (Table 3.3, Entries 4 and 5).
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3.2 Biological Results and Discussions
3.2.1 SAR and Evaluation of New Derivatives using SPA Assay
As seen in previous chapters, the new compounds were evaluated for G9a and EZH2
inhibitory activities using SPA assay. BIX-01294 and previously identified hits 3–5
were used as positive controls. They exhibited IC50 values in the nanomolar to
low-micromolar range against G9a and in the moderate micromolar range against
EZH2 (Table 3.4). For the derivatives in which the benzenoid ring was replaced
with a furan, thiophene, or imidazole ring, no significant G9a inhibitory activity
was observed. While obvious interactions are not apparent in this region of the
quinazoline G9a inhibitors, the benzenoid ring seems to play an important role in
binding to G9a. In addition, dioxanquinazolines 93-96 and desmethoxyquinazolines
97-100 were previously shown to be inactive against G9a (Table 2.8). Moreover,
the recently reported G9a inhibitor A-366 shares a similar benzenoid feature in
this regard (Figure 1.4.B.2, [32]). Together these results show that the benzenoid
ring and dimethoxy substituents are important for inhibitory activity against G9a.
On the other hand, the thieno[2,3-d]pyrimidine derivative 158 still showed weak
inhibitory activity against EZH2 (IC50 = 33 µM). Compound 158 also exhibited
47% inhibition against G9a at 50 µM. Although the IC50 of 158 against G9a was not
determined, it was far less active than BIX-01294. Therefore, unlike BIX-01294 and
other derivatives, 158 retains the inhibitory activity against EZH2, but dramatically
loses the inhibitory activity against G9a.
In the inhibitors in which the dimethoxybenzenoid moiety was retained but the
N-3 of quinazoline was replaced with a carbon atom (183 and 180), significant
activities against G9a were observed (IC50 = 0.013 and 0.031 µM, respectively).
Indeed, to our delight, 180 and 183 were found to be 3- to 5-fold more potent
than their parental inhibitors, BIX-01294 and compound 3. However, 180 and
183 exhibited similar inhibitory activities against EZH2 (IC50 = 15 and 44 µM,
respectively) as the parental inhibitors. These findings might imply that the SARs of
N-3 against G9a and EZH2 are di↵erent. Removing the N-3 of the quinazoline ring
can significantly increase the inhibitory activity against G9a but not that against
EZH2. This result is clearly in agreement with our initial inhibitor-G9a crystal
structure analysis, which suggested that the N-3 nitrogen of the quinazoline sca↵old
is not essential for G9a binding (Figure 3.1). These SAR studies are consistent with
the proposal that 2,4-diamino-6,7-dimethoxyquinoline and -quinazoline derivatives
act as conformationally restricted bioisosteres of G9a substrate inhibitors.
In light of the excellent potencies of our quinoline inhibitors 183 and 180 against
G9a in the nanomolar range and against EZH2 in the moderate micomolar range,
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Table 3.4: SAR, biological results and calculated pKas* of the new derivatives.
G9a EZH2 G9a EZH2 IC50 (EZH2/G9a)
BIX-01294 (1) 6 25 0.067 15 224 8.13 (+2.22)
3 5 53 0.101 24 238 5.60 (+2.22)
4 7 48 0.472 16 34 7.47 (+2.22)
5 15 50 3.190 22 7 8.10 (+2.22)
150 99 99 ND ND ND 4.57(+0.70)
147 98 88 ND ND ND 4.66(+0.70)
148 97 99 ND ND ND 5.31(+0.70)
149 102 95 ND ND ND 5.77(+0.70)
158 47 39 ND 33 ND* 5.68(+0.70)
155 62 60 ND ND ND 5.77(+0.70)
156 91 83 ND ND ND 6.42(+0.70)
157 104 78 ND ND ND 6.88(+0.70)
162 81 57 ND ND ND 3.28(+2.22)
159 88 80 ND ND ND 3.35(+2.22)
160 93 83 ND ND ND 3.86(+2.22)
169 67 75 ND ND ND 3.15(+2.22)
167 101 95 ND ND ND 3.73(+2.22)
183 5 23 0.013 15 1154 10.57(+2.22)
180 5 48 0.031 44 1419 9.84(+2.22)
N-1 pKaat 50 µM
IC50 (µM)
SelectivityCompound
Enzyme Activity (%)
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*pKa values were calculated by Sandeep Sundriyal using the Epik 2.7 program
implemented in Schrodinger. ND = not determined
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the selectivities of these compounds were examined in a methyltransferase enzyme
panel and compared to those of BIX-01294 by our collaborator at SGC (Table 3.5).
The methyltransferase enzyme panel consisted of 28 additional methyltransferases
including 16 HKMTs, six protein arginine methyltransferases (PRMTs), and three
DNA methyltransferases (DNMTs; Table 3.5). Compounds 183 and 180 were found
to be equipotent against G9a and GLP, which is not surprising given the high
degree of homology between the G9a and GLP SET domains. Such dual G9a/GLP
activity is a common feature of diaminoquinazoline inhibitors and was shared by
BIX-01294. However, to our delight, quinoline inhibitors 183 and 180 were found to
be inactive against all other methyltransferases in the panel with the exception of
SETD2, for which the inhibitory activities were conserved at 50 and 10 µM for both
quinoline and BIX-01294. SETD2 is a member of the HKMT family and methylates
H3K36 (Figure 3.4.A). To date, no diaminoquinazoline G9a inhibitors, including
UNC0624 and UNC0638, have been reported to inhibit SETD2. Furthermore, the
non-quinazoline G9a inhibitor A-336 showed no significant inhibition against SETD2
at 50 µM [32]. Indeed, the inhibitory activity of SETD2 was unexpected. The SETD2
inhibition was selective over another H3K36-specific methyltransferase, ASH1L. The
selectivities for G9a/GLP and EZH2 inhibition were likely facilitated by the similarity
between their substrate peptides (ARKST and ARKSA, respectively; Figure 3.4.B),
which were recognised by the same reader proteins [158], along with the crosstalk
between G9a and EZH2 (see Chapter 2). However, the peptide substrates of G9a and
SETD2 were di↵erent (Figure 3.4.B), and the similarity between the G9a and SETD2
SET domains was only 32.5% when those sequences were aligned using UniProt
(http://www.uniprot.org). Therefore, this result might be related to o↵-target e↵ects,
and a further investigation of the e↵ect of SETD2 inhibition is recommended.
3.2.2 SAR and pKa Measurement
A comparison of the calculated pKa values revealed that quinolines 183 and 180 are
more basic than the corresponding parental quinazoline BIX-01294 and compound
3, respectively (Table 3.4). This computational prediction is in agreement with the
experimental data, which demonstrate that diaminoquinolines are be more basic than
the analogous quinazolines [141, 142, 143]. The quinoline derivatives were predicted
to have the highest pKa values (10.57 and 9.84 for 183 and 180, respectively) of
all the prepared analogues. Interestingly, all inactive molecules were predicted to
have lower pKa values. A similar analysis of quinazoline and quinoline activities
based on pKa-dependent interactions was previously described for the design of
↵1-adrenoreceptor antagonists [141, 142, 143].
In order to confirm the calculated values, the pKas of compound 183 and BIX-
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Table 3.5: Selectivity data of BIX-01294, 180 and 183.
50 10 1 50 10 1 50 10 1
G9a 2 2 9 1 2 7 1 1 3
GLP 2 1 3 1 1 2 1 1 2
SUV39H2 83 98 102 85 105 116 74 95 107
SETDB1 79 97 99 101 98 104 82 93 95
PRDM9 58 89 95 54 87 90 67 89 104
SETD7 114 106 104 109 105 107 106 106 106
MLL1 78 96 101 89 92 103 73 93 99
SETD8 101 108 106 100 84 104 97 98 99
SUV420H1 80 105 108 86 93 101 69 92 97
SUV420H2 84 100 107 101 99 106 94 104 107
PRMT1 103 104 99 105 97 102 100 98 103
PRMT3 83 99 94 95 98 103 77 100 99
PRMT5 99 95 98 101 97 102 103 101 104
PRMT6 76 99 100 71 93 99 40 116 100
PRMT7 100 100 95 101 94 98 99 109 101
PRMT8 81 92 118 69 88 100 46 97 95
DOT1L 112 113 103 109 105 101 122 116 90
EZH1 76 95 99 93 101 108 69 100 103
EZH2 35 76 97 55 88 101 25 72 93
SMYD2 65 94 106 76 99 112 59 95 111
NSD1 280 169 108 447 208 112 567 284 131
NSD2 293 161 111 361 180 106 615 227 119
NSD3 248 157 110 567 208 109 701 285 121
SETD2 6 67 94 22 77 104 1 44 94
ASH1L 176 124 109 257 138 106 380 177 111
METTL21A 89 101 97 88 100 97 97 97 101
METTL21D 84 93 89 86 92 84 81 91 92
BCDIN3D 50 71 90 55 78 103 35 56 79
DNMT1 126 105 105 137 115 110 140 130 99
DNMT3A/3L 120 124 101 127 117 107 111 131 113
DNMT3B/3L 115 112 97 113 108 101 110 113 105
BIX-01294 (µM) 180 (µM) 183 (µM)Protein
Enzyme Activity (%)
These data were generated by SGC and the assay details can be found in the experimental section.
01294 were measured by Sirius Analytical Ltd. The samples were initially investigated
using a fast-UV titration from pH 2–12 at concentrations of 31–19 µM under aqueous
conditions at 25  C in an ionic environment (0.15 M KCl). No precipitation or
decomposition of the sample was observed, and three approximate pKa values were
collected from the spectroscopic data for each sample. The assignment of each pKa
value is based on the calculated pKa and UV-vis data (Figure 3.5). As expected,
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Figure 3.4: Selectivity of compound 183 on SETD2. (A) phylogenetic tree of PKMTs,
modified from [159]. (B) Sequence of the histone 3 peptide.
BIX-01294 and compound 183 were found to be tribasic due to the presence of
two aliphatic basic centres (the benzylpiperidine nitrogen and the homo piperazine
nitrogen) in addition to N-1 (Table 3.6). The experimental pKa values of BIX-01294
(1) were 6.94 ± 0.01, 8.24 ± 0.05 and 9.22 ± 0.04. The experimental pKa values
of quinoline 183 were 7.14 ± 0.01, 8.05 ± 0.02 and 9.50 ± 0.01. Since the largest
spectral changes for BIX-01294 and 183 are expected upon ring protonation, the
UV-vis spectra observed upon each protonation event can be used to assign the
pKa of N-1 (Figure 3.5). Therefore, we assigned the pKa of the N-1 of quinazoline
BIX-01294 to be 6.94 ± 0.01 and that of the N-1 of quinoline 183 to be 9.50 ± 0.01.
Table 3.6: Experimental and calculated pKa of BIX-01294 and compound 138.
Compound Measured pKa* Calculated pKa** Assignment
BIX-01294
6.94 ± 0.01 8.13 ± 2.22 N-1
8.24 ± 0.05 8.51 ± 0.78 N-homopiperazine
9.22 ± 0.04 10.53±0.78 N-benzylpiperidine
183
7.14 ± 0.01 8.18 ± 0.78 N-homopiperazine
8.05 ± 0.02 10.35 ± 0.78 N-benzylpiperidine
9.50 ± 0.01 10.57 ± 2.22 N-1
*pKa experiments were conducted by Sirius Analytical Ltd. **Sequential pKa values were
calculated by Sandeep Sundriyal using the Epik 2.7 program implemented in Schrodinger.
105
Figure 3.5: pKa determination of BIX-01294 (A) and compound 138 (B) by three
independent UV-vis measurements. ‘B’ corresponds to the free base species, and ‘BH’,
‘BH2’ and ‘BH3’ correspond to the mono-, di-, and tri-protonated species, respectively.
The largest spectral change, which is assigned to protonation/deprotontation at N-1,
is observed upon moving from BH2 to BH3 for BIX-01294 and from B to BH for
compound 183. These data were generated by Sirius Analyticals
.
These data strongly suggest that a protonated N-1 position is required for good
G9a binding through a strong electrostatic interaction with Asp1088. Indeed, the
Henderson-Hasselbach equation indicates that under the given assay conditions
(pH 8), the N-1 will be protonated in 96.9% of 183 molecules, whereas N-1 will be
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protonated in only 8.0% of BIX-01294 molecules. However, we note that an alternative
explanation exists for the excellent potencies of our quinoline hit compounds; that is,
the enthalpy loss due to the breakage of a hydrogen bond between N-3 and water
before ligand binding is not compensated, unlike with the quinazoline inhibitor [160].
3.2.3 Phenotypic Screening of New Derivatives
With the exception of the thienopyrimidine derivatives 155–162, the new derivatives
were screened in our phenotypic assay by our collaborators (Table 3.7). Compound 3
was used as the positive control due to its ability to reactivate KRT17 and FBXO32.
In general, none of the compounds showed a significant increase in activity of GAPDH
at 10 µM (data not shown); thus, there was no need to screen at lower concentrations,
as is necessary when there is a toxic e↵ect.
As a result, furo[3,2d]pyrimidine derivatives 148–150 were assigned as the positive
controls in the initial screening, and these compounds were tested to investigate their
dose-dependent behaviours at various concentrations. Surprisingly, 147 was the only
furo[3,2d]pyrimidine derivative that could not reactivate both KRT17 and FBXO32.
Compound 147 was negative in our cell-based assay, even though the R1 side-chain
of 147 (1-methyl-piperazine) is the same as that of compound 3.
In contrast to the enzymatic assay results, which demonstrated that compounds
148–150 did not significantly inhibit G9a and EZH2 at 50 µM (Table 3.4), 148–150
showed a positive result; that is, they could reactivate the EZH2 target genes KRT17
and FBXO32. These contradictory results might have several possible explanations
related to the underlying mechanism and o↵-target e↵ects. However, it was too early
to confirm the EZH2 inhibitory activity in the cell-based assay. Notably, not all
furo[3,2d]pyrimidine derivatives showed positive results in the assay.
The purine derivatives 169 and 167 were able to reactivate FBXO32 but failed to
reactivate KRT17; thus, they were classified as negatives. As in the enzymatic assay
(Table 3.4), compounds 169 and 167 did not show significant inhibition against G9a
and EZH2 at 50 µM.
Unexpectedly, although the quinolines 183 and 180 exhibited inhibitory activities
in enzymatic assay (Table 3.4), they were classified as negative in our cell-based
assay (Table 3.7). Both compounds could reactivate FBXO32 but not KRT17 at 10
µM. Indeed, compounds 183 and 180 were found to be equally potent against both
G9a and EZH2. However, many more factors must be taken into consideration in
the cell-based assay. For example, quinoline and quinazoline might have di↵erent
physical properties that could a↵ect their activities in cells. We calculated the cLogP
values for 183, 180, and their parental compounds (BIX-01294 and compound 3,
respectively) using ACD/I-Lab (https://ilab.acdlabs.com/iLab2/). The quinolines
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Table 3.7: Phenotypic screening of new derivatives at 10 µM
Compound KRT17 FBXO32 JMJD3 EZH2 Comments
3 8.45 6.13 5.31 0.35 Positive (Hit)
150 3.22 6.32 7.16 0.45 Positive
147 2.09 1.55 1.43 0.92 Negative
148 7.14 5.32 5.12 0.32 Positive
149 5.93 11.7 7.19 0.41 Positive
169 1.65 7.17 9.33 0.79 Negative
167 2.02 4.8 3.18 0.69 Negative
183 1.13 6.13 11.23 0.91 Negative
180 0.14 3.29 1.32 1.9 Negative
183 and 180 were calculated to have the higher cLogP values (5.62 ± 1.51 and 5.3
± 1.51, respectively), while BIX-01294 and compound 3 showed lower cLogP values
(2.81 ± 1.47 and 2.42 ± 1.47, respectively).
Building on these results, we would like to test the thieno-pyrimidine 155-162
in our phenotypic screening assay. Thieno-pyrimidine 158 exhibited inhibitory
activity against EZH2 but not G9a (Table 3.4) and thus might be able to distinguish
EZH2 inhibitory activity from G9a inhibitory activity in our compound library.
Moreover, in light of the inhibitory activities shown by the furo[3,2d]pyrimidine
derivatives, this result suggested that the new sca↵old derivatives might lead us to
non-quinazoline/quinoline-based compounds.
3.3 Conclusion and Future Work
The synthetic route towards HKMT inhibitors based on novel sca↵olds has been
investigated using various heterocyclic methodologies. We have designed and syn-
thesised a variety of heterocyclic derivatives in order to identify novel G9a and EZH2
inhibitors and to better define the pharmacophoric features associated with the core
heterocycle, although the purification of several final compounds presented some
challenges. The generated library compounds were evaluated in a biochemical assay
by SGC and in a cell-based assay by Browns group.
The enzymatic screening resulted in the identification of the potent and selective
G9a/GLP inhibitors 183 and 180, which are based on quinoline sca↵olds. Both
compounds retained EZH2 inhibitory activity. The selectivity assessment of the
new derivatives from the enzymatic assay panel revealed that both quinazoline
BIX-01294 and the quinolines 183 and 180 exhibited inhibitory activities against
SETD2. Moreover, we discovered that the thieno[2,3-d]pyrimidine derivative 158
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showed inhibitory activity against EZH2. Furo[3,2d]pyrimidine derivatives 148–
150 were able to reactivate EZH2 target genes in our phenotypic screening, which
appeared to the enzymatic results that found no significant inhibition of G9a and
EZH2. Further investigations will be carried out on the underlying mechanisms and
o↵-target proteins.
For further investigation, the synthesis of isoquinoline analogues might provide
us better understanding of the directional binding of N -1 and this might contribute
to the selectivity for EZH2 over G9a (Figure 3.6). This may imply that increasing
N -1 basicity improves inhibition of G9a, but not EZH2. Therefore, the removal of
N -1 might dramatically decrease the inhibitory activity against G9a. In contrast,
the inhibitory activity against EZH2 might be retained, if there is no important
interaction between N -1 and any amino acid of EZH2. Moreover, the reported
SARs of the side chains from chapter 1 could be implemented for the novel sca↵olds,
including the quinoline and thieno[2,3-d]pyrimidine derivatives in order to maximise
the inhibitory activity against EZH2 (Figure 3.6).
In addition, the X-ray crystal structure of EZH2 and its partner proteins was
recently published in October 2015 [161]. The active SET domain was bound
to a H3K27 peptide and a SAH cofactor. This has provided insight for further
structure-based drug design studies.
Figure 3.6: Future work
.
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Chapter 4
Experimental Section
4.1 Compound Characterisation and Analysis
General methods All dry and anhydrous reaction solvents were obtained from
Aldrich Chemical Company or were freshly distilled from calcium hydride (dichloro-
methane, toluene, triethylamine, pyridine, n-hexane) and magnesium (methanol),
sodium benzophenone (tetrahydrofuran, diethylether). All reagents and other solvents
were obtained from commercial suppliers.
All reactions were performed under an atmosphere of dry nitrogen unless otherwise
stated. Bulk solutions were evaporated under reduced pressure using a Bu¨chi rotary
evaporator. All organic extracts were dried over magnesium sulphate.
Flash column chromatography was carried out using Merck Kiesegel 60 silica gel
(230–400 mesh, 0.040 0.063 mm). Thin- layer chromatography (TLC) was performed
on aluminium plates using Merck Kiesegel 60 F254 (230–400 mesh) fluorescent treated
silica which were visualised under ultraviolet light (254 nm), or by staining with
potassium permanganate or ninhydrin solution as appropriate. Preparative TLC
plates were purchased from Analtec, inc.
Melting points analysis were carried out on a Reichert-Thermovar melting point
apparatus.
Infrared spectra were recorded neat on Perkin-Elmer Paragon 1000 Fourier
transform spectrometer with automated background subtraction. Only selected
absorptions are reported and are of strong or medium strength unless stated otherwise
and given in wave numbers (cm-1).
All 1H and 1C NMR spectra were recorded using Bruker 400 MHz spectrometers
or Bruker AV 500. Chemical shifts ( ) are quoted in units of parts per million
(ppm) downfield from tetramethylsilane and are referenced to a residual solvent peak.
Coupling constants (J ) are given in Hertz (Hz). The 1H NMR spectra are reported
as follows: ppm (multiplicity, coupling constants J / Hz, number of protons). NMR
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spectra were conducted by Imperial College London Department of Chemistry NMR
Service. High and low resolution mass spectrometry (EI, ES, and CI) were recored
on Micromass Platform II and Micromass AutoSpec-Q spectrometers.
All compounds tested in biological assay were found to be pure (>95%, based on
UV spectrum) using LCMS. LCMS gradient: From 95:5, A:B to 5:95, A:B over 18
minutes, where A is water (0.1% formic acid), and B is methanol. Column : XBridge
C18 columns with dimensions 4.6 mm x 100 mm.
General procedures
Method 1: A mixture of the appropriate 2,4-dichloroquinazoline (1 equivalent),
primary amine (1.5 eq.) and DIPEA (3 eq.) in dry THF (5 mL, otherwise stated)
was stirred overnight at room temperature and then concentrated under reduced
pressure. The crude product was purified by flash chromatography (0—4% methanol
in dichloromethane) to a↵ord the expected 4-substituted quinazoline.
Method 2: Secondary amine (10 equivalent) was added to the 2-chloroquinazo-
line (1 equivalent) in toluene (2 mL) and the mixture was heated overnight at 130
 C. The reaction mixture was concentrated under reduced pressure and the residue
was purified by chromatography to a↵ord the expected substituted quinazoline.
Method 3: Secondary amine (5–10 equivalent) was added to the 2-chloroquina-
zoline (1 equivalent) and the reaction mixture was heated at 185  C in microwave for
30 minutes. The residue was purified by flash chromatography to a↵ord the expected
substituted quinazoline.
Compound 3: N -(1-Benzylpiperidin-4-yl)-6,7-dimethoxy-2-(4-methylpiperazin-1-
yl) quinazolin-4-amine [113]
Small scale synthesis: Following general procedure 2, heat-
ing, N -(1-benzylpiperidin-4-yl)-2-chloro-6,7-dimethoxyquina-
zolin-4-amine (11, 124 mg, 0.3 mmol) , and 1-methyl piper-
azine (0.33 mL, 3.0 mmol) for 36 hours, the reaction mixture
was purified by column chromatography (0–4% 7 M ammonia
methanol in dichloromethane) to yield the title product as a
yellow solid (114 mg, 80%) Large scale synthesis: The mixture of the N -(1-ben-
zylpiperidin-4-yl)-2-chloro-6,7-dimethoxyquinazolin-4-amine (11, 2.0 g, 4.8 mmol)
and 1-methyl piperazine (1.6 mL, 14.53 mmol) was heated (neat) for 2 hours. The
reaction mixture was purified by column chromatography (0–4% ammonia methanol
in dichloromethane) to yield the title product as a yellow solid (1.402 g, 43%). mp
98–100  C; IR (cm 1) 2930, 1633, 1574, 1495, 1432, 1234, 1214; 1H NMR (400 MHz,
CDCl3,  ) 7.34–7.27 (m, 5H), 6.90 (s, 1H), 6.70 (s, 1H), 5.02 (d, J = 7.2 Hz, 1H),
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4.19–4.09 (m, 1H), 3.94 (s, 3H), 3.92 (s, 3H), 3.86 (m, 4H), 3.55 (s, 2H), 2.91 (m, 2H),
2.49 (m, 4H), 2.34 (s, 3H), 2.21 (m, 2H) 2.15 (m, 2H), 1.62 (qd, J = 2.9, 11.5 Hz,
2H); 13C (100 MHz, CDCl3,  ) 158.2, 157.8, 154.5, 147.4, 145.7, 137.8, 129.2 (2C),
128.3 (2C), 127.2, 105.3, 103.0, 100.9, 62.9, 56.4, 56.1, 55.02 (2C), 52.4 (2C), 48.3,
46.1, 44.1 (2C), 31.9 (2C); HRMS (ESI) (m/z ) calcd. for C27H37N6O2: 477.2978,
found: 477.2970.
Compound 4: N -(1-Benzylpiperidin-4-yl)-6,7-dimethoxy-2-(piperidine-1-yl) quina-
zolin-4-amine [113]
Small scale synthesis: Following general procedure 2, heat-
ing N -(1-benzylpiperidin-4-yl)-2-chloro-6,7-dimethoxyquinazo-
lin-4-amine (11, 62 mg, 0.15 mmol), and piperidine (0.14 mL,
1.5 mmol) for 24 hours, The reaction mixture was purified by
column chromatography (0–4% ammonia methanol in dichloro-
methane) to yield the title product as a yellow solid (68 mg,
quant). Large scale synthesis: The mixture of the N -(1-benzylpiperidin-4-yl)-2-
chloro-6,7-dimethoxyquinazolin-4-amine (11, 2.0 g, 4.84 mmol) and piperidine (2.75
mL, 14.5 mmol) was heated (neat) for 2 hours and the reaction mixture was purified
by column chromatography (5% methanol and 1% TEA in dichloromethane) to yield
the title product as a yellow solid (1.650 g, 73%). mp 92–94  C; IR (cm 1) 2929,
1571, 1495, 1428, 1368, 1277, 1233, 1213; 1H NMR (400 MHz, CDCl3,  ) 7.34–7.24
(m, 5H), 6.90 (br s, 1H), 6.68 (s, 1H), 4.95 (br s, 1H), 4.19–4.09 (m, 1H), 3.95 (s,
3H), 3.93 (s, 3H), 3.84–3.78 (m, 4H), 3.55 (s, 2H), 2.91 (m, 2H), 2.21 (m, 2H) 2.15
(m, 2H), 1.64 (m, 8H); 13C (100 MHz, CDCl3,  ) 160.3, 157.6, 152.4, 149.2, 137.4,
132.4 (2C), 131.2, 130.7, 130.3 (2C), 105.5, 103.5, 99.9, 61.7, 57.4, 56.9, 52.6 (2C),
48.2, 47.4 (2C), 29.4 (2C), 26.7 (2C), 25.1; HRMS (ES) m/z calcd. for C27H36N5O2:
462.2868, found: 462.2855.
Compound 5: N -(1-Ben-zyl-pi-per-idin-4-yl)-6,7-di-me-th-oxy-2-(4-(pyridin-2-yl)pi-
per-azin-1 -yl) qui-na-zo-lin-4-amine [113]
Small scale synthesis: Following general procedure
2, heating N -(1-benzylpiperidin-4-yl)-2-chloro-6,7-dime-
thoxyquinazolin-4-amine (11, 123.87 mg, 0.3 mmol), and
1-(2-pyridyl)piperazine (0.44 mL, 3.0 mmol) for 48 hours,
the reaction mixture was purified by column chromato-
graphy (0–4% ammonia methanol in dichloromethane) to
yield the title product as a yellow solid (160 mg, 97%).
Large scale synthesis: The mixture of N -(1-benzylpiperidin-4-yl)-2-chloro-6,7-di-
methoxyquinazolin-4-amine (11, 2 g, 4.84 mmol) and 1-(2-pyridyl)piperazine (2.1
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mL, 14.5 mmol) were heated (neat) for 2 hours and the reaction mixture was purified
by column chromatography (0–3% ammonia methanol in dichloromethane) to yield
the title product as yellow solid (262 mg, 10%). mp 98–100  C; IR (cm 1) 2929,
1571, 1495, 1428, 1368, 1277, 1233, 1213; 1H NMR (400 MHz, MeOD,  ) 8.16 (m,
1H), 7.76 (br s, 1H), 7.62 (m, 3H), 7.51 (m, 3H), 7.19 (br s, 1H), 6.92 (m, 1H), 6.75
(m, 1H), 4.62 (m, 1H), 4.34 (br s, 2H), 4.04 (m, 4H), 3.98 (s, 3H), 3.96 (s, 3H), 3.77
(m, 4H), 3.57 (d, J = 12.4 Hz, 2H), 3.30 (m, 2H), 2.36–2.28 (m, 2H), 2.19–2.16 (m,
2H); HRMS (ESI) m/z calcd. for C31H38N7O2: 540.3087, found: 540.3093.
Compound 10: 2,4-Dichloro-6,7-dimethoxyquinazoline [162]
A mixture of quinazolinedione (2.00 g, 9.0 mmol), POCl3 (7.5 mL,
81.0 mmol), N,N -diethylaniline (1.4 mL, 9.0 mmol) was stirred under
reflux for 4.5 hours. Then the mixture was cooled down to room
temperature and was slowly added into 150 mL of ice-cooled water.
The precipitaites were filtrated and washed with water to a↵ord the
title compound as a white solid (1.922 g, 83%). mp 156–158  C; 1H NMR (400
MHz, CDCl3,  ) 7.35 (s, 1H), 7.27 (s, 1H), 4.06 (s, 3H), 4.05 (s, 3H);
13C (100 MHz,
CDCl3)   162.9, 155.3 , 150.9, 145.0, 137.0, 107.6, 98.2, 56.2, 40.4, 39.5; MS (ES)
(m/z ) 259 [M+H]+
Compound 11: N -(1-Benzylpiperidin-4-yl)-2-chloro-6,7-dimethoxyquinazolin-4-
amine [24]
Following general procedure 1, using 2,4-dichloro-6,7-dimethoxy-
quinazoline (10, 518 mg, 2 mmol), 4-amino-1-benzylpiperidine
(0.82 mL, 3.0 mmol) and DIEA (0.51 mL, 4.0 mmol) in THF (6
mL) for overnight, the reaction mixture was purified by column
chromatography (5% methanol in dichloromethane) to yield the
title product as a yellow solid (576 mg, 70%). mp 116–118  C; IR
(cm 1) 2936, 1739, 1508, 1267, 1454, 1366; 1H NMR (400 MHz, CDCl3,  ) 7.37–7.26
(m, 5H), 7.14 (s, 1H), 6.84 (s, 1H), 5.47 (br s, 1H), 4.36–4.27 (m, 1H), 4.00 (s,
3H), 3.98 (s, 3H), 3.58 (s, 2H), 2.93 (d, J = 11.3 Hz, 2H), 2.26 (t, J = 11.5 Hz,
2H), 2.16 (d, J = 11.4 Hz, 2H), 1.66 (qd, J = 11.8, 3.7 Hz, 2H); 13C (100 MHz,
CDCl3  ) 159.3, 156.2, 154.9, 149.0, 147.9, 138.2, 129.1(2C), 128.2 (2C), 127.1, 107.0,
106.8, 100.1, 63.0, 56.3, 56.1, 52.3 (2C), 48.6, 32.1 (2C); HRMS (ES) (m/z ) calcd for
C22H26N4O2Cl: 413.1745, found, 413.1744.
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Compound 12: (Azetidin-1-yl)-4-((1-benzylpiperidin-4-yl)oxy)-6,7-dimethoxyqui-
nazoline
Following general procedure 2, heating N -(1-benzylpiperidin-4-
yl)-2-chloro-6,7-dimethoxyquinazolin-4-amine (11, 100 mg, 0.243
mmol), and azetidine (0.082 mL, 1.214 mmol) for 24 hours, the
reaction mixture was purified by column chromatography (0–3%
ammonia methanol in dichloromethane) to yield the title product
as a yellow solid (101 mg, 96%). mp 136–138  C; IR (cm 1) 3229,
2938, 1625, 1572; 1H NMR (400 MHz, CH3OD,  ) 7.40 (s, 1H), 7.34–7.26 (m, 5H),
6.87 (s, 1H), 4.19–4.21 (m, 1H), 4.10 (t, J = 7.2 Hz, 4H), 3.89 (s, 3H), 3.88 (s, 3H),
3.55 (s, 2H), 2.97 (d, J = 12.0 Hz, 2H), 2.31 (quin, J = 7.6 Hz, 2H), 2.16 (dt, J
= 12.0, 3.2 Hz, 2H), 2.06 (d, J = 12.0 Hz, 2H), 1.70 (dq, J = 12.0, 3.2 Hz, 2H);
13C (100 MHz, CH3OD,  ) 158.9, 154.4, 147.7, 145.5, 137.0, 129.4 (2C), 127.9 (2C),
127.0, 103.7, 103.6, 102.7, 62.7, 55.4, 54.7, 52.5 (2C), 49.9, 48.2, 30.6 (2C), 15.5; MS
(ES) m/z [M+H]+ 434.35
Compound 13: 4-((1-Benzylpiperidin-4-yl)oxy)-6,7-dimethoxy-2-(pyrrolidin-1-yl)
quinazoline
Following general procedure 2, heating N -(1-benzylpiperidin-4-
yl)-2-chloro-6,7-dimethoxyquinazolin-4-amine (11, 100 mg, 0.243
mmol), and pyrolidine (0.10 mL, 1.214 mmol) for 24 hours, the
reaction mixture was purified by column chromatography (0–3%
ammonia methanol in dichloromethane) to yield the title product
as a white solid (42 mg, 38%). mp 96–98  C; IR (cm 1) 3398,
2935, 1627, 1572; 1H NMR (400 MHz, CH3OD  ) 7.36 (s, 1H), 7.32–7.23 (m, 5H),
6.90 (s, 1H), 4.18–4.10 (m, 1H), 3.87 (s, 3H), 3.86 (s, 3H), 3.56 (t, J = 6.8 Hz, 4H),
3.52 (s, 2H), 2.95 (d, J = 12.0 Hz, 2H), 2.14 (td, J = 12.0, 3.2 Hz, 2H), 2.08 (d, J =
12.0 Hz, 2H), 1.95 (quin, J = 4.0, 2.8 Hz, 4H), 1.98 (dq, J = 12.0, 3.2 Hz, 2H). 13C
(100 MHz, CH3CD,  ) 158.6, 157.6, 154.3, 148.2, 145.0, 137.0, 129.4 (2C), 127.92
(2C), 127.1, 103.8, 103.2, 102.8, 62.7, 55.4, 54.7, 52.5 (C), 48.2 (2C), 46.2, 32.0 (2C),
25.1 (2C); MS (ES) m/z [M+H]+ 448.27
Compound 14: 2-(Azepan-1-yl)-4-((1-benzylpiperidin-4-yl)oxy)-6,7-dimethoxyqui-
nazoline
Following general procedure 2, heating N -(1-benzylpiperidin-4-
yl)-2-chloro-6,7-dimethoxyquinazolin-4-amine (11, 123 mg, 0.3
mmol, and Hexamethyleneimine (0.34 mL, 3.0 mmol) for 24
hours, the reaction mixture was purified by column chromato-
graphy (0–5% ammonia methanol in dichloromethane) to yield
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the title product as a white solid (84 mg, 58%). mp 101–103;
IR (cm 1) 2927, 2852, 1627, 1589, 1567, 1491;  C; 1H NMR (400 MHz, CDCl3)
  7.37–7.29 (m, 4H), 7.28–7.23 (m, 1H), 7.17 (s, 1H), 6.89 (s, 1H), 5.29–5.24 (m,
1H), 3.96 (s, 3H), 3.93 (s, 3H), 3.78 (t, J = 6.0 Hz, 4H), 3.57 (s, 2H), 2.84–2.75 (m,
2H), 2.42–2.33 (m, 2H), 2.16–2.06 (m, 2H), 2.01–1.90 (m, 2H), 1.84–1.75 (m, 4H),
1.58–1.49 (m, 4H); 13C (100 MHz, CDCl3)   165.0, 158.4, 155.3, 151.3, 145.4, 138.6,
129.2 (2C), 128.3 (2C), 127.2, 105.0, 104.5, 102.6, 71.6, 63.2, 56.1, 56.1, 51.0 (2C),
47.2 (2C), 31.1 (2C), 28.5 (2C), 27.4 (2C). HRMS (ES) (m/z ) calcd. for C28H37N5O2:
476.3026, found: 476.3061.
Compound 15: tert-Butyl 4-4-[(1-benzylpiperidin-4-yl)amino]-6,7-dimethoxyquina-
zolin- 2-ylpiperazine-1-carboxylate
Following general procedure 2, heating N -(1-benzylpiper-
idin-4-yl)-2-chloro-6,7-dimethoxyquinazolin-4-amine (11,
400 mg, 0.96 mmol), and Boc-piperazine (549 mg, 2.90
mmol) for 72 hours, the reaction mixture was purified
by column chromatography (0–5% ammonia methanol
in dichloromethane) to yield the title product as a white
solid (498 mg, 51%). mp 88–90  C; 1H NMR (400 MHz,
CH3OD,  ) 7.45 (s, 1H), 7.38–7.30 (m, 5H), 6.91 (s, 1H), 5.53 (br s, 1H), 4.32–4.19
(m, 1H), 3.95 (s, 3H), 3.93 (s, 3H), 3.82 (t, J = 8.0 Hz, 4H), 3.61 (s, 2H), 3.21–2.95
(m, 4H), 2.22 (t, J = 8.4 Hz, 2H), 2.25 (d, J = 8.0 Hz, 2H), 1.89–1.68 (m, 4H),
1.23–1.16 (m. 9H) ; 13C (100 MHz, CH3OD)   162.8, 162.7, 159.1, 158.3, 152.1, 149.7,
141.0, 133.8 (2C), 131.9 , 131.0, 108.5, 107.6, 106.4, 83.9, 66.6 (2C), 59.3, 58.7, 56.4,
52.1 (2C), 52.1, 50.9, 47.8 (2C), 34.8 (2C), 31.3 (3C); HRMS (ES) (m/z ) calcd. for
C31H43N6O4: 563.3346, found: 563.3336.
Compound 16: N -(1-Benzylpiperidin-4-yl)-6,7-dimethoxy-2-(4-phenylpiperazin-1-
yl) quinazolin-4-amine
Following general procedure 2, heating N -(1-benzylpiper-
idin-4-yl)-2-chloro-6,7-dimethoxyquinazolin-4-amine (11,
123 mg, 0.3 mmol) , and 1-phenylpiperazine (0.46 mL,
3.0 mmol) for 24 hours, the reaction mixture was purified
by column chromatography (0–2% ammonia methanol in
dichloromethane) to yield the title product as a yellow
solid (56 mg, 35%). mp 74–76  C; IR (cm 1) 3393.93,
2932.75, 2826.47; 1H NMR (400 MHz, CH3OD,  ) 7.38 (s, 1H), 7.34–7.28 (m, 4H),
7.26–7.19 (m, 3H),7.00–6.94 (m, 2H), 6.85–6.80 (m, 2H), 4.17–4.09 (m, 1H), 3.90 (t, J
= 4.8 Hz, 4H), 3.87 (s, 3H), 3.85 (s, 3H), 3.27 (s, 2H), 3.18 (t, J = 5.2 Hz, 4H), 2.97
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(d, J = 12 Hz, 2H), 2.17 (t, J = 12.0 Hz, 2H), 2.06 (d, J = 12.0 Hz, 2H), 1.72–168
(m, 2H); HRMS (ES) (m/z ) calcd. for C32H38N6O2: 539.3134, found: 539.3120.
Compound 18: N -(1-(4-Fluorobenzyl)piperidin-4-yl)-6,7-dimethoxy-2-(4-methylpi-
perazin-1-yl) quinazolin-4-amine
Following general procedure 3, heating 2-chloro-N -(1-(4-
fluorobenzyl)piperidin-4-yl)-6, 7-dimethoxyquinazolin-4-
amine (50 mg, 0.116 mmol), and methyl piperazine (0.12
mL, 1.16 mmol), the reaction mixture was purified by
column chromatography (0–5% ammonia methanol in
dichloromethane) to yield the title product as a white
solid (40 mg, 70%). mp 75–78  C; IR (cm 1) 3395, 2938, 2795, 1627, 1573; 1H NMR
(400 MHz, CDCl3,  ) 7.30 (t, J = 17.6 Hz, 2H), 6.99 (t, J = 17.6 Hz, 2H), 6.92 (s,
1H), 6.72 (s, 1H), 5.07 (d, J = 6.8 Hz, 1H), 4.19–4.11 (m, 1H), 3.95 (s, 3H), 3.93 (s,
3H), 3.87 (t, J = 4.8 Hz, 4H), 3.51 (s, 2H), 2.90 (d, J = 12.0 Hz, 2H), 2.50 (t, J =
4.8 Hz, 4H), 2.35 (s, 3H), 2.19 (q, J = 12.0 Hz, 4H), 1.64–160 (m, 2); 13C (100 MHz,
CDCl3,  ) 163.2 (d, J = 243.3 Hz), 158.2, 154.4, 149.1, 145.5, 134.1 (d, J = 2.8 Hz),
130.6 (d, J = 7.9 Hz), 130.5, 115.1, 115.0 (2C), 106.1, 103.1, 100.6, 62.2, 56.3, 55.9,
55.2 (2C), 52.4 (2C), 48.2, 46.3, 44.0 (2C), 32.2 (2C); HRMS (ES) (m/z ) calcd. for
C27H36FN6O2: 495.2884, found: 495.2892.
Compound 19: N -(1-(4-Fluorobenzyl)piperidin-4-yl)-6,7-dimethoxy-2-(piperidin-1-
yl)
quinazolin-4-amine
Following general procedure 3, heating 2-chloro-N -(1-
(4-fluorobenzyl)piperidin-4-yl)-6,7-dimethoxyquinazolin- 4-
amine (50 mg, 0.116 mmol), and piperidine (0.11 mL, 1.16
mmol), the reaction mixture was purified by column chro-
matography (0–4% ammonia methanol in dichloromethane)
to yield the title product as a yellow solid (16 mg, 70%).
mp 79–82  C; IR (cm 1) 3394.5, 2934.7, 2862.7, 2254.66, 1629.6, 1571.2; 1H NMR
(400 MHz, CDCl3,  ) 7.31–7.28 (m, 2H), 7.03-6.99 (m, 3H), 6.83 (s, 1H), 5.40 (br. s,
1H), 4.18 - 4.10 (m, 1H), 3.94 (s, 3H), 3.92 (s, 3H), 3.83-3,82 (m, 4H), 3.51 (s, 2H),
2.88 (d, J = 11.6 Hz, 2H), 2.22–2.13 (m, 4H), 1.82–1.64 (m, 8H); 13C (100 MHz,
CDCl3,  ) 163.2 (d, J = 243.1 Hz), 160.7, 158.1, 154.3, 145,4, 134.1, 130.5 (d, J =
8.2 Hz, 2C), 115.1, 114.9 (2C), 105.3, 102.7, 101.0, 62.2, 56.3, 56.0, 52.5 (2C), 48.4,
45.3 (2C), 32.0 (2C), 25.9 (2C), 24.9 ; HRMS (ES) (m/z ) calcd. for C27H35FN5O2:
480.2775, found: 480.2787.
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Compound 20: N -(1-(4-Fluorobenzyl)piperidin-4-yl)-6,7-dimethoxy-2-(4-(pyridin-
2-yl) piperazin-1-yl)quinazolin-4-amine
Following general procedure 3, heating 2-chloro-N -(1-
(4-fluorobenzyl)piperidin-4-yl)-6,7-dimethoxyquinazo-
lin-4-amine (50 mg, 0.116 mmol), and 1-(2-pyridyl)pi-
perazine (0.18 mL, 1.16 mmol), the reaction mixture
was purified by column chromatography (0–5% am-
monia methanol in dichloromethane) to yield the title
product as a yellow solid (62 mg, 96%). mp 79–82  C;
IR (cm 1) 3396, 2937, 2843, 2254, 1627, 1574; 1H NMR (400 MHz, CDCl3,  ) 8.20
(d, J = 3.6 Hz, 1H), 7.52 (t, J = 6.8 Hz, 1H), 7.32–7.27 (m, 2H), 7.04–6.99 (m, 3H),
6.82 (s, 1H), 6.70 (d, J = 7.6 Hz, 1H), 6.66–6.63 (m, 1H), 5.35 (br s, 1H), 4.21–4.13
(m, 1H), 4.00–3.97 (m, 4H), 3.97 (s, 3H), 3.95 (s, 3H), 3.67–3.64 (m, 4H), 3.52 (s,
2H), 2.90 (d, J = 12.0 Hz, 2H), 2.23–2.14 (m, 4H), 1.66–163 (m, 2H); 13C (100 MHz,
CDCl3,  ) 163.2 (d, J = 243.2), 161.1, 159.6, 158.5, 158.3, 154.4, 147.9, 145.6, 137.5,
134.0, 130.6 (d, J = 8.1 Hz, 2C), 115.1, 114.9, 113.3, 107.2, 105.8, 103.2, 100.8, 62.2,
56.3, 56.0, 52.4 (2C), 48.5 (2C), 45.2 (2C), 43.9 (2C), 32.1 (2C); HRMS (ES) (m/z )
calcd. for C31H37FN7O2: 558.2993, found: 558.2975.
Compound 21: N -(1-(3-Fluorobenzyl)piperidin-4-yl)-6,7-dimethoxy-2-(4-methylpi-
perazin -1-yl) quinazolin-4-amine
Following general procedure 3, heating 2-chloro-N -(1-(3-
fluorobenzyl)piperidin-4-yl)-6,7-dimethoxyquinazolin-4-a-
mine (50 mg, 0.116 mmol), and methyl piperazine (0.12
mL, 1.16 mmol), the reaction mixture was purified by
column chromatography (0–5% ammonia methanol in di-
chloromethane) to yield the title product as a yellow solid
(51 mg, 71%). mp 101–104  C; IR (cm 1) 3397, 2937, 2796, 1627, 1574 ; 1H NMR
(400 MHz, CDCl3,  ) 7.27 (m, 1H), 7.01 (d, J = 7.2 Hz, 2H), 6.98–6.92 (m, 2H),
6.73 (s, 1H), 5.06 (d, J = 6.8 Hz, 1H), 4.20–4.11 (m, 1H), 3.96 (s, 3H), 3.95 (s, 3H),
3.55 (t, J = 4.8 Hz, 4H), 3.55 (s, 2H), 2.90 (d, J = 12.0 Hz, 2H), 2.50 (t, J = 4.8 Hz,
4H), 2.32 (s, 3H), 2.14–2.03 (m, 4H), 1.63 (qd, J = 12.0, 3.6 Hz, 2H); 13C (100 MHz,
CDCl3,  ) 164.2 (d, J = 243.4 Hz), 158.2, 154.4, 149.1, 145.3, 141.3 (d, J = 6.8 Hz),
129.5 (), 124.4, 115.7, 114.0, 113.8, 106.1, 103.1, 100.5, 62.5, 56.3, 55.9, 55.2 (2C),
48.1, 46.3 (2C), 44.0 (2C), 32.3 (2C); HRMS (ES) (m/z ) calcd. for C27H36FN6O2:
495.3884, found: 495.2897.
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Compound 22: N -(1-(3-Fluorobenzyl)piperidin-4-yl)-6,7-dimethoxy-2-(piperidin-1-
yl) quinazolin-4-amine
Following general procedure 3, heating 2-chloro-N -(1-(3-
fluorobenzyl) piperidin-4-yl)-6,7-dimethoxyquinazolin-4-a-
mine (50 mg, 0.116 mmol), and piperidine (0.12 mL, 1.16
mmol), the reaction mixture was purified by column chro-
matography (0–4% ammonia methanol in dichloromethane)
to yield the title product as a yellow solid (47 mg, 85%).
mp 66–69  C; IR (cm 1) 3399, 2934, 2852, 2254, 1628; 1H NMR (400 MHz, CDCl3,
 ) 7.30–7.25 (m, 1H), 7.01 (d, J = 7.6 Hz, 2H), 6.99-6.93 (m, 2H), 6.82 (s, 1H), 5.27
(br s, 1H), 4.20–4.18 (m, 1H), 3.94 (s, 3H), 3.93 (s, 3H), 3.84-3.78 (m, 4H), 3.54 (s,
2H), 2.89 (d, J = 11.6 Hz, 2H), 2.24-2.13 (m, 4H), 1.70–1.66 (m, 8H); 13C (100 MHz,
CDCl3,  ) 164.1 (d, J = 243.0 Hz), 161.7, 158.2, 154.3, 145.3, 141.5 (d, J = 6.8 Hz),
129.6 (d, J = 6.8 Hz), 124.3, 115.0, 113.9, 113.7, 105.6, 102.8, 100.9, 62.4, 56.3, 56.0,
52.6 (2C), 48.3, 45.2 (2C), 32.1 (2C), 25.9 (2C), 25.0; HRMS (ES) (m/z ) calcd. for
C27H35FN5O2: 480.2775, found: 480.2769.
Compound 23: N -(1-(2-Fluorobenzyl)piperidin-4-yl)-6,7-dimethoxy-2-(4-methylpi-
perazin-1-yl) quinazolin-4-amine
Following general procedure 3, heating 2-chloro-N -(1-(2-
fluorobenzyl)piperidin-4-yl)-6,7-dimethoxyquinazolin-4-am-
ine (50 mg, 0.116 mmol), and methyl piperazine (0.12 mL,
1.16 mmol), the reaction mixture was purified by column
chromatography (0–5% ammonia methanol in dichlorometh-
ane) to yield the title product as a yellow solid (56 mg, 98%).
mp 85–88  C; IR (cm 1) 3396, 2937, 2796, 2256, 1627, 1574;
1H NMR (400 MHz, CDCl3,  ) 7.49 (t, J = 7.6Hz, 1H), 7.28–7.23 (m, 1H), 7.13 (t,
J = 7.6 Hz, 1H), 7.05 (t, J = 4.8 Hz, 1H), 6.91 (s, 1H), 6.7 (s, 1H), 5.06 (d, J = 7.2
Hz, 1H), 4.19–4.09 (m, 1H), 3.95 (s, 3H), 3.93 (s, 3H), 3.87 (br s, 4H), 3.64 (s, 2H),
2.93 (d, J = 12.0 Hz, 2H), 2.50 (t, J = 4.8 Hz, 4H), 2.35 (s, 3H), 2.55–2.14 (m, 2H),
2.15 (d, J = 10.0 Hz, 2H),1.64 (qd, J = 12.0, 2.8 Hz, 2H); 13C (100 MHz, CDCl3,  )
162.6 (d, J = 159.8 Hz), 158.8, 158.2, 154.4, 149.1, 145.5, 131.5 (d, J = 3.7 Hz) ,
128.8 (d, J = 8.4 Hz), 124.8 (d, J = 14.9 Hz), 123.8, 115.2 (d, J = 2.21 Hz), 106.1,
103.1, 100.6, 56.2, 55.9, 55.3, 55.2, 55.1, 52.3 (2C), 48.0, 46.3, 39.8 (2C), 29.7 (2C);
HRMS (ES) (m/z ) calcd. for C27H36FN6O2: 495.2884, found: 495.2882.
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Compound 24: 6,7-Dimethoxy-N -(1-(3-methoxybenzyl)piperidin-4-yl)-2-(4-meth-
ylpiperazin-1-yl)quinazolin-4-amine
Following general procedure 3, heating 2-chloro-6,7-dime-
thoxy-N -(1-(3-methoxybenzyl)piperidin-4-yl)quinazolin-
4-amine (50 mg, 0.113 mmol), and methyl piperazine
(0.12 mL, 1.13 mmol), the reaction mixture was purified
by column chromatography (0–6% ammonia methanol
in dichloromethane) to yield the title product as a yellow
solid (45 mg, 79%). mp 62–64  C; IR (cm 1) 3396, 2937, 2836, 2795, 2255, 1627,
1574; 1H NMR (400 MHz, CDCl3,  ) 7.27–7.23 (m, 1H), 6.93 (m, 1H), 6.81 (dd, J =
10.0, 8 Hz, 1H), 6.73 (s, 1H), 5.07 (d, J = 6.8 Hz, 1H), 4.19–4.10 (m, 1H), 3.95 (s,
3H), 3.94 (s, 3H), 3.87 (br s, 4H), 3.82 (s, 3H), 3.55 (s, 2H), 2.92 (d, J = 12.0 Hz,
2H), 2.50 (t, J = 4.8 Hz, 4H), 2.29 (s, 3H), 2.18–2.143 (m, 4H), 1.63 (qd, J = 11.2,
2.8 Hz, 2H); 13C (100 MHz, CDCl3,  ) 159.6, 158.8, 158.2, 154.4, 149.1, 145.5, 140.1,
129.1, 121.4, 114.6, 112.3, 106.1, 103.1, 100.6, 63.0, 56.3, 55.9, 55.2 (2C), 55.0, 52.6
(2C), 48.2, 46.3, 44.0 (2C), 32.2 (2C); HRMS (ES) (m/z ) calcd. for C28H37N6O3:
507.3084, found: 507.3098.
Compound 78a: 4-Benzyloxy-3-methoxy-benzonitrile [24]
4-Hydroxy-3-methoxybenzonitrile (7.85 g, 52.64 mmol) in DMF (100
mL) was ice-cooled, followed by addition of potassium carbonate
(10.914 g, 78.96 mmol) and then benzyl bromide (6.9 mL, 57.9 mmol).
The reaction mixture was stirred overnight at room temperature. The
mixture was poured onto brine (180 mL), and the resulting precipitates were filtered,
washed with water and dried under vacuum to a↵ord the title compound as a pale
orange solid (12.60 g, quant). mp 238–130  C; IR (cm 1) 2223, 1595, 1512, 1267,
1241, 1132, 984; 1H NMR (400 MHz, CDCl3,  ) 7.43-7.31 (m, 5H), 7.21 (dd, J =
8.2, 1.9 Hz, 1H), 7.09 (d, J = 1.9 Hz, 1H), 6.90 (d, J = 8.2 Hz, 1H), 5.20 (s, 2H),
3.90 (s, 3H); 13C (100 MHz, CDCl3,  ) 151.9, 149.6, 135.7, 128.7 (2C), 128.2 (2C),
127.2, 126.2, 119.2, 114.3, 113.2, 104.1, 70.8, 56.1; HRMS (CI) (m/z ) calcd. for
C15H17N2O2: 257.1292, found: 257.1290.
Compound 78b: 4,5-Dibenzyloxybenzonitrile
3,4-Dihydroxybenzonitrile (10.0 g, 74.0 mmol) in DMF (100 mL) was
ice-cooled, followed by addition of potassium carbonate (27.80 g, 162.8
mmol) and then benzyl bromide (17.8 mL, 185.0 mmol). The reaction
mixture was stirred overnight at room temperature. The mixture was
poured onto brine (180 mL), and the resulting precipitates were filtered, washed with
water and dried under vacuum to a↵ord the title compound as a white solid (20.1 g,
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83%). mp 34–36  C; 1H NMR (400 MHz, CDCl3,  ) 7.48-7.36 (m, 10H), 7.25 (dd, J
= 4.4, 2 Hz, 1H), 7.18 (d, J = 2.0 Hz, 1H), 6.98 (d, J = 4.4 Hz, 1H), 5.24 (s, 2H),
5.19 (s, 2H); 13C (100 MHz, CDCl3,  ) 152.8, 148.7, 136.1, 136.0 (2C), 128.7 (2C),
128.2 (2C), 127.3 (2C), 127.1 (2C), 126.8 (2C), 119.1, 117.4, 114.0, 104.2, 71.3, 70.9;
HRMS (ES) (m/z ) calcd. for C21H18NO2: 316.1346, found: 316.1338.
Compound 79a: 4-Benzyloxy-5-methoxy-2-nitrobenzonitrile [24]
A solution of 4-benzyloxy-3-methoxybenzonitrile (78a ,12.04 g, 50.3
mmol) in acetic anhydride (100 mL) was cooled to 0  C, followed by
slow addition of 69 wt% nitric acid (18.2 mL, 55 mmol). The reaction
mixture was stirred overnight at room temperature, then poured into
ice-water. The resulting precipitates were collected, washed with water and dried
to provide the title product as a yellow solid (14.35 g, 95%). mp 128–130  C; IR
(cm 1) 2228, 1572, 1533, 1517, 1336, 1288, 1223, 1057, 750; 1H NMR (400 MHz,
CDCl3,  ) 7.85 (s, 1H), 7.46–7.37 (m, 5H), 7.21 (s, 1H), 5.27 (s, 2H), 4.01 (s, 3H);
13C (100 MHz, CDCl3,  ) 153.9, 151.3, 142.6, 135.9, 129.1 (2C), 128.9 (2C), 128.6,
117.2, 116.2, 110.1, 100.3, 71.3, 57.6; HRMS (CI) (m/z ) calcd. for C15H16N3O4:
302.1141, found: 303.1141.
Compound 79b: 4,5-Dibenzyloxy-2-nitrobenzonitrile
A solution of 4,5-dibenzyloxybenzonitrile (78b, 20 g, 63.42 mmol)
in acetic anhydride (150 mL) was cooled to 0  C, followed by slow
addition of 69 wt% nitric acid (23 mL). The reaction mixture was
stirred overnight at room temperature, then poured into ice-water.
The resulting precipitates were collected, washed with water and dried to provide
the little product as a yellow solid (20.80 g, 91%). mp 152–154  C; IR (cm 1) ; 1H
NMR (400 MHz, CDCl3,  ) 7.86 (s, 1H), 7.46–7.36 (m, 10H), 7.24 (s, 1H), 5.29 (s,
2H), 5.27 (s, 2H); 13C (100 MHz, CDCl3,  ) 152.9, 151.7, 142.7 (2C), 134.6 (2C),
128.9 (2C), 128.7 (2C), 127.4 (2C), 127.2 (2C), 117.7, 115.4, 110.0, 100.8, 71.7, 71.5;
HRMS (ES) (m/z ) calcd. for C21H17N2O4: 361.1188, found: 361.1180.
Compound 79c: 6-Nitrobenzo[d][1,3]dioxole-5-carbonitrile
A solution of benzo[d][1,3]dioxole-5-carbonitrile (3.63 g, 24.7 mmol)
in acetic anhydride (150 mL) was cooled to 0  C, followed by slow
addition of 69 wt% nitric acid (10 mL). The reaction mixture was
stirred for 24 hours at room temperature, then poured into ice-cooled
water. The resulting precipitates were collected, washed with water and dried to
provide the tittle product as a yellow solid (3.95 g 76%). mp 92–94  C; IR (cm 1)
3115, 3059, 2923, 2229; 1H NMR (400 MHz, CDCl3,  ) 7.73 (s, 1H), 7.19 (s, 1H),
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6.28 (s, 2H); 13C (100 MHz, CDCl3,  ) 152.4, 151.7, 145.16, 115.03, 113.0, 106.2,
104.5, 102.9; HRMS (EI) (m/z ) calcd. for C8H4N2O4: 192.0171, found: 192.0168.
Compound 80a: 2-Amino-4-benzyloxy-2-methoxybenzonitrile [24]
Tetrabutylammonium bromide (10.40 g, 36.8 mmol) was added to a
solution of 4-benzyloxy-5-methoxy-2-nitrobenzonitrile (79a, 13.35 g,
46.9 mmol) in dichloromethane (200 mL), followed by slow addition
of a solution of sodium dithionite (54.99 g, 315.84 mmol) in water
(200 mL). The mixture was stirred overnight at room temperature and then basified
with 2 N sodium hydroxide. The aqueous layer was extracted with dichloromethane
(50 mL). The organic layer was concentrated, and the residue poured onto water.
The precipitate was filtered and dried to yield the title product (11.94 g, 66%). IR
(cm 1) 3440, 3352, 3243, 2205, 1641, 1620, 1505, 1239, 1119, 985; 1H NMR (400
MHz, CDCl3,  ) 7.40–7.31 (m, 5H), 6.82 (s, 1H), 6.26 (s, 1H), 5.13 (s, 2H), 4.18 (br
s, 2H), 3.81 (s, 3H); 13C (100 MHz, CDCl3,  ) 153.8, 148.7, 140.9, 136.7, 128.9 (2C),
128.5 (2C), 128.4, 119.1, 114.8, 100.6, 84.3, 70.0, 56.7; HRMS (CI) (m/z ) calcd. for
C15H16N3O4: 272.1391, found: 272.1402.
Compound 80b: 2-Amino-4,5-dibenzyloxy-benzonitrile
Tetrabutylammonium bromide (5.17 g, 18.32 mmol) was added to
a solution of 4,5-dibenzyloxy-2-nitrobenzonitrile (79b, 20.0 g, 55.5
mmol) in dichloromethane (250 mL), followed by slow addition of a
solution of sodium dithionite (38.65, 222.0 mmol) in water (250 mL).
The mixture was stirred overnight at room temperature and then basified with 2
N sodium hydroxide. The aqueous layer was extracted with dichloromethane (50
mL). The organic layer was concentrated, and the residue poured onto water. The
precipitate was filtered and purified by column chromatography (10% methanol in
dichloromethane) to yield the title product (1.0 g, 5.5%). The starting material was
recovered (10.5 g, 52.5%) mp 122–124  C; IR (cm 1) 3362, 3064, 2211,1636; 1H NMR
(400 MHz, CDCl3,  ) 7.86 (s, 1H), 7.46-7.36 (m, 10H), 7.24 (s, 1H), 5.29 (s, 2H), 5.27
(s, 2H), 4.15 (br s, 2H); HRMS (ES) (m/z ) calcd. for C21H19N2O2: 330.1368, found:
330.1377.
Compound 80c: 6-Aminobenzo[d][1,3]dioxole-5-carbonitrile
Tetrabutylammonium bromide (2.64 g, 8.19 mmol) was added to a
solution of 6-nitrobenzo[d][1,3]dioxole-5-carbonitrile (79c, 3.0 g, 24.6
mmol) in dichloromethane (25 mL), followed by slow addition of a
solution of sodium dithionite (17.12 g, 98.3 mmol) in water (25 mL).
The mixture was stirred for 3 days at room temperature and then basified with 2
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N sodium hydroxide. The aqueous layer was extracted with dichloromethane (50
mL). The organic layer was concentrated and precipitate by adding HCl in ether.
The salt was washed with ether and basified by 2 N sodium hydroxide. The aqueous
layer was washed with ethyl acetate. The organic layer was dried and concentrated
under reduced pressure to give a yellow solid (1.6 g, 40%) mp 108–110  C; IR (cm 1)
3171, 3032, 2834, 2199; 1H NMR (400 MHz, CDCl3,  ) 6.73 (s, 1H), 6.25 (s, 1H),
5.93 (s, 2H), 4.24 (br s, 2H); 13C (100 MHz, CDCl3,  ) 153.0, 147.7, 140.0, 118.1,
109.3, 101.8, 96.7, 86.6; HRMS (ES) (m/z ) calcd. for C8H6N2O2: 162.0429, found:
162.0421.
Compound 81a: Methyl-5-(benzyloxy)-2-cyano-4-methoxyphenylcarbamate [24]
Methyl chloroformate (3.1 mL , 40.5 mmol) was added into the solution
of 2-amino-4-benzyloxy-5-methoxybenzonitrile (80a, 7.00 g, 27 mmol)
and DIEA (17 mL, 100 mmol) in co-solvent DMA : DCM (50 mL
: 25 mL) at 0  C. The reaction solution was stirred overnight at
room temperature, then 150 mL of water was added. The resulting
precipitates were collected, washed with water and dried to a↵ord the
title compound as a yellow solid (9.11 g, quant). mp 118–120  C; IR (cm 1) 3329,
2223, 1716, 1595, 1510 1220, 1128, 996; 1H NMR (400 MHz, DMSO-d6,  ) 9.55 (br s,
1H), 7.47–7.37 (m, 5H), 7.35 (s, 1H), 7.19 (s, 1H), 5.14 (s, 2H), 3.80 (s, 3H), 3.67
(s, 3H); 13C (100 MHz, DMSO-d6,  ) 155.2, 152.2, 147.1, 136.5, 135.7, 129.0, 128.7
(2C), 128.5 (2C), 117.6, 114.9, 111.2, 99.8, 70.6, 56.6, 52.5; HRMS (CI) (m/z ) calcd.
for C17H20N3O4: 330.1454, found: 330.1462.
Compound 81b: Methyl-4,5-(dibenzyloxy)-2-cyano-4-methoxyphenylcarbamate
Methyl chloroformate (0.4 mL, 5.0 mmol) was added to a the solution
of 2-amino-4,5-dibenzyloxy-benzonitrile (80b, 1.1g, 3.3 mmol) and
DIEA (5.8 mL, 13.2 mmol) in co-solvent DMA : DCM (10 mL : 5 mL)
at 0  C. The reaction solution was stirred overnight at room temper-
ature, then 150 mL of water was added. The resulting precipitates
were collected, washed with water and dried to a↵ord the title compound as a yellow
solid (1.1 g, quant). mp 102–104  C; IR (cm 1) 3066, 2221, 1795, 151.96 cm; 1H
NMR (400 MHz, CDCl3,  ) 7.47–7.36 (m, 10H), 7.187 (s, 1H), 6.84 (s, 1H), 5.21 (s,
2H), 5.19 (s, 2H), 3.81 (s, 3H); HRMS (ES) (m/z ) calcd. for C23H20N2O4: 388.1423,
found: 388.1428.
Compound 81c: Methyl 6-cyanobenzo[d][1,3]dioxol-5-ylcarbamate
Methyl chloroformate (1.08 mL, 13.8 mmol) was added to a the
solution of 6-aminobenzo[d][1,3]dioxole-5-carbonitrile (80c, 1.1g, 3.3
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mmol) and DIEA (5.8 mL, 13.2 mmol) in co-solvent DMA : DCM
(10 mL : 20 mL) at 0  C. The reaction solution was stirred overnight
at room temperature, then 150 mL of water was added. The resulting precipitates
were collected, washed with water and dried to a↵ord the title compound as a yellow
solid (1.41 g, 69%). mp 106–108  C; 1H NMR (400 MHz, CDCl3,  ) 7.76 (s, 1H),
7.10 (br s, 1H), 6.91 (s, 1H), 6.07 (s, 2H), 3.83 (s, 3H); 13C (100 MHz, CDCl3,  )
153.4, 152.7, 143.4, 138.1, 116.6, 109.7, 109.3, 102.5, 101.7, 52.9; HRMS (ES) (m/z )
calcd. for C10H9N2O4: 221.0562, found: 221.0558.
Compound 82a: 7-(Benzyloxy)-6-methoxyquinazoline-2,4(1H,3H )-dione [24]
Methyl 5-(benzyloxy)-2-cyano-4-methoxyphenyl carbamate (81a,
8.1 g, 26.1 mmol) was mixed with hydrogen peroxide (50 mL of 35
wt.% solution in water, 224 mmol) and sodium hydroxide (10.4 g,
260.0 mmol) in ethanol (300 mL) and the resulting mixture was
stirred for 4 hours under reflux. The solution was cooled to room
temperature, and acidified with 1 N HCl. The resulting precipitates were filtered,
washed with water and dried to a↵ord the title product as a pale yellow solid (5.27
g, 70%). mp 226–228  C; IR (cm 1) 1718, 1649, 1618, 1512, 1267, 1107, 838 cm 1;
1H; 1H NMR (400 MHz, DMSO-d6,  ) 11.12 (s, 1H), 10.94 (s, 1H), 7.50–7.38 (m,
5H), 7.30 (s, 1H), 6.80 (s, 1H), 5.16 (s, 2H), 3.80 (s, 3H); 13C (100 MHz, DMSO-d6,
 ) 163.6, 154.1, 152.3, 145.2, 139.2, 136.6, 128.9 (2C), 128.6 (2C), 128.5, 107.8,
107.2, 100.6, 70.4, 56.2; HRMS (CI) (m/z ) calcd. for C16H15N2O4: 299.1032, found:
299.1036.
Compound 82b: 6,7-(Dibenzyloxy)-quinazoline-2,4(1H,3H )-dione
Methyl-4,5-(dibenzyloxy)-2-cyano-4-methoxyphenylcarbamate (81b,
1.0 g, 2.8 mmol) was mixed with hydrogen peroxide (1.9 mL of 35
wt.% solution in water, 28 mmol) and sodium hydroxide (0.56 g, 14.0
mmol) in ethanol 10 mL) and the resulting mixture was stirred for
5 hours under reflux. The solution was cooled to room temperature,
and acidified with 3 N HCl. The resulting precipitates were filtered, washed with
water and dried to a↵ord the title product as a pale yellow solid (657 mg, 63%). mp
188–190  C; IR (cm 1) 3167, 3033, 2833, 1702, 1620; 1H NMR (400 MHz, DMSO-d6,
 ) 11.09 (s, 1H), 10.94 (s, 1H), 7.47–7.29 (m, 11H), 6.78 (s, 1H), 5.20 (s, 2H), 5.15 (s,
2H); HRMS (ES) (m/z ) calcd. for C22H17N2O4: 373.1188, found: 373.1195.
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Compound 82c: [1,3]Dioxolo[4,5-g]quinazoline-6,8(5H,7H )-dione
Methyl 6-cyanobenzo[d][1,3]dioxol-5-ylcarbamate (81c, 1.4 g, 6.36
mmol) was mixed with hydrogen peroxide (7.3 mL of 35 wt.% solution
in water, 28 mmol) and sodium hydroxide (1.27 g, 31.8 mmol) in
ethanol 50 mL) and the resulting mixture was stirred overnight under
reflux. The solution was cooled to room temperature, and acidified
with 3 N HCl. The resulting precipitates were filtered, washed with water and dried
to a↵ord the title product as a pale yellow solid (796 mg, 61%). mp >200  C; 1H
NMR (400 MHz, DMSO-d6,  )11.17 (s, 1H), 11.0 (s, 1H), 7.20 (s, 1H), 6.63 (s, 1H),
6.11 (s, 2H); 13C (100 MHz, DMSO-d6,  ) 162.6, 153.6, 150.6, 144.1, 138.6, 108.0,
104.5, 102.7, 95; MS cannot be obtained by ES and CI
Compound 83a: 7-(Benzyloxy)-2,4-dichloro-6-methoxyquinazoline [24]
A mixture of 7-(benzyloxy)-6-methoxyquinazoline-2,4(1H,3H )-dione
(82a, 5.24, 17.61 mmol), N,N -diethylaniline (2.8 mL, 17.61 mmol)
and POCl3 (15.0 mL) in acetonitrile (45 mL) was stirred under
reflux for 6 hours. The solution was concentrated under reduced
pressure to 10 mL and the residue was poured onto ice-water (150
mL). The precipitates were collected, washed with water and dried to a↵ord the title
compound (5.3 g, 90%). mp 130–132  C; IR (cm 1) 1611, 1547, 1500, 1424, 1237,
1149, 847; 1H NMR (400 MHz, CDCl3,  ) 7.50–7.35 (m, 5H), 7.36 (s, 1H), 7.29 (s,
1H), 5.32 (s, 2H), 4.08 (s, 3H); 13C (100 MHz, CDCl3,  ) 160.1, 156.8, 153.5, 151.9,
150.4, 134.8, 128.9 (2C), 128.6 (2C), 127.4, 117.9, 107.6, 102.8, 71.4, 56.5; HRMS
(ES) (m/z ) calcd. for C16H13N2O2Cl2: 335.0276, found: 335.0370.
Compound 83b: 6,7-(Dibenzyloxy)-2,4-dichloro-6-methoxyquinazoline
A mixture of 6,7-(dibenzyloxy)-quinazoline-2,4(1H,3H )-dione (82b,
400 mg, 1.07 mmol), N,N -diethylaniline (0.17 mL, 1.07 mmol) and
POCl3 (10.0 mL) in acetonitrile (5 mL) were stirred under reflux for
24 hours. The solution was concentrated under reduced pressure and
the residue was poured onto ice-water (50 mL). The solid was dissolved in dichloro-
methane and washed with water. The combined organic layers were concentrated.
The reaction mixture was purified by column chromatography (dichloromethane)
to yield the title product as white solid (155 mg, 35%). mp 118–120  C; 1H NMR
(400 MHz, CDCl3,  ) 7.52–7.30 (m, 11H), 5.33 (s, 2H), 5.32 (s, 2H);
13C (100 MHz,
CDCl3,  ) 160.0, 157.2, 153.5, 150.8 150.3, 135.4 (2C), 135.0 (2C), 128.8 (2C), 128.4
(2C), 127.3 (2C), 127.1 (2C), 115.8, 107.8, 104.9, 71.2, 71.1; HRMS (ES) (m/z ) calcd.
for C22H16N2O2Cl2: 410.0581, found: 410.0589.
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Compound 83c: 6,8-Dichloro-[1,3]dioxolo[4,5-g]quinazoline [162]
A mixture of [1,3]dioxolo[4,5-g]quinazoline-6,8(5H,7H )-dione (82c,
750 mg, 3.64 mmol), N,N -diethylaniline (0.57 mL, 3.64 mmol) and
POCl3 (7 mL) in acetonitrile (15 mL) were stirred under reflux for
24 hours. The solution was concentrated under reduced pressure
and the residue was poured onto ice-water (50 mL). The precipitate were collected,
washed with water and dried to a↵ord the title compound (605 mg, 80%). mp
188–190  C; 1H NMR (400 MHz, DMSO-d6,  ) 7.65 (s, 1H), 7.48 (s, 1H), 6.44 (s,
2H); HRMS (EI) (m/z ) calcd. for C9H4Cl2N2O2: 241.9650, found: 241.9654.
Compound 83d: 2,4-Dichloroquinazoline
A mixture of commercially available quinazoline-2,4(1H,3H )-dione (2
g, 12.33 mmol), N,N -diethylaniline (1.93 mL, 12.33 mmol) and POCl3
(10.3 mL) in acetonitrile (14 mL) were stirred under reflux for 24 hours.
The solution was concentrated under reduced pressure and the residue
was poured onto ice-water (50 mL). The solid was dissolved in dichloromethane and
washed with water. The organic layer was purified using a thin layer of silica gel.
The residue was concentrated under reduced pressure and dried to a↵ord the title
product as a white solid (2.2 g, 90%). mp 90–92  C; IR (cm 1) 3066, 3044, 2446,
1542; 1H NMR (400 MHz, DMSO-d6,  ) 8.31(d, J = 8.0 Hz, 1H), 8.18 (t, J = 7.2 Hz,
1H), 8.06 (d, J = 7.2 Hz, 1H), 7.92 (t, J =8.0 Hz, 1H); 13C (100 MHz, DMSO-d6,  )
163.9, 162.4, 152.9, 137.5, 135.5, 130.6, 128.0, 126.9; MS (ES) m/z [M+H]+ 199.9
Compound 84a: 7-(Benzyloxy)-N-(1-benzylpiperidin-4-yl)-2- chloro-6-methoxy-
quinazolin-4-amine
Following general procedure 1, using 7-(benzyloxy)-2,4-dichloro-
6-methoxy-quinazoline (83a, 500 g, 1.4 mmol), 4-amino-1-ben-
zylpiperidine (1.04 mL, 2.24 mmol) and DIPEA (1.04 mL, 5.98
mmol) in THF (10 mL) for 24 hours, the reaction mixture was
purified by column chromatography (0–4% ammonia methanol in
dichloromethane) to yield the title product as a pale yellow solid
(245 g, 43%). mp 110–112  C; IR (cm 1) 584, 1514, 1452, 1260, 1218; 1H NMR (400
MHz, CDCl3,  ) 7.38–7.28 (m, 10H), 7.12 (s, 1H), 7.08 (s, 1H), 6.13 (d, J = 8.0 Hz,
1H), 5.20 (s, 2H), 4.30–4.26 (m, 1H), 3.87 (s, 3H), 3.54 (s, 2H), 2.91-2.88 (m, 2H),
2.20–2.16 (m, 2H), 2.09-2.05 (m, 2H), 1.65-1.60 (m, 2H); 13C (100 MHz, CDCl3,  )
159.3, 156.1, 154.0, 149.3, 147.7, 138.0, 135.5, 129.2 (2C), 128.7 (2C), 128.2 (2C),
127.2 (2C), 127.1 (2C), 108.5, 106.9, 100.2, 70.8, 60.4, 56.3, 52.3 (2C), 48.5, 32.0
(2C); HRMS (ES) (m/z ) calcd. for C28H30ClN4O2: 489.2057, found: 489.2047.
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Compound 84b: 6,7-Bis(benzyloxy)-N -(1-benzylpiperidin-4-yl)-2-chloroquinazo-
lin-4-amine
Following general procedure 1, using 6,7-bis(benzyloxy)-2,4-
dichloroquinazoline (83b, 200 mg, 0.48 mmol), 4-amino-1-benzyl-
piperidine (0.20 mL, 0.98 mmol) and DIPEA (0.13 mL, 0.73 mmol)
in THF (5 mL) for 24 hours, the reaction mixture was purified by
column chromatography (20% petroleum ether in ethylacetate) to
yield the title product as a pale yellow crystalline solid (272 mg,
quant). mp 70–72  C; IR (cm 1) 3261, 2938, 2802, 1735, 1618, 1578, 1438 ; 1H NMR
(400 MHz, CDCl3,  ) 7.41–7.28 (m, 15H), 7.15 (s, 1H), 7.11 (s, 1H), 5.93 (d, J = 8.0
Hz, 1H), 5.22 (s, 2H), 5.10 (s, 2H), 4.31–4.23 (m, 1H), 3.55 (s, 2H), 2.87 (d, J = 12.0
Hz, 2H), 2.23 (t, J = 11.2 Hz, 2H), 2.07 (d, J = 9.6 Hz, 2H), 1.62 (dq, J = 12.0,
3.6 Hz, 2H); 13C (100 MHz, CDCl3,  ) 159.3, 156.4, 154.5, 148.3, 147.9, 138.1, 136.3,
135.7, 129.2 (2C), 128.6 (2C), 128.2 (2C), 128.1 (2C), 128.0 , 127.2 (2C), 127.1 (2C),
126.9 (2C), 108.9, 107.0, 103.7, 71.5, 70.6, 63.6, 52.2 (2C), 48.4, 32.0 (2C); HRMS
(ES) (m/z ) calcd. for C34H34ClN4O2: 565.2358, found: 565.2370.
Compound 84c: N -(1-Benzylpiperidin-4-yl)-6-chloro[1,3]dioxolo[4,5-g]quinazolin-8-
amine
Following general procedure 1, using 6,8-dichloro-[1,3]dioxolo[4,5-
g]quinazoline (83c, 590 mg, 2.43 mmol), 4-amino-1-benzylpiper-
idine (0.99 mL, 4.48 mmol) and DIPEA (0.64 mL, 3.64 mmol) in
THF (10 mL) for 24 hours, the reaction mixture was purified by
column chromatography (20% petroleum ether in ethylacetate) to
yield the title product as a a pale yellow solid (729 mg, 75%). mp
178–180  C; IR (cm 1) 3389, 2914, 2765, 1723, 1615, 1578; 1H NMR (400 MHz,
CDCl3,  ) .734-7.27 (m, 5H), 7.06 (s, 1H), 6.97 (s, 1H), 6.09 (s, 2H), 5.51 (d, J =
8.0 Hz, 1H), 4.28-4.20 (m, 1H), 3.56 (s, 2H), 2.89 (d, J = 8.0 Hz, 2H), 2.24 (t, J
= 10.4 Hz, 2H), 2.11 (d, J = 10.4 Hz, 2H), 1.61 (dq, J = 12.0, 3.6 Hz, 2H); 13C
(100 MHz, CDCl3,  ) 159.4, 156.3, 152.9, 149.5, 147.3, 138.1, 129.2 (2C), 128.3 (2C),
127.1, 108.0, 105.2, 102.2, 97.4, 63.1, 52.2 (2C), 48.2, 32.0 (2C); HRMS (ES) (m/z )
calcd. for C21H22ClN4O2: 397.1429, found: 397.1431.
Compound 84d: N -(1-Benzylpiperidin-4-yl)-2-chloroquinazolin-4-amine
Following general procedure 1, using 2,4-dichloroquinazoline (83d,
500 mg, 2.52 mmol), 4-amino-1-benzylpiperidine (0.94 mL, 4.62
mmol) and DIPEA (1.07 mL, 6.16 mmol) in THF (10 mL), the
reaction mixture was purified by column chromatography (3%
methanol in dichloromethane) to yield the title product as a white
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solid (728 mg. 82%). IR (cm 1) 3065, 2444, 1611, 1541; 1H NMR
(400 MHz, CDCl3,  ) 8.16 (d, J = 8.4 Hz, 1H), 7.74 (t, J = 7.2 Hz, 1H), 7.57 (d, J
= 8.4 Hz, 1H) 7.47 (t, J = 7.2 Hz, 1H), 7.35–7.23 (m, 5H), 5.46 (s, 1H), 4.27–4.19
(m, 1H), 3.55 (s, 2H), 2.98 (d, J = 8.0 Hz, 2H), 2.24 (dt, J = 12.0, 2.4 Hz, 2H), 2.15
(dd, J = 10.0, 2.0 Hz, 2H), 1.74 (dq, J = 12.0, 3.6 Hz, 2H); MS (ES) m/z : [M]+
352.1.
Compound 85: 7-(Benzyloxy)-N -(1-benzylpiperidin-4-yl)-6-methoxy-2-(4-methyl-
piperazin-1-yl)quinazolin-4-amine
Following general procedure 2, heating 7-(benzyloxy)-N -(1-
benzylpiperidin-4-yl)-2-chloro-6-methoxy-quinazolin-4-amine (
84a, 0.15 mmol) and 1-methyl piperazine (1.5 mmol) for 24
hours, the reaction mixture was purified by column chroma-
tography (0–4% ammonia methanol in dichloromethane) to
yield the title product as a white solid (40 mg, 49%) mp 58–60
 C; IR (cm 1) 3297.07, 2934.46, 2795.42, 1573.94; 1H NMR (400 MHz, CDCl3,  )
7.49-7.43 (m, 3H), 7.40–7.29 (m, 8H), 6.95 (s, 1H), 6.83 (s, 1H), 5.19 (s, 2H), 4.70
(d, J = 8.0 Hz, 2H), 4.20–4.12 (m, 1H), 3.92 (s, 3H), 3.82 (br s, 4H), 3.66 (s, 2H),
3.02 (d, J = 12.0, 2H), 2.54 (t, J = 4.8 Hz, 4H), 2.23 (t, J =11.6 Hz, 2H), 2.09 (d,
J = 10.8 Hz, 2H), 1.75-1.70 (m, 2H) ; HRMS (EI) (m/z ) calcd. for C33H41N6O2:
553.3291, found: 553.3304.
Compound 86: 7-(Benzyloxy)-N -(1-benzylpiperidin-4-yl)-6-methoxy-2-(piperidin-
1-yl)quinazolin-4-amine
Following general procedure 3, heating 7-(benzyloxy)-N -(1-ben-
zylpiperidin-4-yl)-2-chloro-6-methoxy-quinazolin-4-amine (84a,
40 mg, 0.08 mmol) and piperidine (0.07 mL, 0.80 mmol), the
reaction mixture was purified by column chromatography (0–
4% ammonia methanol in dichloromethane) to yield the title
product as a white solid (32 mg, 46%) mp 66–68  C; IR (cm 1)
3398, 2930, 2846, 1628; 1H NMR (400 MHz, CDCl3,  ) 7.46 (d, J = 8.0 Hz, 2H),
7.38–7.27 (m, 9H), 6.75 (s, 1H), 5.20 (br s, 2H), 4.16–4.09 (m, 1H), 3.91 (s, 3H), 3.79
(br s, 4H), 3.54 (s, 2H), 2.90 (d, J = 12.0 Hz, 2H), 2.23–2.12 (m, 4H), 1.63 (br s,
8H); HRMS (ES) (m/z ) calcd. for C33H40N5O2: 538.2706, found: 538.2725.
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Compound 87: 7-(Benzyloxy)-N -(1-benzylpiperidin-4-yl)-6-methoxy-2-(4-(pyridin-
2-yl)piperazin-1-yl)quinazolin-4-amine
Following general procedure 3, heating 7-(benzyloxy)-N -(1-
benzylpiperidin-4-yl)-2-chloro-6-methoxy-quinazolin-4-am-
ine (84a, 40 mg, 0.08 mmol) and 1-(2-pyridinyl)piperazine
(0.12 mL, 0.80 mmol), the reaction mixture was purified
by column chromatography (0–4% ammonia methanol in
dichloromethane) to yield the title product as a yellow
solid (19 mg, 44%). mp 78–80  C; IR (cm 1) 3398, 2926,
2846, 1928 ; 1H NMR (400 MHz, CDCl3,  ) 8.22 (d, J = 3.6 Hz, 1H), 7.52–7.48 (m,
3H), 7.39–7.27 (m, 8H), 7.02 (br s, 1H), 6.75 (s, 1H), 6.70 (d, J = 8.0 Hz, 1H), 6.63
(m, 1H), 5.25 (s, 2H), 5.12 (br s, 1H), 4.19–4.11 (m, 1H), 3.96 (br s, 4H) 3.93 (s, 3H),
3.64 (t, J = 5.2 Hz, 4H), 3.59 (s, 2H), 2.97 (d, J = 12.0 Hz, 2H), 2.25–2.14 (m, 4H),
1.77 (dq, J = 10.0, 3.6 Hz, 2H); 13C (100 MHz, CDCl3,  ) 159.6, 158.2, 156.2, 148.0,
146.0, 137.5, 136.3, 129.2, 128.6 (2C), 128.3 (2C), 128.0 (2C), 127.4 (2C), 127.1 (2C),
113.3, 107.2, 103.3, 101.2, 63.1, 56.6, 52.5 (2C), 45.3, 43.9, 32.1 (2C); HRMS (ES)
(m/z ) calcd. for C37H42N7O2: 616.3400, found: 616.3408.
Compound 88: 7-(Benzyloxy)-N -(1-benzylpiperidin-4-yl)-6-methoxy-2-morpholi-
noquinazolin-4-amine
Following general procedure 3, heating 7-(benzyloxy)-N -(1-
benzylpiperidin-4-yl)-2- chloro- 6-methoxy-quinazolin-4-amine
(84a, 40 mg, 0.08 mmol) and morpholine (0.07 mL, 0.80 mmol),
the reaction mixture was purified by column chromatography
(0–4% ammonia methanol in dichloromethane) to yield the title
product as a white solid (12 mg, 37%). mp 76–78  C; IR (cm 1)
3390, 2919, 2853, 1628; 1H NMR (400 MHz, CDCl3,  ) 7.45 (d, J = 7.2 Hz, 2H),
7.39-7.27 (m, 8H), 6.97 (br s, 1H), 6.74 (s, 1H), 5.21 (s, 2H), 5.10 (br s, 1H), 4.17-4.09
(m, 1H), 3.91 (s, 3H), 3.79 (s, 8H), 3.56 (s, 2H), 2.92 (d, J = 12.0 Hz, 2H), 2.21 (t, J
= 11.2 Hz, 2H), 2.13 (d, J = 11.2 Hz, 2H), 1.65 (dq, J = 12.0, 4.0 Hz, 2H).; 13C (100
MHz, CDCl3,  ) 158.2, 158.8, 146.0, 138.1, 136.2, 129.2 (2C), 128.6 (2C), 128.2 (2C),
128.0 (2C), 127.4 (2C), 127.1 (2C), 107.5, 103.5, 101.2, 70.5, 67.9, 67.1, 63.1, 56.5,
52.5 (2C), 48.2, 44.6, 32.1 (2C), 25.6. HRMS (ES) (m/z ) calcd. for C32H38N5O3:
540.2975, found: 540.2951.
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Compound 89: 6,7-Bis(benzyloxy)-N -(1-benzylpiperidin-4-yl)-2-(4-methylpiper-
azin-1-yl) quinazolin-4-amine
Following general procedure 3, heating 6,7-bis(benzyloxy)-N -
(1-benzylpiperidin-4-yl)-2-chloroquinazolin-4-amine (84b, 40
mg, 0.07 mmol) and methyl piperazine (0.08 mL, 0.70 mmol),
the reaction mixture was purified by column chromatography
(0–4% ammonia methanol in dichloromethane) to yield the
title product as a yellow solid (12 mg, 27%). mp 64–66  C; IR
(cm 1) 3398, 2926, 2846, 1928; 1H NMR (400 MHz, CH3OD,  ) 7.40 (s, 1H), 7.48
(d, J = 8.0 Hz, 4H), 7.39–7.26 (m, 11H), 6.69 (s, 1H), 5.21 (s, 2H), 5.14 (s, 2H),
4.17–4.09 (m, 1H), 3.82 (br s, 4H), 2.99 (d, J = 12.0 Hz, 2H), 2.51 (t, J = 7.2 Hz,
4H), 2.34 (s, 3H), 2.21 (t, J = 12.0 Hz, 4H), 2.07 (d, J = 12.0 Hz, 2H), 1.73 (dq, J
= 12.0, 2.7 Hz, 2H); HRMS (ES) (m/z ) calcd. for C39H45N6O2: 629.3604, found:
629.3628.
Compound 90: 6,7-Bis(benzyloxy)-N -(1-benzylpiperidin-4-yl)-2-(piperidin-1-yl)qui-
nazolin-4-amine
Following general procedure 3, heating 6,7-bis(benzyloxy)-N -(1-
benzylpiperidin-4-yl)-2-chloroquinazolin-4-amine (84b, 40mg,
0.07 mmol) and piperidine (0.07 mL, 0.70 mmol), the reaction
mixture was purified by column chromatography (0–4% ammo-
nia methanol in dichloromethane) to yield the title product as a
yellow solid (32 mg, 76%). mp 64–66  C; IR (cm 1) 3314, 2920,
2847, 1624, 1547; 1H NMR (400 MHz, CH3OD,  ) 7.51 (s, 1H), 7.40 (d, J = , 11.2
Hz, 4H), 7.31–7.22 (m, 10H), 6.88 (s, 1H), 5.11 (s, 2H), 5.04 (s, 2H), 4.07–3.99 (m,
1H), 3.66 (t, J = 11.2 Hz, 4H), 3.49 (s, 2H), 2.90 (d, J = 12.0 Hz, 2H), 2.10 (t, J =
12.0 Hz, 4H), 2.00 (d, J = 8.0 Hz, 2H), 1.69–1.53 (m, 8H); HRMS (ES) (m/z ) calcd.
for C39H44N5O2: 614.3495, found: 614.3484.
Compound 91: 6,7-Bis(benzyloxy)-N -(1-benzylpiperidin-4-yl)-2-(4-(pyridin-2-yl)
piperazin-1-yl)quinazolin-4-amine
Following general procedure 3, heating 6,7-bis(benzyloxy)-
N - (1-benzylpiperidin-4-yl) -2-chloroquinazolin-4-amine
(84b, 40 mg, 0.07 mmol) and 1-(2-pyridinyl)piperazine
(0. 12 mL, 0.70 mmol), the reaction mixture was purified
by column chromatography (0–4% ammonia methanol in
dichloromethane) to yield the title product as a a yellow
solid (21 mg, 37%). mp 62–64  C; IR (cm 1) 3388, 2928,
2850, 2065; 1H NMR (400 MHz, CH3OD,  ) 8.05 (t, J = 2.4 Hz, 1H), 7.56–7.51 (m,
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2H), 7.51 (d, J = 2.0 Hz, 4H), 7.44–7.28 (m, 11H), 6.93 (s, 1H), 6.82 (d, J = 8.8 Hz,
1H), 6.64 (t, J = 3.2 Hz, 1H), 5.17 (s, 2H), 5.09 (s, 2H), 4.17-4.15 (m, 1H), 3.86 (t,
J = 8.0 Hz, 4H), 3.60–3.45 (m,4) 2.96 (d, J = 12.0 Hz, 2H), 2.19 (t, J = 12.0 Hz,
4H), 2.00 (d, J = 10.0 Hz, 2H), 1.69 (dq, J = 12.0, 3.2 Hz, 4H) ; HRMS (ES) (m/z )
calcd. for C43H46N7O2: 692.3719, found: 692.3727.
Compound 92: 6,7-Bis(benzyloxy)-N -(1-benzylpiperidin-4-yl)-2-morpholinoquina-
zolin- 4-amine
Following general procedure 3, heating 6,7-bis(benzyloxy)-N -
(1-benzylpiperidin-4-yl)-2-chloroquinazolin-4-amine (84b, 40
mg, 0.07 mmol) and morpholine (0.07 mL, 0.70 mmol), the
reaction mixture was purified by column chromatography (0–
4% ammonia methanol in dichloromethane) to yield the title
product as a white solid (12 mg, 27%). mp 64–66  C; IR (cm 1)
3390, 2919, 2853, 1628; 1H NMR (400 MHz, CH3OD,  ) 7.61 (s, 1H), 7.49–7.47 (d, J
= 8.0 Hz, 4H), 7.39–7.28 (m, 11H), 6.97 (s, 1H), 5.21 (s, 2H) 5.14 (s, 2H), 4.17–4.10
(m, 1H), 3.74 (br s, 8H), 3.58 (s, 2H), 2.98 (d, J = 12.0 Hz, 2H), 2.20 (t, J = 12.0
Hz, 2H), 2.07 (d, J = 8.0 Hz, 2H), 1.70 (dq, J = 12.0, 3.6 Hz, 2H). ; HRMS (ES)
(m/z ) calcd. for C38H42N5O3: 616.3288, found: 616.3260.
Compound 93: N -(1-Benzylpiperidin-4-yl)-6-(4-methylpiperazin-1-yl)-[1,3]dioxolo
[4,5-g] quinazolin-8-amine
Following general procedure 3, heating N -(1-benzylpiperidin-4-
yl)-6-chloro[1,3]dioxolo[4,5-g]quinazolin-8-amine (84c, 70 mg,
0.17 mmol) and methyl piperazine (0.1 mL, 0.88 mmol), the
reaction mixture was purified by column chromatography (0–
4% ammonia methanol in dichloromethane) to yield the title
product as a yellow solid (28 mg, 35%). mp 58–60  C; IR
(cm 1) 3395, 2918, 2848, 2797, 1614; 1H NMR (400 MHz, CH3OD,  ) 7.39–7.28 (m,
5H), 6.85 (s, 1H), 6.77 (s, 1H), 5.97 (s, 2H), 4.96–4.94 (m, 1H), 3.84 (br s, 4H), 3.55
(s, 2H), 2.88 (d, J = 12.0 Hz, 2H), 2.48 (t, J = 4.8 Hz, 4H), 2.34 (s, 3H), 2.21 (t, J
= 12.0 Hz, 4H), 2.07 (d, J = 12.0 Hz, 2H), 1.73 (dq, J = 12.0, 0.8 Hz, 2H); 13C (100
MHz, CH3OD,  ) 159.9, 157.7, 151.3, 149.6, 142.8, 137.4, 128.3 (2C), 127.4 (2C),
126.2, 103.1, 103.0, 100.4, 96.6, 62.3, 54.3, 53.3, 51.5 (2C), 45.4, 43.0, 39.0 31.2 (2C),
28.8; HRMS (ES) (m/z ) calcd. for C26H33N6O2: 461.2665, found: 461.2647.
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Compound 94: N -(1-Benzylpiperidin-4-yl)-6-(piperidin-1-yl)-[1,3]dioxolo[4,5-g]qui-
nazolin-8-amine
Following general procedure 3, heating N -(1-benzylpiperidin-
4-yl)-6-chloro[1,3]dioxolo[4,5-g]quinazolin-8-amine (84c, 70 mg,
0.17 mmol) and piperidine (0.09 mL, 0.88 mmol), the reaction
mixture was purified by column chromatography (0–4% ammo-
nia methanol in dichloromethane) to yield the title product as
a yellow solid (68 mg, 87%). mp 150–154  C; IR (cm 1) 3320,
2928, 2850, 2807, 2065, 1613; 1H NMR (400 MHz, CDCl3,  ) 7.34–7.27 (m, 5H), 6.87
(s, 1H), 6.78 (s, 1H), 5.95 (s, 2H), 4.99 (br s, 1H), 4.14–4.05 (m, 1H), 3.78 (t, J =
5.4 Hz, 4H), 3.54 (s, 2H), 2.88 (d, J = 12.0 Hz, 2H), 2.10 (t, J = 10.4 Hz, 2H), 2.12
(d, J = 10.4 Hz, 2H), 1.62–1.60 (m, 8H); HRMS (ES) (m/z ) calcd. for C26H32N5O2:
446.2556, found: 446.2548.
Compound 95: N -(1-Benzylpiperidin-4-yl)-6-(4-(pyridin-2-yl)piperazin-1-yl)-[1,3]di-
oxolo [4,5-g]quinazolin-8-amine
Following general procedure 3, heating N -(1-benzylpiper-
idin-4-yl)-6-chloro[1,3]dioxolo[4,5-g]quinazolin-8-amine (84c,
70 mg, 0.17 mmol) and 1-(2-pyridinyl)piperazine (1.2 mL,
0.88 mmol), the reaction mixture was purified by column
chromatography (0–4% ammonia methanol in dichloro-
methane) to yield the title product as a white solid (21 mg,
22%). mp 170–172  C; IR (cm 1) 2921, 2847, 2796, 1591;
1H NMR (400 MHz, CDCl3,  ) 8.11–8.01 (m, 1H), 7.69–7.56 (m, 1H), 7.38–7.28 (m,
6H), 6.88 (d, J = 8.0 Hz, 2H), 6.81 (s, 1H), 6.71–6.68 (m, 1H), 4.23–4.20 (m, 1H),
3.91 (t, J = 10.0 Hz, 4H), 3.62–3.58 (m, 6H), 3.02 (d, J = 12.0 Hz, 2H), 2.27 (t, J
= 12.0 Hz, 2H), 2.09 (d, J ) = 12.0 Hz, 2H), 1.72 (dq, J = 12.0, 4.0 Hz, 2H); HRMS
(ES) (m/z ) calcd. for C30H34N7O2: 524.2774, found: 524.2766.
Compound 96: N -(1-Benzylpiperidin-4-yl)-6-morpholino-[1,3]dioxolo[4,5-g]quina-
zolin-8-amine
Following general procedure 3, heating N -(1-benzylpiperidin-
4-yl)-6-chloro[1,3]dioxolo[4,5-g]quinazolin-8-amine (84c, 70 mg,
0.17 mmol) and morpholine (0.07 mL, 0.88 mmol), the reaction
mixture was purified by column chromatography (0–4% ammo-
nia methanol in dichloromethane) to yield the title product as
a white solid (25 mg, 32%). mp 194–198  C; IR (cm 1) 2925,
2816, 2505, 1612; 1H NMR (400 MHz, CH3OD,  ) 7.34–7.287 (m, 6H), 6.78 (s, 1H),
6.04 (s, 2H), 4.15–4.08 (m, 1H), 3.74 (br s, 8H), 3.59 (s, 2H), 2.98 (d,J = 12.0 Hz,
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2H), 2.22 (t, J = 10.4 Hz, 2H), 2.05 (d, J = 10.4 Hz, 2H), 1.70 (dq, J = 12.0, 3.6
Hz, 2H); HRMS (ES) (m/z ) calcd. for C25H30N5O3: 448.2349, found: 448.2358.
Compound 97: N -(1-Benzylpiperidin-4-yl)-2-(4-methylpiperazin-1-yl)quinazolin-4-
amine
Following general procedure 3, heating N -(1-benzylpiperidin-
4-yl)-2-chloroquinazolin-4-amine (84d, 100 mg, 0.28 mmol)
and 1-methyl piperazine (0.09 mL, 1.42 mmol), the reaction
mixture was purified by column chromatography (0–4% am-
monia methanol in dichloromethane) to yield the title product
as a yellow solid (102 mg, 87%). mp 150–152  C; IR (cm 1)
3066, 2923, 2796, 1611, 1557; 1H NMR (400 MHz, CH3OD,  ) 7.93–7.91 (d, J =
11.2 Hz, 1H), 7.52 (t, J = 10.0 Hz, 1H), 7.39–7.27 (m, 6H), 7.10 (t, J = 11.2 Hz,
1H), 4.19–4.11 (m, 1H), 3.87 (br s, 4H), 3.51 (s, 2H), 2.98 (d, J = 12.0 Hz, 2H), 2.52
(t, J = 12.0 Hz, 4H), 2.34 (s, 1H), 2.21(t, J = 12.0 Hz, 4H), 2.07 (d, J = 12.0 Hz,
2H), 1.73 (dq, J = 12.0, 3.6 Hz, 2H); 13C (100 MHz, CH3OD,  ) 159.7, 158.7, 151.0,
137.0, 132.3, 129.4 (2C), 127.9 (2C), 127.1, 123.9, 122.0, 121.1, 110.8, 62.6, 54.5, 52.3
(2C), 46.9 (2C), 44.7, 43.9 (2C), 30.6 (2C); MS (ES) (m/z ): [M+H]+ 417.32.
Compound 98: N -(1-Benzylpiperidin-4-yl)-2-(piperidin-1-yl)quinazolin-4-amine
Following general procedure 3, heating N -(1-benzylpiperidin-4-
yl)-2-chloroquinazolin-4-amine (84d, 0.28 mmol) and piperidine
(1.42 mmol), the reaction mixture was purified by column chro-
matography (0–4% ammonia methanol in dichloromethane) to
yield the title product as as a yellow solid (42 mg, 37%). mp
70–72  C; IR (cm 1) 2927, 2850, 2802, 1562; 1H NMR (400
MHz, CDCl3,  ) 7.95–7.94 (d, J = 7.2 Hz, 1H), 7.56–7.52 (t, J = 8.0 Hz, 1H), 7.49
(d, J = 12.0 Hz, 1H), 7.34–7.23 (m, 5H), 7.14 (t, J = 12.0 Hz, 1H), 4.18-4.08 (m,
1H), 3.80 (t, J = 5.6 Hz, 4H), 3.56 (s, 2H), 2.98 (d, J = 12.0 Hz, 2H), 2.19 (t, J =
12.0 Hz, 2H), 2.05 (d, J ) = 12.0 Hz, 2H), 1.77–1.62 (m, 8H); 13C (100 MHz, CDCl3,
 ) 159.4, 153.7, 149.0, 147.0, 136.9, 132.9, 129.4 (2C), 127.9 (2C), 127.1, 122.4, 121.8,
110.3, 62.5, 52.3(2C), 45.2(2C), 30.4(2C), 25.6(2C), 24.4; MS (ES) (m/z ): [M+H]+
402.3.
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Compound 99: N -(1-Benzylpiperidin-4-yl)-2-(4-(pyridin-2-yl)piperazin-1-yl)quina-
zolin-4-amine
Following general procedure 3, heating N -(1-benzylpiper-
idin-4-yl)-2-chloroquinazolin-4-amine (84d, 100 mg, 0.28
mmol) and 1-(2-pyridinyl)piperazine(0. 14 mL, 1.42 mmol),
the reaction mixture was purified by column chromato-
graphy (0–4% ammonia methanol in dichloromethane) to
yield the title product as a yellow solid (53 mg, 40%). mp
66–68  C; IR (cm 1) 2921, 2845, 1618, 1592, 1549; 1H
NMR (400 MHz, CH3OD,  ) 8.10 (d, J = 4.8 Hz, 1H), 7.93 (d, J = 8.0 Hz, 1H),
7.60–7.51 (m, 2H), 7.41-7.26 (m, 6H), 7.09 (t, J = 8.0 Hz, 1H), 6.84 (d, J = 8.0 Hz,
2H), 6.71-69 (m, 1H), 4.20–4.17 (m, 1H), 3.97 (br s, 4H), 3.59 (br s, 6H), 2.99 (d, J
= 10.0 Hz, 2H), 2.24 (t, J = 10.0 Hz, 2H), 2.08 (d, J = 12.0 Hz, 2H), 1.75-171 (m,
2H); MS (ES) (m/z ): [M+H]+ 480.44.
Compound 100: N -(1-Benzylpiperidin-4-yl)-2-(4-methylhomopiperazin-1-yl)quina-
zolin-4 -amine
Following general procedure 3, heating N -(1-benzylpiperidin-
4-yl)-2-chloroquinazolin-4-amine (84d, 100 mg, 0.28 mmol)
and 1-methyl homopiperazine (0.17 mL, 1.42 mmol), the
reaction mixture was purified by column chromatography
(0–4% ammonia methanol in dichloromethane) to yield the
title product as a yellow solid (102 mg, 81%). mp 150–152
 C; IR (cm 1) 2935, 2799, 1619, 1567, 1533; 1H NMR (400 MHz, CH3OD,  ) 7.95
(d, J = 7.2 Hz, 1H), 7.52 (t, J = 8.0 Hz, 1H), 7.41 (d, J = 8.0 Hz, 1H), 7.34–7.13
(m, 5H), 7.11 (t, J = 7.2 Hz, 1H), 5.42 (br s, 1H), 4.18–4.09 (m, 1H), 3.96 (t, J =
4.8 Hz, 2H), 3.86 (t, J = 5.6 Hz, 2H), 3.57 (s, 2H), 2.97 (d, J = 12.0 Hz, 2H), 2.88
(t, J = 4.8 Hz, 2H), 2.74 (t, J = 5.6 Hz, 2H), 2.49 (s, 3H), 2.04 (t, J = 12.0 Hz, 2H),
2.06-2.03 (m, 4H), 1.72 (dq, J = 12.0, 3.2 Hz, 2H); HRMS (ES) (m/z ) calcd. for
C26H35N6: 431.2903, found: 431.2923.
Compound 101: 6,7-Dimethoxy-2,4-bis(4-methylpiperazin-1-yl)quinazoline
A mixture of 2,4-dichloro-6,7-dimethoxyquinazoline (10, 40 mg,
0.154 mmol), 1-methyl piperazine (0.17 mL, 1.54 mmol) was
heated (neat) using a microwave reactor at 185  C for 30 min.
The reaction mixture was purified by column chromatography (0–
5% methanol in 5%TEA dichloromethane, then 0–2% ammonia
in methanol in dichloromethane) to yield the title product as
a yellow solid (15 mg, 24%) mp 56–58  C; IR (cm 1) 2933.7,
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2842.59, 2790.5, 1623, 1554.9; 1H NMR (400 MHz, CDCl3,  ) 7.00 (s, 1H), 6.96 (s,
1H), 3.99 (s, 3H), 3.94 (s, 3H), 3.91 (br s, 4H), 3.64 (t, J = 4.4 Hz, 4H), 2.64 (t, J
= 4.8 Hz, 4H), 2.55 (t, J = 4.4 Hz, 4H), 2.40 (s, 3H), 2.38 (s, 3H); 13C (100 MHz,
CDCl3,  ) 164.8, 158.3, 154.5, 151.4, 145.0, 105.8, 105.6, 104.2, 56.0(2C), 55.1(2C),
54.8(2C), 49.6(2C), 46.3, 46.2, 43.9(2C); HRMS (ES) (m/z ) calcd. for C20H31N6O2:
387.2508, found: 387.2523.
Compound 102: 6,7-Dimethoxy-2,4-di(piperidin-1-yl)quinazoline
A mixture of 2,4-dichloro-6,7-dimethoxyquinazoline (10, 40 mg,
0.154 mmol), piperidine (0.15 mL, 1.54 mmol) was heated (neat)
using a microwave reactor at 185  C for 30 min. The reaction
mixture was purified by column chromatography (0–4% methanol
in 5%TEA dichloromethane, then 0–3% ammonia in methanol in
dichloromethane) to yield the title product as a yellow solid (32
mg, 59%). mp 48–51  C; IR (cm 1) 2931.2, 2850.8, 1624.2, 1573.5; 1H NMR (400
MHz, CDCl3,  ) 7.00 (s, 1H), 6.98 (s, 1H), 3.99 (s, 3H), 3.93 (s, 3H), 3.84 (br s,
4H), 3.54 (br s, 4H), 1.79-1.76 (m, 6H), 1.66 (br s, 6H); 13C (100 MHz, CDCl3,  ,
missing 3 Ar-C) 165.4, 154.2, 144.6, 105.6, 104.5, 56.03, 55.95, 50.99 (2C), 45.1 (2C),
25.9 (4C), 25.03, 24.96; HRMS (ES) (m/z ) calcd. for C20H29N4O2: 357.2291, found:
357.2292.
Compound 103: 6,7-Dimethoxy-2,4-di(piperidin-1-yl)quinazoline
A mixture of 2,4-dichloro-6,7-dimethoxyquinazoline (10, 40
mg, 0.154 mmol), 1-(2-pyridyl)piperazine (0.24 mL, 1.54
mmol) was heated (neat) using a microwave reactor at 185
 C for 30 min. The reaction mixture was purified by column
chromatography (0–5% methanol in 5%TEA dichlorometh-
ane, then 0–1% ammonia in methanol in dichloromethane)
to yield the title product as a yellow solid (12 mg, 15%). mp
>190  C; IR (cm 1) 3005 2928, 2845, 1672; 1H NMR (400
MHz, CDCl3,  ) 8.24 (br s, 2H), 7.54 (d, J = 9.2 Hz, 2H),
7.07 (s, 1H), 7.02 (br s, 1H), 6.75–6.66 (m, 4H), 4.02 (br s, 7H), 3.94 (br s, 3H), 3.78
(br s, 7H), 3.69 (br s, 5H); 13C (100 MHz, CDCl3,  ) 164.6, 162.3, 159.4, 159.3, 154.8,
153.5, 151.5, 147.9 (2C), 145.4, 137.6, 137.5, 113.8, 113.4, 107.2, 105.8, 104.8, 104.1,
56.2, 56.0, 49.3 (2C), 45.2, 45.0, 44.1 (2C), 29.6, 29.3; HRMS (ES) (m/z ) calcd. for
C28H33N8O2: 513.2726, found: 513.2734.
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Compound 104: (4,4’-(6,7-Dimethoxyquinazoline-2,4-diyl)bis(piperazine-4,1-diyl))
bis (furan-2-ylmethanone
A mixture of 2,4-dichloro-6,7-dimethoxyquinazoline (10, 40
mg, 0.154 mmol), 1-(2-furoyl)piperazine (278.0 mg, 1.54
mmol) was heated (neat) using a microwave reactor at 185
 C for 30 min. The reaction mixture was purified by column
chromatography (0–2% ammonia in methanol in chloroform)
to yield the title product as a white solid (12mg, 15%) mp
60–64  C; IR (cm 1) 2922, 2852, 1623, 1573; 1H NMR (400
MHz, CDCl3,  ) 7.538 (s, 2H), 7.10 (s, 1H), 7.09 (d,J = 15.2
Hz, 2H), 7.01 (s, 1H) 6.534 (t, J = 4.8 Hz, 2H), 4.02–3.87
(m, 18H), 3.72 (br s, 4H); 13C (100 MHz, CDCl3,  ) 169.9, 163.5, 160.9, 159.2, 147.5,
144.1, 144.0, 135.8, 117.5, 117.1, 111.6, 111.4, 107.2, 104.5, 104.5, 104.4, 103.9, 102.9,
56.3, 56.2, 49.4, 49.3, 45.2, 45.1, 39.8 (2C), 29.6 (2C); HRMS (ES) (m/z ) calcd. for
C28H31N6O6: 547.2305, found: 547.2294.
Compound 105a: 2-Chloro-6,7-dimethoxy-4-(4-methylpiperazin-1-yl)quinazoline
[119]
A mixture of 2,4-dichloro-6,7-dimethoxyquinazoline (10, 260 mg, 1.0
mmol) and 1-methyl piperazine (1.00 mL) in methanol (10 mL) was
stirred for one hour at room temperature. The precipitates were
filtrated and washed with ethyl acetate and dried under reduced
pressure. The fine precipitates were heated up to 155  C in isopropanol
and then left at the room temperature to obtain a re-crystallised
product (67 mg, 21%). mp 156–158  C; IR (cm 1) 2939, 2794, 1617,
1570; 1H NMR (400 MHz, CDCl3,  ) 7.19 (s, 1H), 7.07 (s, 1H), 4.01 (s, 3H), 3.99
(s, 3H), 3.8 (t, J = 4.4 Hz, 4H), 2.63 (t, J = 4 Hz, 4H), 2.39 (s, 3H); HRMS (ES)
(m/z ) calcd. for C15H20N4O2Cl: 323.1275, found: 323.1287.
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Compound 105b: 2-Chloro-6,7-dimethoxy-4-(piperidin-1-yl)quinazoline
A mixture of 2,4-dichloro-6,7-dimethoxyquinazoline (10, 260 mg, 1.0
mmol) and piperidine (1.00 mL) in methanol (10 mL) was stirred for
one hour at room temperature. The precipitates were filtrated and
washed with ethyl acetate and dried under reduced pressure. The fine
precipitates were heated up to 155  C in isopropanol and then left
at the room temperature to obtained a re-crystallised product (235
mg, 77%) mp 166–168  C; IR (cm 1) 2935, 2848, 1618, 1575; 1H NMR (400 MHz,
CDCl3,  ) 7.17 (s, 1H), 7.07 (s, 1H), 4.00 (s, 3H), 3.98 (s, 3H), 3.69 (t, J = 5.2 Hz,
4H), 1.79 (m, 6H); 13C (100 MHz, CDCl3,  ) 165.2, 155.2, 154.8, 150.6, 148.0, 109.3,
107.0, 103.6, 56.2, 56.0, 50.8 (2C), 25.8 (2C), 24.6; HRMS (ES) (m/z ) calcd. for
C15H19N3O2Cl: 308.1166, found: 308.1168.
Compound 105c: 2-Chloro-6,7-dimethoxy-4-(4-(pyridin-2-yl)piperazin-1-yl)quina-
zoline
A mixture of 2,4-dichloro-6,7-dimethoxyquinazoline (10, 260 mg, 1.0
mmol) and 1-(2-pyridyl)piperazine (1.00 mL) in methanol (10 mL)
was stirred for one hour at room temperature. The precipitates
were filtrated and washed with ethyl acetate and dried under reduced
pressure. The fine precipitates were heated up to 155  C in isopropanol
and then left at the room temperature to obtained a re-crystallised
product (310 mg, 81%). mp 182–184  C; IR (cm 1) 2946, 2854, 1598,
1571; 1H NMR (400 MHz, CDCl3,  ) 8.22 (d, J = 3.2 Hz, 1H), 7.56-
7.51 (m, 1H), 7.19 (s, 1H), 7.12 (s, 1H), 6.73–6.68 (m, 2H), 4.00 (s, 3H), 3.97 (s, 3H),
3.89 (t, J = 2.8 Hz, 4H), 3.78 (t, J = 2.8 Hz, 4H); 13C (100 MHz, CDCl3,  ) 164.8,
159.1, 155.2, 154.9, 150.7, 148.5, 148.0, 137.7, 114.0, 109.3, 107.2, 107.1, 103.2, 56.3,
56.1 49.2 (2C), 44.9 (2C); HRMS (ES) (m/z ) calcd. for C19H21N5O2Cl: 386.1384,
found: 386.1384.
Compound 105d: 4-(2-Chloro-6,7-dimethoxyquinazolin-4-yl)morpholine
A mixture of 2,4-dichloro-6,7-dimethoxyquinazoline (10, 260 mg, 1.0
mmol) and morpholine (1.00 mL) in methanol (10 mL) was stirred for
one hour at room temperature. The precipitates were filtrated and
washed with ethyl acetate and dried under reduced pressure. The fine
precipitaties were heated up to 155  C in isopropanol and then left at
the room temperature to obtained a re-crystallised product (165 mg,
51%). mp 184–186  C; IR (cm 1) 2962, 2887, 2842, 1618, 1574; 1H NMR (400 MHz,
CDCl3,  ) 7.21 (s, 1H), 7.06 (s, 1H), 4.02 (s, 3H), 4.00 (s, 3H), 3.91 (t, J = 4.4 Hz,
4H), 3.78 (t, J = 3.7 Hz, 4H); 13C (100 MHz, CDCl3,  ) 164.8, 155.2, 154.9, 150.8,
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148.5, 109.2, 107.1, 103.0, 66.6 (2C), 56.3, 56.1, 50.0 (2C); HRMS (ES) (m/z ) calcd.
for C14H17ClN3O3: 310.0958, found: 310.0999.
Compound 106: N -(1-Benzylpiperidin-4-yl)-6,7-dimethoxy-4-(piperidin-1-yl)qui-
nazolin-2 -amine
A mixture of 2-chloro-6,7-dimethoxy-4-(piperidin-1-yl)qui-
nazoline (105b, 60 mg, 0.2 mmol), 4-amino-1-benzylpi-
peridine (0.20 mL, 1.0 mmol) and DIEA (0.175 mL, 1.0
mmol) in toluene (2 mL) was heated using a microwave
reactor at 155  C for 11 hours. The temperature was
increased to 185 C for 3 hours. The mixture was purified
by column chromatography (0–3% ammonia methanol in dichloromethane) to a↵ord
a yellow solid (22 mg, 23%). mp 42–44  C; IR (cm 1) 2935, 2849, 1637, 1565; 1H
NMR (400 MHz, CDCl3,  ) 7.34–7.33 (m, 5H), 7.00 (s, 1H), 6.89 (s, 1H), 3.97 (s,
3H), 3.95–3.94 (m, 1H), 3.92 (s, 3H), 3.55–3.51 (m, 6H), 2.85 (d, J = 11.6 Hz, 2H),
2.23 (t, J = 9.4 Hz, 2H), 2.07 (d, J = 9.4 Hz, 2H), 1.92–1.88 (m, 1H), 1.76 (br s,
6H), 1.60 (q, J = 12.8, 9.6 Hz, 2H); 13C (100 MHz, CDCl3,  ) 165.7, 157.6, 154.5,
144.7, 138.4, 129.2, 129.1, 128.4, 128.1, 128.0, 126.9, 105.8, 104.8, 104.5, 63.2, 56.0,
55.9. 52.3, 50.9 (2C), 48.0, 34.5, 32.5 (2C), 25.4 (2C), 24.8; HRMS (ES) (m/z ) calcd.
for C27H36N5O2: 462.2869, found: 462.2865.
Compound 107: (N -(1-Benzylpyrrolidin-3-yl)-6,7-dimethoxy-4-(piperidin-1-yl)qui-
nazolin-2-amine
A mixture of 2-chloro-6,7-dimethoxy-4-(piperidin-1-yl)quina-
zoline (105b, 60 mg, 0.2 mmol), 1-benzyl-3-aminopyrrolidine
(0.17 mL, 1.0 mmol) and DIEA (0.175 mL, 1.0 mmol) in tolu-
ene (2 mL) was heated in a microwave reactor 155  C for 15
hours. The mixture was purified by column chromatography
(0–3% ammonia methanol in dichloromethane) to a↵ord a
yellow solid (17 mg, 19%) mp 50–52  C; IR (cm 1) 2935, 2830, 1623, 1564; 1H NMR
(400 MHz, CDCl3,  ) 7.36–7.30 (m, 5H), 6.99 (s, 1H), 6.90 (s, 1H), 4.66–4.58 (m,
1H), 3.98 (s, 3H), 3.92 (s, 3H), 3.74 (s, 1H) 3.65 (s, 2H), 3.59 (br s, 4H), 2.94 (t, J =
8.8 Hz, 1H), 2.75 (q, J = 8.8, 7.6 Hz, 1H), 2.55 (t, emphJ = 4.0 Hz, 1H), 2.42–2.33
(m, 1H), 1.75 (br s, 8H); 13C (100 MHz, CDCl3,  ) 164.7, 154.9 , 145.1, 138.7, 134.4,
132.0, 129.7, 128.8, 128.3, 128.2, 126.9, 105.3, 105.0, 104.8, 60.9, 60.3, 56.2, 56.0, 52.8,
50.7, 50.6, 32.5, 30.4, 25.9 (2C), 24.7; HRMS (ES) (m/z ) calcd. for C26H34N5O2:
448.2713, found: 448.2700.
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Compound 108: N -(1-Benzylpiperidin-3-yl)-6,7-dimethoxy-4-(piperidin-1-yl)qui-
nazolin-2 -amine
A mixture of 2-chloro-6,7-dimethoxy-4-(piperidin-1-yl)quina-
zoline (105b, 60 mg, 0.2 mmol), 1-benzyl-3-aminopiperidine
(0.12 g, 0.6 mmol) and DIEA (0.175 mL, 1.0 mmol) in toluene
(2 mL) was heated using a microwave reactor 155  C for 20
hours. The mixture was purified by column chromatography
(0–3% ammonia methanol in dichloromethane) to a↵ord a
yellow solid (39 mg, 42%) mp 64–66  C; IR (cm 1) 2933, 2852, 1635, 1600; 1H NMR
(400 MHz, CH3OD,  ) 7.36–7.25 (m, 5H), 7.11 (s, 1H), 6.85 (s, 1H), 4.11–4.08 (m,
1H), 3.93 (s, 3H), 3.87 (s, 3H), 3.74-3.73 (m, 4H), 3.72 (d, J = 10.4 Hz, 2H), 3.67 (d,
J = 10.4 Hz, 2H), 2.94 (br s, 1H), 2.70 (br s,1H), 2.42 (br s, 1H), 2.28 (br s, 1H),
1.89–1.55 (m, 8H); 13C (100 MHz, CH3OD,  ) 165.1, 157.1, 147.2, 138.0, 134.1, 130.7,
130.1, 129.4 (2C), 128.6 (2C), 107.7, 105.0, 101.6, 63.8, 58.5, 56.7, 56.6, 54.7, 51.7
(2C), 45.8, 30.59, 27.2(2C), 25.0, 23.8 ; HRMS (ES) (m/z ) calcd. for C27H36N5O2:
462.2869, found: 462.2871.
Compound 109: N -(1-Benzylpiperidin-4-yl)-6,7-dimethoxy-4-(4-(pyridin-2-yl)pi-
perazin-1 -yl)quinazolin-2-amine
A mixture of 2-chloro-6,7-dimethoxy-4-(piperidin-1-yl)qui-
nazoline (105c, 72 mg, 0.2 mmol), 4-amino-1-benzylpiper-
idine (0.20 mL, 1.0 mmol) and DIEA (0.175 mL, 1.0 mmol)
in toluene (2 mL) was heated in a microwave reactor at
155 C for 11 hours. The temperature was increased to 155
 C for 15 hours . The mixture was purified by column
chromatography (0–2% ammonia methanol in chloroform,
then 0–1.5% 7M ammonia methanol in chloroform) to a↵ord
the yellow solid (5 mg, 5%). mp 59–62  C; IR (cm 1) 2924, 2851, 1594, 1570; 1H
NMR (400 MHz, CDCl3,  ) 8.23 (d, J = 5.6, 1H), 7.55–7.52 (m, 1H), 7.36-7.31 (m,
4H), 7.31–7.27 (m, 1H), 7.04 (s, 1H), 6.93 (s, 1H), 6.71–6.68 (m, 2H), 3.98 (s, 3H),
3.98–3.91 (m, 1H) 3.91 (s, 3H), 3.85 (m, 3H), 3.77–3.76 (m, 5H), 3.58 (br s, 2H),
2.88–2.86 (m, 2H), 2.32–2.24 (m, 2H), 2.08-2.06 (m, 2H), 1.70–1.66 (m, 2H); 13C (100
MHz, CDCl3,  ) 164.8, 161.3, 159.9, 159.0, 148.0, 145.4, 137.6, 129.2, 129.1, 128.2,
127.1, (2C) 113.9, 107.1, 106.4, 104.9, 104.8, 103.8, 63.0, 56.3, 56.1, 51.9, 51.8, 49.2,
44.9, 32.1, 32.0 (2C), 31.9, 31.8, 29.7; HRMS (ES) (m/z ) calcd. for C31H38N7O2:
539.3009, found: 540.3688.
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Compound 110: (N -(1-Benzylpiperidin-3-yl)-6,7-dimethoxy-4-(4-(pyridin-2-yl)pi-
perazin-1-yl)quinazolin-2-amine
A mixture of 2-chloro-6,7-dimethoxy-4-(4-(pyridin-2-yl)pi-
perazin-1-yl)quinazoline (105c, 60 mg, 0.2 mmol), 1-benzyl-
3-aminopiperidine (0.12 g, 1.0 mmol) and DIEA (0.175 mL,
1.0 mmol) in toluene (2 mL) was heated using a microwave
reactor at 155  C for 18 hours. The mixture was purified
by column chromatography (0–2% ammonia methanol in
dichloromethane) to a↵ord a yellow solid (38 mg, 42%). mp
43–45  C; IR (cm 1) 2933, 2840, 1623, 1593; 1H NMR (400
MHz, CDCl3) 8.24 (dd, J = 4.0, 0.8 Hz, 1H), 7.55 (t, J = 4.8 Hz, 1H), 7.37-7.20
(m, 5H), 7.04 (s, 1H), 6.91 (s, 1H), 6.74–6.68 (m, 2H), 4.20–4.16 (m, 1H), 3.99 (s,
3H), 3.92 (s, 3H), 3.74–3.71 (m, 8H), 3.58 (d, J = 13.2 Hz, 1H), 3.48 (d, J = 13.2
Hz, 1H), 2.85 (br s, 1H), 2.41–2.30 (m, 2H), 1.81 (br s, 2H), 1.62 (d, J = 6.4 Hz,
2H) 13C (100 MHz, CDCl3,  ) 164.6, 159.1, 155.2 (2C), 148.0, 145.3, 138.2, 137.6,
134.4, 129.7, 129.2, 128.9, 128.6, 128.1, 126.9, 113.8, 107.0, 104.8, 63.1, 58.4, 56.3,
56.1, 53.7(2C), 49.1, 47.6, 44.8, 29.8 (2C), 29.6, 23.0; HRMS (ES) (m/z ) calcd. for
C31H38N7O2: 540.3068, found: 540.3087.
Compound 111: 4-(1-Benzylpiperidin-4-ylamino)-2-chloro-6-methoxyquinazolin-7-
ol
7-(Benzyloxy)-N-(1-benzylpiperidin-4-yl)-2- chloro-6-methoxy-qui-
nazolin-4-amine (84, 1.0 g, 2.05 mmol) was added to a flask con-
taining Pd/C (100 mg) in 40 mL of ethyl acetate: ethanol (1:1).
The atmosphere was exchanged with hydrogen gas via a balloon,
and the suspension stirred at room temperature for 5 hours. The
suspension was filtered through celite and then washed with eth-
anol. The filtrated solution was concentrated under reduced pressure and the mixture
was purified by column chromatography (6% methanol in dichloromethane) to a↵ord
the title product as a pale yellow solid (461 mg, 58%). mp 151–153  C; IR (cm 1)
3237, 2938, 158, 1502, 1434, 1271, 1249, 1216; 1H NMR (400 MHz, CDCl3) 10.34 (s,
1H), 7.96 (d, J = 7.5 Hz, 1H), 7.66 (s, 1H), 7.37–7.25 (m, 5H), 6.90 (s, 1H), 4.17–4.05
(m, 1H), 3.91 (s, 3H), 3.53 (s, 2H), 2.95–2.85 (m, 2H), 2.10 (t, J = 9.1 Hz, 2H),
1.95–1.87 (m, 2H), 1.75–1.65 (m, 2H); 13C (100 MHz, CDCl3,  ) 159.7, 155.5, 153.5,
148.6, 147.7, 139.0, 129.2, 128.6, 127.4, 110.0, 106.6, 103.3, 62.4, 56.7, 52.7, 49.1,
48.5, 31.8; HRMS (ES) (m/z ) calcd. for C21H24N4O2Cl: 399.1598, found: 399.1599.
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Compound 112: 5-(4-(1-Benzylpiperidin-4-ylamino)-2-chloro-6-methoxyquinazolin-
7-yloxy) pentanenitrile
To a solution of 4-((1-benzylpiperidin-4-yl)amino)-2-chloro-6-me-
thoxyquinazolin-7-ol (84, 399 mg, 1.0 mmol) and 5-bromo-
pentanenitrile (0.14 ml, 1.2 mmol), potassium carbonate (416
mg, 3 mmol) and TBAB (32 mg, 0.1 mmol) were added and the
suspension was warmed to 50  C for 24 hours. The suspension was
filtrated and concentrated under reduced pressure. The mixture
was purified by column chromatography (5% methanol in dichloromethane) to a↵ord
the title product as a white solid (400 mg, 83%). mp 80–82  C; IR (cm 1) 2938,
1619, 1583, 1511, 1448, 1340, 1285, 1256; 1H NMR (400 MHz, CDCl3) 7.39–7.35 (m,
5H), 7.10 (s, 1H), 6.85 (s, 1H), 5.51 (d, J = 7.7 Hz, 1H), 4.40–4.25 (m, 1H), 4.16 (t,
J = 5.9 Hz, 2H), 3.99 (s, 3H), 3.62 (s, 2H), 2.97 (d, J = 11.7 Hz, 2H), 2.52 (t, J =
7.2 Hz, 2H), 2.32 (td, J = 11.5, 1.4 Hz, 2H), 2.20–2.13 (m, 2H), 2.10–2.03 (m, 2H),
1.97–1.90 (m, 2H), 1.72 (qd, J = 12.1, 3.6 Hz, 2H); 13C (100 MHz, CDCl3,  ) 159.3,
156.2, 154.0, 149.1, 147.8, 138.1, 129.5 (2C), 128.9, 128.6, 127.9, 127.5, 119.6, 107.0,
67.9, 63.0, 56.3, 52.1 (2C), 48.5, 32.0 (2C), 27.7, 22.6, 17.1; HRMS (ES) (m/z ) calcd.
for C26H30N5O2Cl: 480.2166, found: 480.2156.
Compound 113: 5-(4-(1-Benzylpiperidin-4-ylamino)-6-methoxy-2-(4-methylpiper-
azin-1-yl) quinazolin-7-yloxy)pentanenitrile
1-Methyl piperazine (0.33 mL, 3.0 mmol) was added to a
solution of 5-(4-(1-benzylpiperidin-4-ylamino)-2-chloro-6-me-
thoxyquinazolin-7-yloxy) pentanenitrile (112, 200 mg, 0.42
mmol) in toluene (5 mL) and the solution was heated under
reflux for 48 hours. After the mixture was cooled down to
room temperature, the volatiles were removed under reduced
pressure and the mixture was purified by column chromatography (8% methanol in
dichloromethane) to give the title product as a yellow oil (166 mg, 87%). IR (cm 1)
2933, 1575, 1444, 1245, 1007; 1H NMR (400 MHz, CH3OD) 7.37 (s, 1H), 7.32–7.20
(m, 5 H), 6.86 (s, 1H), 5.48 (s, 1H), 4.16–4.10 (m, 1H), 3.90 (s, 3H), 3.81 (br s, 4H),
3.52 (s, 1H), 3.01 (d, J = 12.0 Hz, 2H), 2.98 (t, J = 12.0 Hz, 2H), 2.52 (t, J = 4.0
Hz, 4H), 2.35 (s, 3H), 2.20 (t, J = 12.0 Hz, 2H), 2.08 (d, J = 12.0 Hz, 2H), 2.01–1.96
(m, 2H), 191–184 (m, 2H), 1.74-1.65 (m, 4H); 13C (100 MHz, CDCl3,  ) 158.9, 158.4,
153.8, 147.6, 146.1, 137.1, 129.5 (2C), 127.9 (2C), 127.1, 105.2, 103.7. 102.7, 67.7,
67.5, 62.7, 55.5, 54.9, 54.5, 54.2, 53.4, 52.5, 44.8, 43.5, 38.9, 30.8, 28.7, 27.6, 22.3,
15.8 ; HRMS (ES) (m/z ) calcd. for C31H41N7O2: 544.3400, found: 544.3405.
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Compound 114: 7-(5-Aminopentyloxy)-N-(1-benzylpiperidin-4-yl)-6-methoxy-2-(4-
methylpiperazin-1-yl)quinazolin-4-amine
2.0 M LiAlH4 in THF (3.5 mL, 0.5 mmol) was added
dropwise to a solution of the 5-(4-(1-benzylpiperidin-4-
ylamino)-6-methoxy-2-(4-methylpiperazin-1-yl) quinazolin-7-
yloxy)pentanenitrile (113, 150 mg, 0.28 mmol) in 20 ml of
THF at 0  C. Water (10 mL) was added after the mixture
was stirred for 2 hours. The solution was diluted with brine
and extracted with chloroform/isopropyl alcohol (9:1, 100 ml
x 6). The combined organic fractions were concentrated under reduced pressure.
The mistuxe was purified by column chromatography (10% ammonia methanol in
dichloromethane) to give the title product as white solid (40 mg, 26%). mp 60–62
 C; IR (cm 1) 2937, 1579, 1448, 1424, 1241, 1007; 1H NMR (400 MHz, CH3OD)
7.40 (s, 1H), 7.35–7.27 (m, 5H), 6.85 (s, 1H), 4.21–4.13 (m, 1H), 4.07 (t, J = 3.6 Hz,
2H), 3.89 (s, 3H), 3.81 (br s, 4H), 3.57 (s, 2H), 2.99 (d, J =12.0 Hz, 2H), 2.68 (t,
J = 6.4 Hz, 2H), 2.50 (t, J = 4.4 Hz, 4H), 2.33 (s, 3H), 2.19 (t, J = 10.0 Hz, 2H),
2.07 (d, J = 16.0 Hz, 2H), 1.88–1.85 (m, 2H), 1.74–1.63 (m, 2H), 1.54–1.49 (m, 4H);
13C (100 MHz, CH3OD,  ) 158.9, 158.2, 154.0, 149.1, 145.6, 138.3, 129.1 (2C), 128.2
(2C), 127.0, 106.8, 103.0, 101.1, 68.6, 63.2, 56.5, 55.7 (2C), 52.6 (2C), 48.2, 46.3, 44.0
(2C), 42.0, 33.4, 32.2 (2C), 28.7, 23.3; HRMS (ES) (m/z ) calcd. for C31H46N7O2:
548.3713, found: 548.3690.
Compound 115a: N -(1-Benzylpiperidin-4-yl)-2-chloro-6-methoxy-7-(octyloxy)qui-
nazolin-4 -amine
4-(1-Benzylpiperidin-4-ylamino)-2-chloro-6-methoxyquinazo-
lin-7-ol (111, 200 mg, 0.50 mmol), 3-(dimethylamino)propan-
1-ol (154.7 mg, 1.5 mmol) and PPh3 (655 mg, 2.5 mmol) were
stirred in THF (15 mL) at 0  C. DIAD (0.49 mL, 2.5 mmol)
was added dropwise and the solution was warmed to room
temperature for 6 hours. The solution was concentrated and
purified by column chromatography (0–5% ammonia methanol in dichloromethane)
to a↵ord the title product as a clear oil (185 mg, 76%). IR (cm 1) 2940, 2820, 1701;
1H NMR (400 MHz, CDCl3) 7.35–7.33 (m, 4H), 7.28 (s, 1H), 7.14 (s, 1H), 6.81 (s,
1H), 5.40 (d, J = 8.0 Hz, 1H) 4.31–4.26 (m, 1H), 4.18 (t, J = 4.0 Hz, 2H), 3.99 (s,
3H), 3.56 (s, 2H), 2.93 (d, J = 12.0 Hz, 2H), 2.47 (t, J = 8.0 Hz, 2H), 2.32 (t, J =
8.0 Hz, 2H), 2.23 (br s, 6H), 2.09-2.03 (m, 2H), 1.79-1.74 (m, 4H); 13C (100 MHz,
CDCl3,  ) 159.0, 156.1, 154.5, 149.2, 148.0, 138.3, 129.1 (2C), 128.2 (2C), 127.1,
108.1, 106.5, 99.8, 67.5, 63.0, 57.5, 56.4, 52.2, 48.2, 45.5 (2C), 45.2, 34.1, 32.2, 27.0,
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22.3 (2C),14.0 MS cannot be obtained by ES
Compound 115b: N -(1-Benzylpiperidin-4-yl)-2-chloro-6-methoxy-7-(octyloxy)qui-
nazolin-4 -amine
Potassium carbonate (331 mg, 2.4 mmol) and TBAB (25 mg, 0.08
mmol) were added to a solution of 4-(1-benzylpiperidin-4-ylamino)-
2-chloro-6-methoxyquinazolin-7-ol (111 in acetone. 1-Bromooctane
(0.155 mL, 1.6 mmol) was then added and the suspension warmed
to 50  C for 36 hours. The suspension was then filtered and the
solids washed with acetone. The filtrate was concentrated and the
residue purified by column chromatography (4% methanol in dichloromethane) to
give the title product as a white solid (318 mg, 78%). mp 54–55  C; IR (cm 1) 3444,
3327, 2925, 2853, 2810, 1618; 1H NMR (400 MHz, CDCl3) 7.35–7.25 (m, 5H), 7.10
(s, 1H), 6.94 (s, 1H), 5.73 (d, J = 7.8 Hz, 1H), 4.35–4.25 (m, 1H), 4.10 (t, J = 6.9
Hz, 2H), 3.95 (s, 3H), 3.57 (s, 2H), 2.95–2.88 (m, 2H), 2.27–2.20 (m, 2H), 2.17–2.11
(m, 2H), 1.93–1.84 (m, 2H), 1.66 (qd, J = 12.0. 3.6 Hz, 2H), 1.50–1.40 (m, 2H),
1.38-1.25 (m, 8H), 0.90 (t, J = 6.8 Hz, 3H); 13C (100 MHz, CDCl3,  ) 159.0, 156.1,
154.6, 149.3, 148.1, 138.3, 129.1 (2C), 128.2 (2C), 127.0, 108.0, 106.4, 99.7, 69.3,
63.0, 56.4, 52.3 (2C), 48.3, 32.2 (2C), 31.7, 29.3 (2C), 29.1, 25.8, 22.6, 14.1; MS (ES)
(m/z ) [M+H]+ 511.3
Compound 116: N -(1-Benzylpiperidin-4-yl)-7-[3-(dimethylamino)propoxy]-6-me-
thoxy-2-(4-methylpiperazin-1-yl)quinazolin-4-amine
Following general procedure 3, heating N -(1-benzylpi-
peridin-4-yl)-2-chloro-6-methoxy-7-(octyloxy)quinazolin-
4-amine (115a, 32 mg, 0.066 mmol) and 1-methyl piper-
azine (0.07 mL, 0.66 mmol), the reaction mixture was
purified by column chromatography (0–5% ammonia
methanol in dichloromethane) to yield the title product
as a white solid (15 mg, 41%). mp 48–50  C; IR (cm 1) 3300, 2912, 2848, 2794, 1625;
1H NMR (400 MHz, CDCl3) 7.36–7.29 (m, 5H), 6.92 (s, 1H), 6.74 (s, 1H), 5.08 (d, J
= 8.0 Hz, 1H), 4.99–4.94 (m, 1H), 4.19–4.13 (m, 3H), 3.92 (s, 3H), 3.87–3.85 (m, 4H),
3.57 (s, 2H), 2.92 (d, J = 12.0 Hz, 2H), 2.51–2.42 (m, 2H), 2.35 (s, 3H), 2.25 (s, 6H),
2.22 (s, 2H), 2,17–2.19 (m, 2H), 2.09–2.03 (m, 2H), 1.66–1.62 (m, 2H), 1.29–1.25 (m,
4H); 13C (100 MHz, CDCl3,  ) 158.8, 158.2, 153.9, 149.1, 145.6, 138.2, 129.1 (2C),
128.2 (2C), 127.0, 107.0, 103.1, 101.3, 67.1, 63.1, 57.4, 56.5, 54.2, 52.5 (2C), 46.2,
45.4, 44.0, 39.8, 32.1 (2C), 27.1, 22.1, 22.0; MS (ES) (m/z ) [M+H]+ 548.4.
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Compound 117: N -(1-Benzylpiperidin-4-yl)-7-[3-(dimethylamino)propoxy]-6-me-
thoxy-2-(4-methylpiperazin-1-yl)quinazolin-4-amine
Following general procedure 3, heating N -(1-benzylpiper-
idin-4-yl)-2-chloro-6-methoxy-7-(octyloxy)quinazolin-4-a-
mine (115a, 40 mg, 0.083 mmol) and 1-methyl homopi-
perazine (0.10 mL, 0.83 mmol), the reaction mixture
was purified by column chromatography (0–5% ammonia
methanol in dichloromethane) to yield the title product
as a white solid (25 mg, 54%). mp 55–56  C; IR (cm 1)
3300, 2912, 2847, 2797, 1625; 1H NMR (400 MHz, CDCl3) 7.37–7.32 (m, 5H), 6.92
(s, 1H), 6.74 (s, 1H), 5.04 (d, J = 8.0 Hz, 1H), 4.16 (t, J = 8.0 Hz, 2H), 4.12-4.10
(m, 1H), 3.99-3.97 (m, 2H), 3.92 (s, 3H), 3.88 (t, J = 8.0 HZ, 2H), 3.56 (s, 2H), 2.99
(d, J = 12.0 Hz, 2H), 2.72–2.70 (m, 2H), 2.60–2.57 (m, 2H), 2.47 (t, J = 8.0 Hz, 2H),
2.38 (s, 3H), 2.26 (s, 6H), 2.18–2.13 (m, 4H), 2.07–2.01 (m, 4H), 1.69–1.56 (m, 2H);
13C (100 MHz, CDCl3,  ) 158.5, 158.0, 153.9, 149.4, 145.2, 138.3, 129.1 (2C), 128.2
(2C), 127.0, 106.9, 102.7, 101.4, 63.1. 60.8, 58.9, 57.3, 57.1, 56.2, 52.5 (2C), 48.3,
47.2, 47.0, 46.6, 45.7, 45.4, 32.2, 29.7, 27.7, 27.2; MS (ES) (m/z ) [M+H]+ 562.4.
Compound 118: N -(1-Benzylpiperidin-4-yl)-7-(octyloxy)-6-methoxy-2-(4-methylpi-
perazin-1-yl)quinazolin-4-amine
Following general procedure 3, heating N -(1-benzylpiperidin-4-
yl)-2-chloro-6-methoxy-7-(octyloxy)quinazolin-4-amine (115b,
60 mg, 0.125 mmol) and 1-methyl piperazine (0.14 mL, 1.25
mmol), the reaction mixture was purified by preparative-TLC
(2% ammonia methanol in dichloromethane) to yield the title
product as a white solid (52 mg, 72%). mp 46–48  C; IR
(cm 1) 2922, 2874, 2790, 1792, 1625, 1525; 1H NMR (400 MHz, CDCl3) 7.37–7.29
(m, 5H), 6.90 (s, 1H), 6.73 (s, 1H) 4.99 (d, J = 8.0 Hz, 1H), 4.16–4.14 (m, 1H) 4.11
(t, J = 8.0 Hz, 2H) 4.01–3.98 (m, 4H), 3.91 (s, 3H), 3.89 (t, J = 8.0 Hz, 2H), 3.57 (s,
2H), 2.95–2.91 (m, 2H), 2.73–2.71 (m, 2H), 2.61–2.58 (m, 2H), 2.39 (s ,3H), 2.24–2.21
(m, 2H), 2.07–2.02 (m, 2H), 1.92–1.89 (m, 2H), 1.68–1.60 (m, 2H), 1.38–1.36 (m,
2H), 1.34–1.28 (m, 6H), 0.92–0.86 (m, 3H); 13C (100 MHz, CDCl3,  ) 158.5, 158.0,
154.2, 149.5, 145.3, 138.5, 129.2 (2C), 128,2 (2C), 127,0, 106.8, 102.6, 101.3, 68.8,
63.1, 58.9, 57.3, 56.7. 52.5 (2C), 48.3, 46.6, 45.8, 45.7, 32.2 (2C), 31.8, 29.3, 29.1,
28.8, 27.8, 25.9, 22.6, 14.0; HRMS (ES) (m/z ) calcd. for C34H50N6O2: 575.4073,
found: 575.4068.
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Compound 119: N -(1-Benzylpiperidin-4-yl)-7 -(octyloxy)-6-methoxy-2-(4-methyl-
homopiperazin-1-yl)quinazolin-4-amine
Following general procedure 3, heating N -(1-benzylpiperidin-4-
yl)-2-chloro-6-methoxy-7-(octyloxy)quinazolin-4-amine (115b,
30 mg, 0.06 mmol) and 1-methyl homopiperazine (0.09 mL, 0.6
mmol), the reaction mixture was purified by column chroma-
tography (0–4% ammonia methanol in dichloromethane), then
preparative TLC (2% ammonia methanol in dichloromethane)
to yield the title product as a white solid (26 mg, 76%). mp
35–38  C; IR (cm 1) 2952, 2893, 2797, 1625; 1H NMR (400 MHz, CDCl3) 7.37–7.30
(m, 5H), 6.92 (s,1H), 6.75 (s, 1H), 5.08 (br s, 1H), 4.18–4.11 (m, 1H), 4.09 (t, J =
12.0 Hz, 2H), 3.92 (s, 3H), 3.89–3.87 (m, 4H), 3.57 (s, 2H), 2.93 (d, ( J) = 12.0 Hz,
2H), 2.51 (t, J= 8.0 Hz, 4H), 2.36 (s, 3H), 2.26–2.22 (m, 2H), 2.18–2.13 (m, 2H),
1.89 (quin, J = 8.0 Hz, 2H), 1.68–1.59 (m, 2H), 1.48–1.45 (m, 2H), 1.38–1.27 (m,
10H), 0.92–0.88 (m, 3H); 13C (100 MHz, CDCl3,  ) 158.8, 158.2, 154.1, 146.2, 145.7,
138.4, 129.1 (2C), 128.2 (2C), 127.0, 106.8, 103.0, 101.2, 68.8, 63.1, 56.5, 55.2 (2C),
52.5 (2C), 48.2, 46.3, 44.0 (2C), 32.2 (2C), 31.7 (2C), 29.2, 29.1, 28.8, 25.9, 22.6,
14.1; HRMS (ES) (m/z ) calcd. for C35H53N6O2: 589.8490, found: 589.4243.
Compound 120: N -(1-Benzylpiperidin-4-yl)-N -[3-(dimethylamino)propyl]-6-meth-
oxy-7-(octyloxy)quinazoline-2,4-diamine
Following general procedure 3, heating N -(1-benzylpiper-
idin-4-yl)-2-chloro-6-methoxy-7-(octyloxy)quinazolin-4-ami-
ne (115b, 60 mg, 0.125 mmol) and N,N -dimethylpropane-
1,3-diamine (0.16 mL, 1.25 mmol), the reaction mixture
was purified by column chromatography (0–4% ammonia
methanol in dichloromethane) to yield the title product
as a yellow solid (32 mg, 44%). mp 40–41  C; IR (cm 1) 2926, 2854, 2763, 1625,
1578; 1H NMR (400 MHz, CDCl3) 7.37–7.25 (m, 5H), 6.87 (s, 1H), 6.82 (s, 1H), 5.39
(br s, 2H), 4.25–4.14 (m, 1H), 4.08 (t, J = 6.9 Hz, 2H), 3.90 (s, 3H), 3.56 (s, 2H),
3.54–3.47 (m, 2H), 2.92 (d, J = 11.5 Hz, 2H), 2.40 (t, J = 6.9 Hz, 2H), 2.24 (s, 6H),
2.25–2.10 (m, 4H), 1.92–1.75 (m, 4H), 1.64 (qd, J = 12.2, 3.4 Hz, 2H), 1.50–1.40 (m,
2H), 1 38–1.25 (m, 8H), 0.89 (t, J = 6.9 Hz, 2H); 13C (100 MHz, CDCl3,  , missing
2-ArC) 158.6, 154.3, 145.7, 138.3, 129.2 (2C), 128.2 (2C), 127.1, 105.6, 103.2, 101.7,
68.9, 63.1, 57.7, 56.6, 52.5 (2C), 48.2, 45.6, 40.1, 32.2 (2C), 31.8, 29.3, 29.2, 28.8,
27.9, 25.9, 22.7, 14.1; HRMS (ES) (m/z ) calcd. for C34H53N6O2: 577.4230, found:
577.4229.
145
Compound 122: Methyl [2-cyano-5-(hexyloxy)-4-methoxyphenyl]carbamate
Methyl chloroformate (0.9 mL , 1.64 mmol) was added into the
solution of 2-amino-4-(hexyloxy)-5-methoxybenzonitrile (121, 1.7
g, 5.82 mmol) and DIEA (4.1 mL, 23.28 mmol) in co-solvent DMA
: DCM (50 mL : 25 mL) at 0  C. The reaction solution was stirred
for 6 hours, then 150 mL of water was added. The resulting
precipitates were collected, washed with water and dried to a↵ord
the title as a white solid (1.89 g, quant). mp 100–102  C; IR (cm 1)
2948, 2925, 2852, 2221, 1711; 1H NMR (400 MHz, CDCl3,  ) 7.82 (br s, 1H), 7.06
(s, 1H), 6.63 (s, 1H), 4.10 (t, J = 8.0 Hz, 2H), 3.86 (s, 3H), 3.83 (s ,3H), 1.92–1.84
(m, 2H), 1.58–1.55 (m, 2H), 1.39–1.33 (m, 4H), 0.94–0.90 (m, 3H); 13C (100 MHz,
CDCl3,  ) 153.6, 145.1, 136.5, 116.8, 113.3, 104.8, 91.2, 69.2, 56.4, 53.6, 52.7, 31.1,
28.7, 25.5, 22.5, 13.9; MS cannot be obtain by ES.
Compound 123: 7-(Hexyloxy)-6-methoxyquinazoline-2,4(1H,3H)-dione
Methyl [2-cyano-5-(hexyloxy)-4-methoxyphenyl]carbamate (122,
1.8 g, 6.16 mmol) was mixed with hydrogen peroxide (8.4 mL of
35 wt.% solution in water, 123 mmol) and sodium hydroxide (2.46
g, 61.6 mmol) in ethanol (300 mL) and the resulting mixture
was stirred for 6 hours under reflux. The solution was cooled to
room temperature, and acidified with 1 N HCl. The resulting
precipitates were filtered, washed with water and dried to a↵ord
the title product as a white solid (1.35 g, 75%). mp 164–168  C; IR (cm 1) 3007,
2929, 2925, 2858, 1716 ; 1H NMR (400 MHz, CDCl3,  ) 10.44 (br s, 1H), 9.24 (br s,
1H), 7.45 (s, 1H), 6.57 (s, 1H), 4.11–4.06 (m, 2H), 3.92 (s, 3H), 1.93–1.85 (m, 2H),
1.38–1.37 (m, 2H), 1.36–1.34 (s, 4H), 0.94–0.90 (m, 3H); HRMS (ES) (m/z ) calcd.
for C15H21N2O4: 293.1501, found: 293.1513.
Compound 124: 2,4-Dichloro-7-(hexyloxy)-6-methoxyquinazoline
A mixture of 7-(hexyloxy)-6-methoxyquinazoline-2,4(1H,3H )-
dione (123, 1.3 g, 4.67 mmol), N,N -diethylaniline (0.74 mL, 4,67
mmol) and POCl3 (4.4 mL) in acetonitrile (10 mL) were stirred
under reflux for 24 hours. The solution was concentrated under
reduced pressure to 10 mL and the residue was poured onto
ice-water (150 mL). The precipitates were collected, washed with
water and dried to a↵ord the title compound as a black solid
(678 mg, 44%). mp 92–94  C; IR (cm 1) 2925, 2864, 1613, 1556; 1H NMR (400
MHz, CDCl3,  ) 7.35 (s, 1H), 7.26 (s, 1H), 4.22 (t, J = 8.0 Hz, 2H), 4.07 (s, 3H),
1.98–1.91 (m, 2H), 1.55–1.50 (m, 2H), 1.38–1.27 (m, 4H), 0.95–0.91 (m, 3H); 13C
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(100 MHz, CDCl3,  ) 159.1, 157.4, 153.4, 151.8, 150.6, 117.6, 106.7, 102.6, 69.8, 56.4,
31.4, 28.5, 25.5, 22.5, 13.9; HRMS (ES) (m/z ) calcd. for C15H19Cl2N2O2: 328.0824,
found: 328.0820.
Compound 125: N -(1-Benzylpiperidin-4-yl)-2-chloro-7-(hexyloxy)-6-methoxyqui-
nazolin-4-amine
Following general procedure 1, using 2,4-dichloro-7-(hexyloxy)-6-
methoxyquinazoline (124, 365 mg, 1.0 mmol), 4-amino-1-benzyl-
piperidine (0.30 mL, 1.5 mmol) and DIPEA (0.35 mL, 2.0 mmol)
in THF (10 mL) for 24 hours, the reaction mixture was purified
by column chromatography (0–3% methanol in dichloromethane)
to yield the title product as a pale yellow solid (291 mg, 60%).
mp 76–78  C; IR (cm 1) 2992, 2847, 2796, 1625; 1H NMR (400
MHz, CDCl3,  ) 7.3–7.25 (m, 5H), 7.06 (s, 1H), 7.04 (s, 1H),
6.05 (d, J = 8.0 Hz, 1H), 4.31–4.25 (m, 1H), 4.03 (t, J = 8.0 Hz, 2H), 3.88 (s, 3H),
3.52 (s, 2H), 2.88 (d, J = 12.0 Hz, 2H), 2.16 (t, J = 12.0 Hz, 2H), 2.11–2.07 (m,
2H), 1.87–1.80 (m, 2H), 1.68–1.62 (m, 2H), 1.45–1.42 (m, 2H), 1.34-1.29 (m, 4H),
0.92–0.88 (m, 3H); 13C (100 MHz, CDCl3,  ) 159.2, 156.0, 154.5, 149.2, 147.9, 138.0,
129.1 (2C), 128.2 (2C), 127.1, 107.6, 106.6, 100.4, 69.1, 62.9, 56.3, 52.2 (2C), 48.4,
32.0 (2C), 31.4, 28.5, 25.5, 22.5, 13.9; HRMS (ES) (m/z ) calcd. for C27H36ClN4O2:
483.2527, found: 483.2521.
Compound 127: N -(1-Benzylpiperidin-4-yl)-7-(hexyloxy)-6-methoxy-2-(4-methyl-
1,4-diazepan-1-yl)quinazolin-4-amine
Following general procedure 3, heating N -(1-benzylpi-
peridin-4-yl)-2-chloro-7-(hexyloxy)-6-methoxyquinazolin-4-amine
( 125, 0.1 mmol) and methyl piperazine (1.0 mmol), the
reaction mixture was purified by column chromatography
(0–3% ammonia methanol in dichloromethane) to yield the
title product as a yellow solid (10 mg, 17%). mp 48–51
 C; IR (cm 1) 2935, 2846, 2796, 1666; 1H NMR (400 MHz,
CDCl3,  ) 7.35–7.30 (m, 5H), 6.90 (s, 1H), 6.74 (s, 1H), 5.07
(d, J = 4.0 Hz, 1H), 4.20–4.17 (m, 1H), 4.10 (t, J = 8.0 Hz, 2H), 3.92 (s, 3H), 3.84
(br s, 4H), 3.57 (s, 2H), 2.94 (d, J = 8.0 Hz, 2H), 2.51 (t, J = 4.0 Hz, 4H), 2.63
(s, 3H), 2.33–2.13 (m, 4H), 1.88 (m, 2H), 1.65–1.55 (m, 2H), 1.49–1.45 (m, 2H),
1.37–1.33 (m, 4H), 0.94–0.90 (m, 3H); 13C (100 MHz, CDCl3,  ) 158.8, 158.2, 154.1,
149.2, 145.7, 138.4, 129.1 (2C), 128.2 (2C), 127.0, 106.8, 103.0, 101.1, 68.8, 63.1, 56.5,
55.2, 52.5 (2C), 48.1, 46.3, 46.1, 44.0, 32.2 (2C), 31.5, 28.8, 28.6, 25.6, 22.5, 14.0;
HRMS (ES) (m/z ) calcd. for C32H47N6O2: 547.3761, found: 547.3766.
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Compound 127: N -(1-Benzylpiperidin-4-yl)-7-(hexyloxy)-6-methoxy-2-(4-methyl-
1,4-diazepan-1-yl)quinazolin-4-amine
Following general procedure 3, heating N -(1-benzylpiperidin-
4-yl)-2-chloro-7-(hexyloxy)-6-methoxyquinazolin-4-amine (125,
0.1 mmol) and methyl homopiperazine (1.0 mmol), the reac-
tion mixture was purified by column chromatography (0–4%
ammonia methanol in dichloromethane) to yield the title
product as a yellow solid (32 mg, 55%). mp 52–54  C IR
(cm 1) 2935, 2846, 2796, 1660; 1H NMR (400 MHz, CDCl3,
 ) 7.35–7.33 (m, 5H), 6.89 (s, 1H), 6.73 (s, 1H), 5.00 (d, J
= 8.0Hz, 1H), 4.15–4.13 (m, 1H), 4.11 (t, J = 8.0 Hz, 2H), 4.00–3.98 (m, 2H),
3.95–3.88 (m, 5H), 3.57 (s, 2H), 2.93–2.90 (m, 2H), 2.71 (m, 2H), 2.59 (m, 2H), 2.39
(s, 3H), 2.24–2.17 (m, 4H), 2.05–2.03 (m, 2H), 1.92–1.88 (m, 2H), 1.66–1.62 (m, 2H),
1.50–1.48 (m, 2H), 1.38–1.33 (m, 4H), 0.96–0.90 (m, 3H); 13C (100 MHz, CDCl3,  )
158.8, 158.2, 154.1, 149.2, 145.7, 138.4, 129.1 (2C), 128.2 (2C), 127.0, 106.8, 103.0,
101.1, 68.8, 63.1, 56.5 (2C), 55.2 (2C), 48.1, 46.3, 46.1, 44.0 (2C), 32.2 (2C), 31.5,
28.8, 28.6, 25.6, 22.6, 14.0; HRMS (ES) (m/z ) calcd. for C33H49N6O2: 561.3917,
found: 561.3895.
Compound 128: N -(1-benzylpiperidin-4-yl)-N -[3-(dimethylamino)propyl]-7-(hex-
yloxy)-6-methoxyquinazoline-2,4-diamine
Following general procedure 3, heatingN -(1-benzylpiper-
idin-4-yl)-2-chloro-7-(hexyloxy)-6-methoxyquinazolin-4-
amine (125, 0.1 mmol) and 3-(dimethylamino)-1-
propylamine (1.0 mmol), the reaction mixture was pur-
ified by column chromatography (0–9% ammonia meth-
anol in dichloromethane) to yield the title product as
a yellow solid (28 mg, 53%). mp 36–38  C; IR (cm 1)
2922, 2853, 2768, 1625; 1H NMR (400 MHz, CDCl3)
7.37–7.32 (m, 5H), 6.87 (s,1H), 6.74 (s, 1H), 5.08 (br s, 1H), 4.22–4.18 (m, 1H), 3.94
(t, J = 8.0 Hz, 2H), 3.92 (s, 1H), 3.57 (s, 2H), 3.54–3.49 (m, 2H), 2,92 (d, J = 12.0
Hz, 2H), 2.40 (t, J = 12.0 Hz, 2H), 2.25 (s, 6H), 2.17–2.12 (m, 4H), 1.91–1.88 (m,
2H), 1.83–1.77 (m, 2H), 1.65–1.61 (m, 2H), 1.50–1.46 (m, 2H), 1.38–1.34 (m, 4H),
1.29–1.24 (m, 4H), 0.94–0.86 (m, 3H); 13C (100 MHz, CDCl3,  ) 159.12, 158.5, 154.2,
148.5, 145.5, 138.4, 129.1 (2C), 128.2 (2C), 127.0, 106.3, 103.3, 101.4, 68.8, 63.1, 57.7,
56.6, 52.5 (2C), 47.9, 45.6, 40.1, 32.3 (2C), 31.5, 29.6, 28.7, 28.0, 25.6, 22.5, 14.9;
HRMS (ES) (m/z ) calcd. for C32H49N6O2: 549.3917, found: 549.3914.
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Compound 129a: 1-Benzylpiperazine [163]
After TritonB in methanol (1.34 ml, 3.2 mmol) was concentrated, N -Boc
piperazine was added. The mixture was stirred at room temperature for
15 min. 0.16 mL Benzyl bromide (0.16 mL, 1.2 mmol) was added into the
mixture dropwise and the resulting mixture was stirred for 3 hours. After
the completion of the reaction, as indicated by thin-layer chromatography
(TLC), the mixture was extracted with ether (3 ⇥ 20ml). The combined
organic layer was washed with water and dried under reduced pressure. The mixture
was purified by column chromatography (5% methanol in dichloromethane) to give
the intermediate as a white solid (177 mg). The purified intermediate was stirred in
1.5 mL of dichloromethane and TFA (1:1) overnight. The mixture was concentrated
and basified by 2 N NaOH. The aqueous layer was extracted with dichloromethane
and dried to give the title product as a yellow oil (50 mg, 27%) 1H NMR (400 MHz,
CDCl3) 7.31–7.25 (m, 5H), 3.51 (s, 2H), 3.10 (br s, 2H), 2.95 (t, J = 5.2 Hz, 4H),
2.48 (br s, 4H); 13C (100 MHz, CDCl3,  ) 137.6, 129.1, 128.3, 128.2, 63.2, 52.9, 45.1;
HRMS (ES) (m/z ) calcd. for C11H17N2: 177.1392, found: 177.1380.
Compound 129b: 1-(6-Phenylhexyl)piperazine
After TritonB in methanol (563 mg, 3.76 mmol) was concentrated, (6-
chlorohexyl)benzene (553.0 mg, 2.82 mmol), acetonitrile (10 mL), and
N -Boc piperazine (350 mg, 1.88 mmol) was added. Then sodium iodide
(1.3 g, 9.4 mmol) in 30 mL of acetonitrile then was subsequently added
into the aforementioned suspension. The resulting mixture was heated
under refluxed overnight. The mixture was then filtrated and the solution
was concentrated. The residue was basified with 2 N sodium hydroxide and the
aqueous was extracted with dichloromethane (3 ⇥ 20ml). The solvent was evaporated
under reduced pressure. The mixture was purified by column chromatography (
5% methanol in dichloromethane) to give the intermediate as a clear oil 62 mg.
The purified intermediate was stirred in 1.5 mL of dichloromethane and TFA (1:1)
overnight. The mixture was concentrated under reduced pressure and basified by 2
N NaOH. The aqueous layer was extracted with dichloromethane and dried to give a
product as a yellow oil (50 mg, 10%) 1H NMR (400 MHz, CDCl3) 7.37–733 (m, 2H),
7.26–7.24 (m, 3H), 3.02 (t, J = 4.8 Hz, 4H), 2.68 (t, J = 8.0, 2H), 2.53 (br s, 4H),
2.40 (t, J = 8.0 Hz, 2H), 1.70 (p, J = 6.8 Hz, 2H), 1.57 (p, J = 6.8 Hz, 2H),1.53-1.49
(m, 4H); HRMS (ES) (m/z ) calcd. for C16H27N2: 247.2174, found: 247.2167.
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Compound 130: 2-(4-Benzylpiperazin-1-yl)-N -(1-benzylpiperidin-4-yl)-6,7-dimeth-
oxyquinazolin-4-amine
Following general procedure 2, heating N -(1-benzylpiper-
idin-4-yl)-2-chloro-6,7-dimethoxyquinazolin-4-amine (11,
0.27 mmol) and 1-benzylpiperazine (133a, 3.0 mL) for
36 hours, the reaction mixture was purified by column
chromatography (0–4% ammonia methanol in dichloro-
methane) to yield the title product as a white solid (50
mg, 32%) mp 82–84  C; IR (cm 1) 3395, 2926, 2804; 1H NMR (400 MHz, CH3OD)
7.35 (s, 1H), 7.30–7.20 (m, 10H), 6.80 (s, 1H), 4.08–3.99 (m, 1H), 3.38 (s, 3H), 3.31
(s, 3H), 3.74 (t, J = 4.8 Hz, 4H), 3.48 (s, 2H), 3.47 (s, 2H), 2.89 (br d, J = 12.0
Hz, 2H), 2.45 (t, J = 4.8 Hz, 4H), 2.09 (t, J = 11.6 Hz, 2H), 1.99 (br d, J =10.8
Hz, 2H), 1.65 (dq, J = 12.0, 3.6 Hz, 2H). ; 13C (100 MHz, CH3OD,  ) 158.8, 158.5,
154.4, 145.7, 137.0, 136.9, 129.4,(2C) 129.3 (2C), 127.9 (2C), 127.9 (2C), 127.0 (2C),
104.2, 103.6, 102.5, 62.7, 62.6, 55.3, 52.7 (2C), 52.5, 43.7, 30.8 (2C); HRMS (ES)
(m/z ) calcd. for C33H41N6O2: 553.3291, found: 553.3287.
Compound 131: N -(1-benzylpiperidin-4-yl)-6,7-dimethoxy-2-(4-(6-phenylhexyl)
piperazin-1-yl)quinazolin-4-amine
Following general procedure 2, heating N -(1-
benzylpiperidin-4-yl)-2-chloro-6,7-dimethoxyqui-
nazolin-4-amine (11, 0.14 mmol) and 1-(6-
phenylhexyl)piperazine (133b, 0.1 mL) for 36
hours, the reaction mixture was purified by
column chromatography (0–4% ammonia meth-
anol in dichloromethane) to yield the title
product as a yellow solid (45 mg, 72%). mp 50–52  C; IR (cm 1) 3393, 2929,
2852, 1626, 1575; 1H NMR (400 MHz, CH3OD) 7.38 (s, 1H), 7.34–7.08 (m, 10H),
6.84 (s, 1H), 4.14–4.06 (m, 1H), 3.86 (s, 3H), 3.85 (s. 3H), 3.77 (br s, 4H), 3.54 (s,
2H), 2.96 (d, J = 12.0 Hz, 2H), 2.58 (t, J = 7.6 Hz, 2H), 2.50 (t, J = 4.8 Hz, 4H),
2.35 (t, J = 8.0 Hz, 2H), 2.16 (dt, J = 12.0, 2.0 Hz, 2H), 2.04 (d, J = 10.0 Hz, 2H),
1.69 (dq, J = 12.4, 3.6 Hz, 2H), 1.63–1.51(m, 6H), 1.34 (t, J = 8.0 Hz, 4H); 13C
(100 MHz, CH3OD,  , missing ArC) 158.9, 154.4, 148.3, 145.7, 142.5, 137.1, 129.4
(2C), 127.9 (2C), 125.3 (2C), 104.5, 103.7, 102.5, 62.7, 58.5, 55.3, 54.8, 52.9, 52.5
(2C), 48.3, 48.2, 46.9, 35.4, 31.2 (2C), 30.8, 28.7, 27.1, 26.0; HRMS (ES) (m/z ) calcd.
for C38H51N6O2: 623.4073, found: 623.4083.
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Compound 132: N -(1-Benzylpiperidin-4-yl)-2-chloro-6-methoxy-7-(4-phenylbut-
oxy) quinazolin-4-amine
To a solution of 4-(1-benzylpiperidin-4-ylamino)-2-chloro-
6-methoxyquinazolin-7-ol (111, 100 mg, 0.25 mmol) and
1-bromo-4-phenylbutane (0.06 ml, 0.3 mmol), potassium
carbonate (103 mg, 0.75 mmol) and TBAB (8 mg, 0.03
mmol) were added and the suspension was warmed to 50
 C for 24 hours. The suspension was filtrated and the filtrant was washed with
acetone. The filtrate was concentrated under reduced pressure and the residue
purified by column chromatography (4% methanol in dichloromethane) to a↵ord the
title product as a clear oil (55 mg, 41%); 1H NMR (400 MHz, CDCl3) 7.36–7.22 (m,
7H), 7.22 (d, J = 7.6 Hz, 2H), 7.12 (s, 1H), 6.83 (s, 1H), 5.44 (d, J =7.2 Hz, 2H),
4.36–4.26 (m, 1H), 4.12 (t, J = 6.4 Hz, 2H), 3.98 (s, 3H), 3.59 (s, 2H), 2.93 (d, J =
7.6 Hz. 2H), 2.72 (t, J = 7.6 Hz, 2H), 2.27 (t, J =10.4 Hz, 2H), 2.16 (d, J = 10.8
Hz, 2H), 1.94 (quin, J = 6.4 Hz, 2H), 1.84 (quin, 7.2 Hz, 2H), 1.69–166 (m, 2H); 13C
(100 MHz, CDCl3,  ) 159.0, 156.1, 154.5, 149.2, 148.0, 141.9, 138.1, 129.1 (2C), 128.4
(2C), 128.2 (2C), 127.1 (2C), 125.8 (2C), 107.9, 106.4, 99.8, 68.9, 65.8, 63.0, 56.4,
52.2, 48.2, 35.5, 32.2, 28.2, 27.7, 15.3; HRMS (ES) (m/z ) calcd. for C31H36ClN4O2:
531.2527, found: 531.2534.
Compound 133: N-(1-Benzylpiperidin-4-yl)-6-methoxy-2-(4-methylpiperazin-1-yl)-
7-(4-phenylbutoxy)quinazolin-4-amine
Following general procedure 2, heating N -(1-benzylpi-
peridin-4-yl)-2-chloro-6-methoxy-7-(4-phenylbutoxy) qui-
nazolin-4-amine (134, 55 mg, 0.1 mmol) and 1-methyl
piperazine (0.12, 1.0 mmol) for 36 hours, the title com-
pound was obtained and purified by column chromato-
graphy (0–4% ammonia methanol in dichloromethane).
This gave the title product as a as white solid (45 mg, 75%). mp 68–70  C; IR
(cm 1) 3347, 2935, 2848; 1H NMR (400 MHz, CH3OD) 7.38 (s, 1H), 7.36–7.09 (m,
9H), 7.07–7.04 (m, 1H), 6.81 (s, 1H), 4.14–4.10 (m, 1H), 4.03 (t, J = 6 Hz, 2H), 3.86
(s, 3H), 3.78 (br s, 4H), 3.55 (s, 2H), 2.97 (d, J = 12.0 Hz, 2H), 2.67 (t, J = 7.2 Hz,
2H), 2.48 (m, 4H), 2.29 (s, 3H), 2.17 (t, J = 12.0 Hz, 2H), 2.04 (d, J = 12.0 Hz, 2H),
1.90–1.78 (m, 4H), 1.77-1.62 (m, 2H) ; 13C (100 MHz, CH3OD,  ) 151.2, 145.9, 129.4
(2C), 128.0 (2C), 127.9 (2C), 127.0 (2C), 125.3, 105.3, 102.7, 68.1, 62.7, 55.4, 54.8,
54.6, 54.0, 53.7 (2C), 48.2, 44.9, 44.8, 43.5, 39.1, 35.1, 30.8 (2C), 28.2, 27.4; HRMS
(ES) (m/z ) calcd. for C36H47N6O2: 595.3760, found: 595.3763.
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Compound 134: tert-Butyl piperidin-4-ylcarbamate [164]
A solution of Boc2O (1.2 g, 5.63 mmol) in 2 mL of acetonitrile was
added to a solution of 4-amino-1-benzylpiperidine (0.8 mL, 5.27 mol) in
8 mL of acetonitrile and the mixture was stirred at room temperature
for 3 hours. The reaction mixture was concentrated under reduced
pressure and the resulting solid was filtered and washed with acetonitrile to give a
title product as a white crystalline solid (700 mg, 43%). mp 122–123  C; IR (cm 1)
3357, 2973, 2949, 2934, 2797; 1H NMR (400 MHz, CDCl3) 7.33–7.22 (m, 5H), 4.42 (br
d, J = 4.4 Hz, 1H), 3.47 (s, 2H), 2.79 (d, J = 11.6 Hz, 2H), 2.08 (t, J = 11.6 Hz, 2H),
1.90 (d, J =12.0, 2H), 1.49 (s, 9H), 1.50–1.30 (m, 2H); HRMS (ES) (m/z ) calcd. for
C17H27N2O2: 291.2073, found: 291.2075. tert-Butyl 1-benzylpiperidin-4-ylcarbamate
(139, 1.5 g, 6.21 mmol) was added to a flask containing Pd/C (10%, 150 mg) in
methanol (20 mL) under nitrogen gas. The atmosphere was exchanged with hydrogen
gas via a balloon, and the suspension was stirred at room temperature for 24 hours.
The suspension was filtered through celite and then washed with methanol. The
filtrate was concentrated under reduced pressure and the residue was purified by
column chromatography (5% ammonia methanol in dichloromethane) to a↵ord the
title product as a white solid (1.14 g, 91%). mp 163-164  C; IR (cm 1) 3357, 2204,
2944, 2928; 1H NMR (400 MHz, CDCl3) 4.44 (br s, 1H), 3.35 (br s, 1H), 3.04 (dt,
J = 12.8, 3.2 Hz, 2H), 2.64 (td, J = 12.4, 2.4 Hz, 2H). 1.93 (d, J = 10.0 Hz, 2H),
1.44 (s, 9H), 1.26 (dq, emphJ = 11.2, 4 Hz, 3H); HRMS (ES) (m/z ) calcd. for
C10H21N2O2: 201.1603, found: 201.1600.
Compound 135a: 1-(4-Phenylbutyl)piperidin-4-amine
A mixture of tert-butyl piperidin-4-ylcarbamate (139, 300 mg, 1.5 mmol),
1-bromo-4-phenylbutane (0.26 mL, 1.5 mmol), and triethylamine (0.23 mL,
1.6 mmol) in tetrahydrofuran (10 mL) was refluxed overnight. Tetrahydro-
furan was removed under reduced pressure, dichloromethane was added
and the mixture was washed with dilute NaHCO3. The organic fractions
were combined, dried, and concentrated under reduced pressure, and the
residue was purified by column chromatography (5% ammonia methanol
in dichloromethane) to give the Boc intermediates (146 mg, 47%) The
intermediate was added dropwise in the mixture of dichloromethane (5 mL) and TFA
(5 mL). The reaction mixture was neutralised with 2 N sodium hydroxide, extracted
with dichloromethane, and dired to give the product as a yellow oil (72 mg, 32%).
1H NMR (400 MHz, CDCl3) 7.31–7.28 (m, 2H), 7.21–7.18 (m, 2H), 2.90 (d, J = 11.6
Hz, 2H), 2.65 (t, J = 7.6 Hz, 2H), 2.36 (t, J = 11.6 Hz, 2H), 2.00 (t, J = 9.2 Hz,
2H), 1.84 (d, J = 12.8 Hz, 2H), 1.65 (quin, J = 12.8 Hz, 2H), 1.55 (quin, J = 8.0
152
Hz, 2H), 1.41 (dq, J = 11.2, 4.0 Hz, 4H); 13C (100 MHz, CDCl3,  ) 155.2, 142.5,
128.3 (2C), 125.7 (2C), 58.6, 52.6 (2C), 48.8, 36.0 35.9 (2C), 30.9, 26.8; HRMS (ES)
(m/z ) calcd. for C15H25N2: 233.2018, found: 233.2018.
Compound 135b: 4-((4-Aminopiperidin-1-yl)methyl)phenyl)(phenyl)methanone
A mixture of tert-butyl piperidin-4-ylcarbamate (139, 300 mg, 1.49
mmol), 4-(bromomethyl)benzophenone (410 mg, 1.49 mmol) and tri-
ethylamine (145.7 ml, 1.63 mmol) in dichloromethane (15 mL) was
stirred at room temperature for 24 hours. 20 mL of water was poured
into the reaction mixture and the mixture was extracted with di-
chloromethane (3 ⇥ 20ml). The organic layer was concentrated under
reduced pressure and dried. The mixture was purified by column
chromatography (3% methanol in dichloromethane) to give a yellow
oil (370 mg, 63%) The purified intermediate was stirred in 10 mL of the mixture
of dichloromethane and TFA (1:1) overnight. The mixture was concentrated under
reduced pressure and basified by 2 N NaOH. The aqueous layer was extracted with
dichloromethane and dried to give the title product product as a yellow oil (240
mg, 54%) 1H NMR (400 MHz, CDCl3) 7.80–7.74 (m, 4H), 7.57 (t, J = 7.6 Hz, 1H),
7.48–7.41 (m, 4H), 3.55 (s, 2H), 2.83 (d, J 11.6 Hz, 2H), 2.67 (m, 1H), 2.06 (t, J =
11.6 Hz, 2H), 1.80 (d, J = 12.0 Hz, 2H), 1.45-1.35 (m, 4H); HRMS (ES) (m/z ) calcd.
for C19H23N2O: 295.1810, found: 295.1801.
Compound 136a: 2-Chloro-6,7-dimethoxy-N -(1-(4-phenylbutyl)piperidin-4-yl)qui-
nazolin-4-amine
Following general procedure 1, using 2,4-dichloro-6,7-dime-
thoxyquinazoline (10, 92 mg, 0.36 mmol), 4-amino-1-benzyl-
piperidine (150 mh, 0.72 mmol) and DIPEA (0.13 mL, 0.718
mmol) in THF (10 mL) for 24 hours, the reaction mixture
was purified by column chromatography (0–3% methanol in
dichloromethane) to yield the title product as a white solid
(81 mg, 49%) mp 80–82  C; IR (cm 1) 3272, 2936, 1630; 1H NMR (400 MHz, CDCl3)
7.30–7.26 (m, 2H), 7.20–7.16 (m, 3H), 7.12 (s, 1H), 6.96 (s, 1H), 5.83 (br d, J =
6.8 Hz, 1H), 4.43–4.33 (m, 1H), 4.02 (s, 3H), 3.96 (s, 3H), 3.14 (d, J = 12.0 Hz,
2H), 2.64 (t, J = 6.4 Hz, 2H), 2.58 (t, J = 6.8 Hz, 2H), 2.41 (t, J = 6.4 Hz, 2H),
2.19 (dd, J = 14.4, 4.0 Hz, 2H), 1.96 (q, J = 5.6 Hz, 2H), 1.67 (t, J = 3.6 Hz, 4H);
13C (100 MHz, CDCl3,  ) 159.1, 156.0, 149.1, 148.1, 141.8, 128.4 (2C), 128.3 (2C),
125.9, 107.2, 106.8, 100.0, 65.8, 58.1, 56.5, 56.2, 53.4, 52.4, 47.3, 35.5, 30.9, 29.0, 25.5;
HRMS (ES) (m/z ) calcd. for C25H31ClN4O2: 455.2214, found: 455.2224.
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Compound 136b: (4-((4-(2-Chloro-6,7-dimethoxyquinazolin-4-ylamino)piperidin-
1-yl)methyl)phenyl)(phenyl)methanone
Following general procedure 1, using 2,4-dichloro-6,7-
dimethoxyquinazoline (10, 156 mg, 0.61 mmol), 4-((4-
aminopiperidin-1-yl)methyl)phenyl) (phenyl) methanone
(135b, 215 mg, 0.73 mmol) and DIPEA (0.21 mL, 1.21
mmol) in THF (10 mL) for 24 hours, the reaction mixture
was purified by column chromatography (0–3% methanol
in dichloromethane) to yield the title product as a pale yellow solid (190 mg, 60%).
1H NMR (400 MHz, CDCl3) 7.30–7.26 (m, 2H), 7.20–7.16 (m, 3H), 7.12 (s, 1H),
6.96 (s, 1H), 5.83 (br d, J = 6.8 Hz, 1H), 4.43–4.33 (m, 1H), 4.02 (s, 3H), 3.96 (s,
3H), 3.14 (d, J = 12.0 Hz, 2H), 2.64 (t, J = 6.4 Hz, 2H), 2.58 (t, J = 6.8 Hz, 2H),
2.41 (t, J = 6.4 Hz, 2H), 2.19 (dd, J = 14.4, 4.0 Hz, 2H), 1.96 (q, J = 5.6 Hz, 2H),
1.67 (t, J = 3.6 Hz, 2H); 13C (100 MHz, CDCl3,  ) 159.0, 155.0, 149.0, 148.1, 143.6,
137.7, 136.4, 132.2 (2C), 130.2 (2C),130.0 (2C), 128.7 (2C), 128.2 (2C), 107.4, 106.6,
99.4, 62.6, 56.3, 56.2, 52.4 (2C), 48,2, 42.5, 32.2 (2C); HRMS (ES) (m/z ) calcd. for
C29H30ClN4O3: 517.2006, found: 517.2005.
Compound 137: 6,7-Dimethoxy-2-(4-methylpiperazin-1-yl)-N -(1-(4-phenylbutyl)
piperidin-4-yl)quinazolin-4-amine
Following general procedure 2, heating 2-chloro-6,7-dime-
thoxy-N-(1-(4-phenylbutyl)piperidin-4-yl)quinazolin-4-amine
(142a, 454 mg, 0.1 mmol) , and 1-methyl piperazine (0.1
mL, 1.0 mmol) for 36 hours, the reaction mixture was
purified by column chromatography (0–4% ammonia
methanol in dichloromethane) to yield the title product
as a white solid (25 mg, 55%). mp 64–66  C; IR (cm 1) 3310, 2933, 1577; 1H NMR
(400 MHz, CH3OD) 7.37 (s, 1H), 7.30–7.26 (m, 2H), 7.23–7.16 (m, 3H), 6.84 (s, 1H),
4.15–4.04 (m, 1H), 3.87 (s, 3H), 3.86 (s, 3H), 3.79 (br s, 4H), 2.98 (br d, J = 11.6
Hz, 2H), 2.62 (t, J = 5.6 Hz, 2H), 2.46 (t, J = 13.2 Hz, 4H), 2.38 (t, J = 7.2 Hz,
2H), 2.30 (s, 3H), 2.11 (t, J = 12.4 Hz, 2H), 2.05 (d, J = 12.0 Hz, 2H), 1.72–1.50
(m, 6H); 13C (100 MHz, CH3OD,  ) 158.9, 154.4, 148.3, 146.5, 145.7, 142.1, 128.0
(2C), 127.9 (2C), 125,4, 104.5, 103.7, 102.5, 58.3, 55.9, 54.8, 54.6, 52.6 (2C), 49.9,
44.8, 43.5, 35.3 (2C), 30.8, 29.2, 25.8; HRMS (ES) (m/z ) calcd. for C30H42N6O2:
519.3447, found: 519.3440.
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Compound 138: (4-((4-(6,7-Dimethoxy-2-(4-methylpiperazin-1-yl)quinazolin-4-yla-
mino) piperidin-1-yl)methyl)phenyl)(phenyl)methanone
Following general procedure 2, heating 4-((4-
(2-chloro-6,7-dimethoxyquinazolin-4-ylamino)piperidin-
1-yl) methyl)phenyl) (phenyl) methanone (142b, 100
mg, 0.20 mmol) , and 1-methyl piperazine (0.22 mL,
2.0 mmol) for 24 hours, the reaction mixture was
purified by column chromatography (0–4% ammonia
methanol in dichloromethane) to yield the title product as a white solid (65 mg,
56%). mp 72–74  C; IR (cm 1) 3310, 2928, 2851, 1650; 1H NMR (400 MHz, CH3OD)
7.79–7.73 (m, 4H), 7.63–7.60 (m, 1H), 7.52–7.48 (m, 4H), 7.38 (s, 1H), 6.84 (s, 1H),
4.15–4.10 (m, 1H), 3.89 (s, 6H), 3.86 (br s, 4H), 3.64 (s, 2H), 2.98 (d, J = 2.4 Hz,
2H), 2.54–2.47 (m, 4H), 2.30 (s, 3H), 2.22 (t, J = 3.6 Hz, 2H), 2.06 (d, J = 6.0 Hz,
2H), 1.73-1.70 (m, 2H); MS m/z [M+H]+: 581.4.
Compound 139, C021: 2-[1,4’-Bipiperidin]-1’-yl-N -cycloheptyl-6,7-dimethoxy-4-
quinazolinamine [165]
Following general procedure 1, using 2-4 dichloroquinazoline
(10, 200 mg, 0.78 mmol scale), the product was obtain as a
white solid (245 mg, 89%). mp 164–166  C; IR (cm 1) 3376,
3313, 2929; 1H NMR (400 MHz, CDCl3) 7.10 (s, 1H), 6.82
(s, 1H), 5.54 (d, 1H), 4.42-4.40 (m, 1H), 3.96 (s, 3H), 3.93 (s,
3H), 2.16-2.08 (m, 2H), 1.72-1.56 (m, 10H); 13C (100 MHz,
CH3OD,  ) 158.72, 156.39, 154.82, 148.93, 148.00, 107.39,
106.70, 99.56, 56.35, 56.24, 52.08, 34.98, 28.21, 24.08; HRMS (ES) (m/z ) calcd.
for C17H23ClN3O2: 455.2214, found: 455.2224. Following the general procedure 2
using 2-chloro-6,7-dimethoxy-N-(1-(4-phenylbutyl)piperidin-4-yl)quinazolin-4-amine
(intermediate, 200 mg, 0.58 mmol) and ,1,4’-bipiperidin (502 mg, 2.9 mmol) for 2
days, the reaction mixture was purified by column chromatography (0–3% ammonia
methanol in dichloromethane) to yield the title product as a yellow solid, 274 mg,
49%). mp 172-174  C; IR (cm 1) 3399, 2924, 2850; 1H NMR (400 MHz, CDCl3) 7.38
(s, 1H), 6.86 (s, 1H), 4.87-4.86 (d, J = 8.90 Hz, 2H), 4.32–4.25 (m, 1H), 3.89 (s, 3H),
3.88 (s, 3H), 3.31–3.29 (m, 2H), 2.81 (m, 2H), 2.57–2.50 (m, 4H), 2.10–2.04 (m, 2H),
1.93–1.90 (m, 2H), 1.79–1.46 (m, 18H); HRMS (ES) (m/z ) calcd. for C27H42N5O2:
468.3339, found: 468.3325.
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Compound 140: tert-Butyl-furan-3-ylcarbamate [144]
A solution of 3-furoic acid (5.6 g, 50 mM) was stirred in tert-butanol
(200 mL), followed by addition of triethylamine (10 mL, 100 mM) and
diphenylphosphorylazide (15 mL, 55 mM). The resulting mixture was
heated and stirred under reflux for 18 hours. The reaction mixture
was cooled to the room temperature and concentrated to 50 mL. The
concentrated mixture then was poured into 300 mL of saturated sodium bicarbonate
solution and the resulting mixture was stirred at 0  C for 2 hours. The solid was
collected by filtration and dried. The residue was purified by column chromatography
(0–2% methanol in chloroform) to yield the title product as a white solid (6.12 g,
68%). 1H NMR (400 MHz, CDCl3,  ) 7.71 (br s, 1H), 7.27 (m, 1H), 6.31 (br s, 1H),
6.28 (s, 1H), 1.51 (s, 9H); HRMS (ES) (m/z ) calcd. for C9H13NO3: 183.0895, found:
183.0895.
Compound 141: Methyl-3-(tert-butoxycarbonylamino)furan-2-carboxylate [166]
A solution of tert-butyl-furan-3-ylcarbamate (140, 2.8 g, 16.8 mM) and
TMEDA (6.27 mL, 41.86 mM) in dried THF (70 mL) was cooled to -78  C
and then n-buLi was added drowise over 10 min. The solution was allowed
to warm to -40  C for 2 hours. Subsequently, methyl chloroformate (1.95
mL, 25.1mM) was added and the mixture was warmed to 0  C for 45 min.
The mixture was diluted with 30 mL of saturated ammonium chloride
solution. The organic layer was washed with brine (50 mL x 3), dried
with magnesium sulfate and concentrated under reduced pressure. The crude oil was
purified by column chromatography to obtain a product as a yellow oil (1.7 g, 42%).
1H NMR (400 MHz, CDCl3,  ) 8.19 (br s, 1H), 7.39 (m, 1H), 7.24 (br s, 1H), 3.94 (s,
3H), 1.51 (s, 9H); 13C (100 MHz, CDCl3,  ) 160.5, 152.0, 145.6, 136.4, 127.8, 106.3,
82.0, 51.6, 28.2 (3C); HRMS (ES) (m/z ) calcd. for C11H16NO5: 241.0950, found:
241.0946.
Compound 142: Methyl-3-aminofuran-2-carboxylate [144]
Methyl 3-(tert-butoxycarbonylamino)furan-2-carboxylate (141,1.7 g, 12
mM) was dissolved in dichloromethane (10 mL) and treated with trifluoro-
acetic acid (5 mL) for 3 hours at room temperature. The mixture was
concentrated and the residue was diluted with dichloromethane (25 mL).
The organic layer was washed with saturated sodium bicarbonate solution (25 mL
⇥ 3), dried, and concentrated under reduced pressure. The residue was purified by
column chromatography (0–1% methanol in dichloromethane) to obtain the product
as a clear oil (580 mg, 58%). 1H NMR (400 MHz, CDCl3,  ) 7.27 (br s, 1H), 6.14
(d, J = 2.0 Hz, 1H), 4.58 (br s, 2H), 3.89 (s, 3H); 13C (100 MHz, CDCl3,  ) 160.6,
156
152.0, 145.8, 125.9, 105.3, 51.0; MS (ESI) [M+H]+ 142.0.
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Compound 143: Methyl-3-ureidofuran-2-carboxylate, [144]
A solution of methyl 3-aminofuran-2-carboxylate (142, 50 mg, 4.04
mmol) in dichloromethane (20 mL) was cooled at - 78  C. followed by
slow addition of chlorosufonyl isocyanate (0.78 mL, 5.65 mmol). The
mixture was allowed to warm to room temperature and stirred for 40
min. The mixture was concentrated under reduced pressure and was
treated with 6 N HCl (10 mL). The mixture was then heated under
reflux for 20 min. After the reaction was cooled to the room temperature, the mixture
was neutralised with a powder of sodium carbonate till pH 8. The solid was collected
by filtration and washed with water. The solid was dried to yield a grey powder
(410 mg, 56%). 1H NMR (400 MHz, CDCl3,  ) 7.27(br s, 1H), 6.14 (d, J = 2.0
Hz, 1H), 4.58 (br s, 2H), 3.89 (s, 3H); 13C (100 MHz, CDCl3,  ) 160.6, 152.0, 150.8,
145.8, 125.9, 105.3, 51.0; HRMS (ES) (m/z ) calcd. for C7H8N2O4: 184.0484, found:
184.0478.
Compound 144: Furo[3,2-d]pyrimidine-2,4-dione [144]
A suspension of methyl-3-ureidofuran-2-carboxylate (143, 400 mg, 2.17
mmol) in methanol (20 mL) was treated with 2 N sodium hydroxide (3
mL). The mixture was heated under reflux for 1.5 hours. The reaction
was allowed to cool down to room temperature and was acidified with 6
N hydrochloric acid to pH3. The solid was collected by filtration, washed
with methanol, and then dried under high vacuum to yield a magenta solid (350 mg,
quant). 1H NMR (400 MHz, DMSO-d6,  ) 11.40 (s, 1H), 11.07 (s, 1H), 8.03 (d, J =
2.0 Hz, 1H), 6.58 (d, J = 2.0 Hz, 1H) ; 13C (100 MHz, DMSO-d6,  ) 154.1, 151.7,
150.8, 138.7, 130.7, 102.8; MS cannot be obtained by ES and CI
Compound 145: 2,4-Dichlorofuro[3,2-d]pyrimidine [144]
Furo[3,2-d]pyrimidine-2,4-dione (585 mg, 3.8 mmol) was stirred in phos-
phoryl chloride at -40  C and then DIEA was slowly added and the
mixture was heated to 110  C for 3 days. The mixture was concen-
trated and poured into ice-cooled water (100 mL). The aqueous layer
was extracted with ethyl acetate (100 mL ⇥ 3). The combined organic layer was
washed with saturated sodium carbonate solution, dried, and concentrated under
reduced pressure to obtain a product as a brown solid (310 mg, 43%). 1H NMR
(400 MHz, CDCl3,  ) 8.10 (d, J = 2.4 Hz, 1H), 7.04 (d, J = 2.4 Hz, 1H);
13C (100
MHz, CDCl3,  ) 159.6, 156.4, 154.0, 143.4, 142.4, 108.2; HRMS (ES) (m/z ) calcd.
for C11H10NO2Cl2: 258.0089, found: 258.0093.
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Compound 146: N -(1-Benzylpiperidin-4-yl)-2-chlorofuro[3,2-d]pyrimidin-4-amine
[166]
Following general procedure 1, using 2,4-dichlorofuro[3,2-
d]pyrimidine (300 mg, 1.6 mmol) 4-amino-benzyl-piperidine (0.65
mL, 3.2 mmol), and DIEA (0.42 mL, 2.4 mmol), the mixture was
obtained and purified by column chromatography (0–3% methanol
in dichloromethane). This gave the title product as a white solid
(410 mg, 74%). mp 30–32  C; IR (cm 1) 3234, 2946, 2810, 2758,
1623, 1567; 1H NMR (400 MHz, CDCl3) 7.73 (br s, 1H), 7.26-7.20 (m, 5H), 6.78
(d, J = 2.4 Hz, 1H), 5.25 (br s, 1H), 4.23-4.14 (m, 1H), 3.56 (s, 2H), 2.89 (d, J =
11.6 Hz, 2H), 2.24 (t, J = 6.0 Hz, 2H), 2.08 (d, J = 11.6 Hz, 2H), 1.68-1.59 (m,
2H); 13C (100 MHz, CDCl3,  ) 154.7, 149.2,148.6, 138.1,133.8, 129.1(2C), 128.2 (2C),
127.1, 107.8, 98.3, 63.0 (2C), 51.9 (2C), 33.3, 32.5; HRMS (ES) (m/z ) calcd. for
C18H20N4OCl: 343.1326, found: 343.1321.
Compound 147: N -(1-Benzylpiperidin-4-yl)-2-(4-methylpiperazin-1-yl)furo[3,2-
d]pyrimidin-4-amine [166]
Following general procedure 3, heating N -(1-benzylpiperidin-
4-yl)-2-chlorofuro[3,2-d]pyrimidin-4-amine (146, 50 mg, 0.15
mmol), and 1-methyl piperazine (0.02 mL, 1.5 mmol), the
title compound was obtained and purified by column chro-
matography (0–5% ammonia methanol in dichloromethane).
This gave the title product as a white solid (61 mg, 99%). mp
36–38  C; IR (cm 1) 3278, 2930, 2846, 2794, 1618, 1586; 1H NMR (400 MHz, CDCl3)
7.55 (d, J = 2.0 Hz, 1H), 7.34–7.26 (m, 5H), 6.61 (d, J = 2.4, 1H), 5.25 (d, J =
8.0 Hz, 1H), 4.12–4.04 (m, 1H), 3.80 (t, J = 4.8 Hz, 4H), 3.55 (s, 2H), 2.89 (d, J =
12.0 Hz, 2H), 2.50 (t, J = 4.8 Hz, 4H), 2.35 (s, 3H), 2.21 (dt, J = 11.2, 1.6 Hz, 2H),
2.09 (dd, J = 12.8, 2.8 Hz, 2H), 1.65–1.61 (m, 2H); 13C (100 MHz, CDCl3,  ) 159.6,
151.3, 148.7 (2C), 138.2, 129.6, 129.6 (2C), 129.1 (2C), 127.0, 107.8, 63.1(2C), 55.1,
52.2 (2C), 46.2, 44.6, 32.5 (2C), 29.6 (2C); HRMS (ES) (m/z ) calcd. for C23H31N6O:
407.2559, found: 407.2593.
Compound 148: N -(1-benzylpiperidin-4-yl)-2-(piperidin-1-yl)furo[3,2-d]pyrimidin-
4-amine [166]
Following general procedure 3, heating N -(1-benzylpiperidin-
4-yl)-2-chlorofuro[3,2-d]pyrimidin-4-amine (146, 50 mg, 0.15
mmol), and piperidine (0.11 mL, 1.5 mmol), the reaction mix-
ture was purified by column chromatography (0–4% ammonia
methanol in dichloromethane) to yield the title product as a
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white solid (21 mg, 45%). mp <30  C; IR (cm 1) 3278, 2924,
2850, 2702, 1616, 1586; 1H NMR (400 MHz, CDCl3) 7.54 (d, J = 2.0 Hz, 1H),
7.36–7.28 (m, 5H), 6.62 (d, J = 2.4, 1H), 4.79 (d, J = 8.0 Hz, 1H), 4.12–4.05 (m,
1H), 3.74 (br s, 4H), 3.58 (s, 2H), 2.91 (d, J = 12.0 Hz, 2H), 2.24 (t, J = 11.2 Hz,
2H), 2.12 (d, J = 11.2 Hz, 2H), 1.65–163 (m, 8H); 13C (100 MHz, CDCl3,  ) 159.8,
151.4, 148, 147.5, 138.1, 129.3, 129.2 (2C), 128.2 (2C), 127.1, 107.3, 63.1 (2C), 52.7
(2C), 45.7 (2C), 32.5 (2C), 29.7, 25.8, 25.0; HRMS (ES) (m/z ) calcd. for C23H30N5O:
392.2450, found: 392.2460.
Compound 149: N -(1-Benzylpiperidin-4-yl)-2-(4-(pyridin-2-yl)piperazin-1-yl)furo
[3,2-d]pyrimidin-4-amine [166]
Following general procedure 3, heating N -(1-benzylpiper-
idin-4-yl)-2-chlorofuro[3,2-d]pyrimidin-4-amine (146, 0.12
mmol), and 1-(2-pyridyl)piperazine (0.11 mL, 1.5 mmol),
the reaction mixture was purified by column chromato-
graphy (0–3% ammonia methanol in dichloromethane) to
yield the title product as a white solid (50 mg, 92%). mp
52–54  C; IR (cm 1) 3290, 2926, 2850, 2766, 1618, 1586;
1H NMR (400 MHz, CDCl3) 8.25 (d, J =7.2 Hz, 1H), 7.80( d, J =2.0 Hz, 1H),
7.53-7.49 (m, 1H), 7.36-7.28 (m, 5H), 6.71 (d, J = 8.4 Hz, 1H), 6.67-6.64 (m, 2H),
4.86(d, J = 8.0 Hz, 1H), 4.15-4.06 (m, 1H), 3.91(t, J = 6.0 Hz, 4H), 3.65(t, J =
6.0 Hz, 4H), 3.58 (s, 2H), 2.91 (d, J = 12.0 Hz, 2H), 2.23 (t, J = 10.4, 2H), 2.12 (d,
J = 10.4 Hz, 2H), 1.68-1.59 (m, 2H); 13C (100 MHz, CDCl3,  ) 159.7, 159.6, 151.4,
148.0, 147.8, 138.2, 137.4, 129.6, 129.1 (2C), 128.2 (2C), 127.1, 113.3, 107.3, 107.2,
63.1 (2C), 52.3 (2C), 45.2 (2C), 44.5 (2C), 32.6 (2C); HRMS (ES) (m/z ) calcd. for
C27H32N7O: 470.2668, found: 470.2655.
Compound 150: N -(1-benzylpiperidin-4-yl)-2-(4-methyl-1,4-diazepan-1-yl)furo[3,2-
d]pyrimidin-4-amine [166]
Following general procedure 3, heating N -(1-benzylpiperidin-
4-yl)-2-chlorofuro[3,2-d]pyrimidin-4-amine (146, 50 mg, 0.15
mmol), and 1-methylhomopiperazine (0.14 mL, 1.5 mmol),
the reaction mixture was purified by column chromatography
(0–7% ammonia methanol in dichloromethane) to yield the
title product as a white solid, (64 mg, 99%). mp < 30  C;
IR (cm 1) 3282, 2928, 2850, 2798, 1616, 1587; 1H NMR (400
MHz, CDCl3) 7.53 (d, J = 2.0 Hz, 1H), 7.35–7.25 (m, 5H), 6.61 (d, J = 2.4 Hz, 1H),
4.80 (d, J = 7.6 Hz, 1H), 4.18–4.04 (m, 1H), 3.95 (t, J = 4.4 Hz, 2H), 3.83 (t, J
= 6.0 Hz, 2H), 3.53 (s, 2H), 2.89 (d, J = 12.0 Hz, 2H), 2.70 (t, J = 4.4 Hz, 2H),
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2.58 (t, J = 6.0 Hz, 2H) 2.38 (s, 3H), 2.20 (dt, J = 10.8, 1.6 Hz, 2H), 2.11 (dd, J =
12.8, 3.2 Hz, 2H), 2.04–1.98 (m, 2H), 1.63–1.60 (m, 2H); 13C (100 MHz, CDCl3,  )
159.2, 151.4, 147.6, 147.4, 138.4, 129.3, 129.1 (2C), 128.2 (2C), 127.0, 107.3, 63.2,
58.8, 57.4, 52.3 (2C), 46.7, 46.2, 41.0, 32.6 (2C), 29.7, 27.7; HRMS (ES) (m/z ) calcd.
for C24H33N6O: 421.2716, found: 421.2721.
Compound 152a: Thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione [148]
A mixture of methyl 3-aminothiophene-2-carboxylate (151a, 5.0 g, 31.8
mmol) and urea (10.0 g, 166 mmol) was heated at 190  C for 2.5 hours
using a microwave reactor. The mixture was cooled down and poured into
100 mL of 2 N sodium hydroxide, following by removing any insoluble
material by paper filtration. The clear mixture was acidified by adding 1
N HCl and recrystallised overnight to obtain the yellow crystalline solid (2.1 g, 35%).
mp >180  C; IR (cm 1) 3017, 2802, 1647, 1533; 1H NMR (400 MHz, DMSO-d6)
11.55 (s, 1H), 11.20 (s, 1H), 8.04 (d, J = 5.2 Hz, 1H), 6.91 (d, J = 5.2 Hz, 1H); 13C
(100 MHz, DMSO-d6,  ) 159.5, 152.0, 146.9, 136.2, 117.6, 111.6; HRMS (ES) (m/z )
calcd. for C6H5N2O2S: 169.0072, found: 169.0076.
Compound 152b: Thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione [144]
A solution of methyl 2-aminothiophene-3-carboxylate (151b, 5.0 g, 31.8
mmol) in anhydrous dichloromethane was cooled down to -78  C, followed
by addition of chlorosulfonyl isocyanate (3.8 mL, 44.5 mmol) over 20 min.
After the temperature of the mixture was allowed to room temperature,
the mixture was evaporated under reduced pressure and the resulting
crude solid was treated with 6 M HCl solution and heated to 100  C for 1 hour.
The mixture was then neutralised with saturated sodium carbonate solution. The
precipitate was filtrated, washed with water and dried to obtain the crude urea
intermediate. To stir suspension of crude in 2-propanol (50 mL), sodium hydroxide
(3 g) was added in 20 mL of water and stirred at 80  C for 3.5 hours. The resulting
mixture was poured into 2 M sodium hydroxide solution (50 mL) and slowly acidified
to pH 3 using 2 N HCl solution. The mixture was allowed to re-crystalise overnight
and the solid was filtrated and washed with water, and dried to a↵ord a brown
crystalline solid (2.8 g, 52%). mp > 180  C; IR (cm 1) 3456, 3092, 2813, 1654; 1H
NMR (400 MHz, DMSO-d6) 11.89 (s, 1H), 11.13 (s, 1H), 7.11 (d, J = 5.2 Hz, 1H),
7.07 (d, J = 5.2 Hz, 1H) ; 13C (100 MHz, DMSO-d6,  ) 159.7, 152.7, 151.1, 122.2,
117.4, 115.7; HRMS (ES) (m/z ) calcd. for C6H5N2O2S: 169.0072, found: 169.0066.
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Compound 153a: 2,4-Dichlorothieno[3,2-d]pyrimidine [148]
A mixture of thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione (152a, 2.0 g,
11.9 mmol), phosphorous oxychloride (20 mL), and DMF (0.2 mL) was
refluxed for 6 hours. The mixture was cooled down and then concentrated
under reduced pressure. The residue was poured into ice-cooled water,
following by paper filtration to obtain white solid (1.9 g, 75%). mp 122–124  C; IR
(cm 1) 3091, 3069, 1548; 1H NMR (400 MHz, CDCl3) 8.14 (d, J = 5.6 Hz, 1H), 7.57
(d, J = 5.6); 13C (100 MHz, CDCl3,  ) 163.4, 156.2, 155.7, 139.1, 129.3, 124.5; MS
cannot be obtained by ES and CI
Compound 153b: 2,4-Dichlorothieno[2,3-d]pyrimidine [144]
A mixture of thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione (152b, 2.8 g,
16.7 mmol), phosphorous oxychloride (30 mL), and DMF (0.3 mL) was
refluxed overnight. The mixture was cooling down and concentrated
under reduce pressure. The residue was poured into ice-cooled water.
The mixture was allowed to recrystalise overnight, following by filtrated
to obtain brown solid (2.3 g, 69%). mp 109-110  C; IR (cm 1) 3091, 3069, 1548; 1H
NMR (400 MHz, CDCl3) 7.65 (d, J = 4.0 Hz, 1H), 7.46 (d, J = 4.0 Hz, 1H); MS
cannot be obtained by ES and CI
Compound 154a: N -(1-Benzylpiperidin-4-yl)-2-chloro-4a,7a-dihydrothieno[3,2-d]
pyrimidin-4-amine
Following general procedure 1, using 2,4-dichlorothieno[3,2-
d]pyrimidine (153a, 5 mmol scale), the the title product was
obtained as a pale yellow solid (1.2 g, 67%). mp 66–68  C; IR
(cm 1) 3233, 2940, 2763, 1580; 1H NMR (400 MHz, CDCl3) 7.74
(d, J = 5.6 Hz, 1H), 7.36-7.26 (m, 6H), 4.97 (br s, 1H), 4.28-4.19
(m, 1H), 3.56 (s, 2H), 2.90 (d, J =12.0 Hz, 2H), 2.25 (dt, J =12,
4Hz, 2H), 2.13 (d, J = 12Hz, 2H), 1.68–1.65 (m, 2H); 13C (100 MHz, CDCl3,  ,
missing 1 Ar-C) 161.4, 157.6, 157.4, 138.2, 132.1, 129.1 (2C), 128.2 (2C), 127.1,
124.8, 63.0, 52.0 (2C), 48.5, 32.5 (2C); HRMS (ES) (m/z ) calcd. for C18H20N4SCl:
359.1097, found: 359.1096.
Compound 154b: N -(1-Benzylpiperidin-4-yl)-2-chloro-4a,7a-dihydrothieno[2,3-d]
pyrimidin-4-amine [166]
Following general procedure 1, using 2,4-dichlorothieno[2,3-
d]pyrimidine (153b, 5 mmol scale), the the title product was
obtained as a pale yellow solid (1.1 g, 67%). mp 55–60  C; IR
(cm 1) 3262, 2941, 2764, 1581; 1H NMR (400 MHz, CDCl3) 7.35-
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7.26 (m, 6H), 7.12 (d, J = 6.0 Hz, 1H), 5.6 (d, J = 8.0 Hz, 1H),
4.29-4.19 (m, 1H), 3.56 (s, 2H), 2.90 (d, J = 12.0 Hz, 2H), 2.25
(t, J = 12, 2H), 2.13 (d, J =12Hz, 2H), 1.66-1.62 (m, 2H); 13C (100 MHz, CDCl3,
 ) 157.1, 156.2, 138.1, 129.1 (2C), 128.2 (2C), 127.1, 123.3, 116.6, 114.7, 63.0, 52.1
(2C), 48.0, 32.2 (2C); HRMS (ES) (m/z ) calcd. for C18H20N4SCl: 359.1097, found:
359.1104.
Compound 155: N -(1-Benzylpiperidin-4-yl)-2-(4-methylpiperazin-1-yl)-4a,7a-dihy-
drothieno [3,2- d]pyrimidin-4-amine [166]
Following general procedure 3, heating N -(1-benzylpiperidin-
4-yl)-2-chloro-4a,7a-dihydrothieno [3,2-d] pyrimidin-4-amine
(154a, 178 mg, 0.50 mmol), and 1-methyl piperazine (0.29
mL, 2.5 mmol), the reaction mixture was purified by column
chromatography (0–5% ammonia methanol in dichlorometh-
ane) to yield the title product as a yellow solid (186 mg, 88%).
mp 57–59  C; IR (cm 1) 2922, 2796, 1580, 1546; 1H NMR (400 MHz, CDCl3) 7.53
(d, J = 5.6 Hz, 1H), 7.35–7.27 (m, 5H), 7.14 (d, J = 5.6 Hz, 1H), 4.58 (d, J = 7.2
Hz, 1H), 4.15–4.04 (m, 1H), 3.86 (t, J = 4.8 Hz, 4H), 3.57 (s, 2H), 2.91 (d, J = 11.6
Hz, 2H), 2.52 (t, J = 4.8 Hz, 4H), 2.37 (s, 3H), 2.22 (t, J = 10.0 Hz, 2H), 2.12 (d, J
= 10.0 Hz, 2H), 1.65–1.62 (m, 2H); 13C (100 MHz, CDCl3,  ) 162.0, 160.9, 156.6,
138.1, 130.1, 129.1 (2C), 128.2 (2C), 127.1, 124.3, 105.8, 63.0, 55.0 (2C), 52.3 (2C),
48.0, 46.1, 44.2 (2C), 32.3 (2C); HRMS (ES) (m/z ) calcd. for C23H31N6S: 423.2331,
found: 423.2326.
Compound 156: N -(1-Benzylpiperidin-4-yl)-2-(piperidin-1-yl)-4a,7a-dihydrothieno
[3,2-d]pyrimidin- 4-amine [166]
Following general procedure 3, heating N -(1-benzylpiperidin-4-
yl)-2-chloro-4a,7a-dihydrothieno[3,2-d]pyrimidin-4-amine (154a,
100 mg, 0.27 mmol), and piperidine (0.32 mL, 2.7 mmol), the
reaction mixture was purified by column chromatography (0–4%
ammonia methanol in dichloromethane) to yield the title product
as a yellow solid (42 mg, 38%). mp 56–58  C; IR (cm 1) 3261,
2924, 2851, 1581; 1H NMR (400 MHz, CDCl3) 7.52 (d, J = 5.6 Hz, 1H), 7.36-7.28
(m, 5H), 7.13 (d, J = 5.6 Hz, 1H), 4.52 (d, J = 7.2 Hz, 1H), 4.18-4.08 (m, 1H), 3.78
(t, J =4.4 Hz, 4H), 3.59 (s, 2H), 2.91 (d, J = 12.0 Hz, 2H), 2.52 (t, J = 11.6 Hz,
2H), 2.13 (d, J = 12.0 Hz, 2H), 1.68-1.55 (m, 8H); 13C (100 MHz, CDCl3,  ) 162.1,
161.0, 156.5, 137.9,129.8, 129.2 (2C), 128.2(2C), 127.2, 124.4, 105.1, 63.0, 52.3, 47.9,
45.4, 32.2, 31.9, 29.6, 29.8, 25.8, 25.0, 22.6, 14.1; MS (ES) (m/z ) [M+H]+ 408.47.
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Compound 157: N -(1-Benzylpiperidin-4-yl)-2-(4-(pyridin-2-yl)piperazin-1-yl)-4a,7a-
dihydrothieno[3,2- d]pyrimidin-4-amine [166]
Following general procedure 3, heating N -(1-benzylpiper-
idin-4-yl)-2-chloro-4a,7a-dihydrothieno [3,2-d] pyrimidin-
4-amine (154a, 100 mg, 0.21 mmol), and 1-(2-pyridyl)pi-
perazine (0.16 mL, 1.05 mmol), the reaction mixture was
purified by column chromatography (0–3% ammonia meth-
anol in dichloromethane) to yield the title product as a
pale yellow solid (85 mg, 83%). mp 71–74  C; IR (cm 1)
2922, 1586, 1550; 1H NMR (400 MHz, CDCl3) 8.22 (d, J = 3.6 Hz, 1H), 7.55–7.53
(m, 2H), 7.36–7.16 (m, 5H), 7.16 (d, J = 5.2 Hz, 1H), 6.70 (d, J = 8.4 Hz, 1H),
6.64–6.63 (m, 1H), 4.71 (d, J = 7.2 Hz, 1H), 4.19–4.11 (m, 1H), 3.96 (t, J = 4.8 Hz,
4H), 3.65 (t, J = 4.8 Hz, 4H), 3.59 (s, 2H), 2.94 (d, J = 12.0 Hz, 2H), 2.24 (t, J =
11.2 Hz, 2H), 2.14 (d, J = 12.0 Hz, 2H), 1.67–1.63 (m, 2H); 13C (100 MHz, CDCl3,
 ) 162.0, 161.0, 159.6, 156.6, 148.0, 137.9, 137.4, 130.3, 129.2 (2C), 128.3 (2C), 127.2,
124.3, 113.3, 107.2, 106.0, 62.8, 52.3, 52.0 (2C), 48.1, 45.2, 44.2, 32.2 (2C); HRMS
(ES) (m/z ) calcd. for C27H32N7S: 486.2480, found: 486.2488.
Compound 158: N -(1-Benzylpiperidin-4-yl)-2-(4-methyl-1,4-diazepan-1-yl) thieno
[3,2-d] pyrimidin-4-amine [166]
Following general procedure 3, heating N -(1-benzylpiper-
idin-4-yl)-2-chloro-4a,7a-dihydrothieno [3,2-d] pyrimidin-4-
amine (154a, 50 mg, 0.13 mmol), and 1-methylhomopiper-
azine (0.16 mL, 1.3 mmol), the reaction mixture was purified
by column chromatography (0–5% ammonia methanol in
dichloromethane) to yield the title product as a white solid,
(42 mg, 34%). mp <30  C; IR (cm 1) 2938, 2798, 1660; 1H NMR (400 MHz, CDCl3)
7.50 (d, J = 5.6 Hz, 1H), 7.34–7.33 (m, 4H), 7.29–7.24 (m, 1H), 7.14 (d, J =5.6 Hz,
1H), 4.53 (d, J = 6.8 Hz, 1H), 4.13–4.04 (m, 1H), 3.96 (t, J = 4.8 Hz, 2H), 3.85 (t, J
= 6.4 Hz, 2H), 3.54 (s, 2H), 2.89 (d, J = 12.0 Hz, 2H), 2.70 (t, J = 4.8 Hz, 2H), 2.57
(t, J = 6.4 Hz, 2H), 2.37 (s, 3H), 2.21–2.10 (m, 4H), 2.04–1.98 (m, 2H), 1.62–158
(m, 2H); 13C (100 MHz, CDCl3,  ) 162.3, 160.7, 156.4, 138.5, 129.7 (2C), 129.0 (2C),
128.3, 127.0, 124.4, 105.0, 63.1,58.7, 57.3, 52.4 (2C), 48.2, 46.7, 46.2, 46.1, 32.4 (2C),
27.7; HRMS (ES) (m/z ) calcd. for C24H33N6S: 437.2484, found: 437.2493.
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Compound 159: N -(1-Benzylpiperidin-4-yl)-2-(4-methylpiperazin-1-yl)thieno[2,3-
d]pyrimidin- 4-amine [166]
Following general procedure 3, heating N -(1-benzylpiperidin-
4-yl)-2-chloro-4a,7a-dihydrothieno [2,3-d] pyrimidin-4-amine
(154b, 100 mg, 0.27 mmol), and 1-methy piperazine (0.15 mL,
1.39 mmol), the reaction mixture was purified by column chro-
matography (0–9% ammonia methanol in dichloromethane)
to yield the title product as a pale yellow solid (105 mg, 93%).
mp <30  C; IR (cm 1) 3299, 2938, 2799, 1659, 1582; 1H NMR (400 MHz, CDCl3)
7.35–7.25 (m, 5H), 6.94 (d, J = 5.6 Hz, 1H), 6.79 (d, J = 5.6 Hz, 1H), 4.92 (d, J =
7.2Hz, 1H), 4.14–4.05 (m, 1H), 3.86 (t, J = 4.4 Hz, 4H), 3.57 (s, 2H), 2.91 (d, J =
11.6 Hz, 2H), 2.50 (t, J = 4.8 Hz, 4H), 2.36 (s, 3H), 2.23 (t, J = 11.2, 2H), 2.12 (d,
J = 9.6 Hz, 2H), 1.64-1.60 (m, 2H); 13C (100 MHz, CDCl3,  ) 169.5, 159.5, 156.5,
137.9, 129.2, 128.9, 128.2 (2C), 127.1, 116.9, 116.4, 108.9, 63.0, 55.3, 55.0, 54.2 (2C),
47.7, 46.1, 44.0, 39.8 (2C), 32.1 (2C); MS (ES) (m/z ) [M+H]+ 423.49.
Compound 160: N -(1-Benzylpiperidin-4-yl)-2-(piperidin-1-yl)thieno[2,3-d]pyrimidin-
4-amine [166]
Following general procedure 3, heating N -(1-benzylpiperidin-4-
yl)-2-chloro-4a,7a-dihydrothieno[2,3-d]pyrimidin-4-amine (154b,
100 mg, 0.27 mmol), and piperidine (0.13 mL, 1.39 mmol), the
reaction mixture was purified by column chromatography (0–
4% ammonia methanol in dichloromethane) to yield the title
product as a yellow solid (81 mg, 74%). mp 47–50  C; IR (cm 1)
2928, 1579, 1543; 1H NMR (400 MHz, CDCl3) 7.36–7.27 (m, 5H), 6.93 (d, J = 6.0
Hz, 1H), 6.75 (d, J = 6.0 Hz, 1H), 4.86 (d, J = 7.2 Hz, 1H), 4.16–4.15 (m, 1H), 3.80
(t, J = 5.6 Hz, 4H), 3.57 (s, 2H), 2.91 (d, J = 12.0 Hz, 2H), 2.23 (t, J = 11.2 Hz,
2H), 2.13 (d, J = 12.0 Hz, 2H), 1.67–1.58 (m, 8H); 13C (100 MHz, CDCl3,  ) 169.8,
159.7, 156.4, 138.2, 129.1 (2C), 128.2 (2C), 127.1, 116.9, 115.7, 108.4, 63.1, 52.4 (2C),
47.7, 45.3 (2C), 32.2 (2C), 25.8, 25.0; MS (ES) (m/z ) [M+H]+ 408.47.
Compound 159: N -(1-Benzylpiperidin-4-yl)-2-(4-methyl-1,4-diazepan-1-yl)thieno[2,3-
d]pyrimidin- 4-amine [166]
Following general procedure 3, heating N -(1-benzylpiper-
idin-4-yl)-2-chloro-4a,7a-dihydrothieno [2,3-d] pyrimidin-4-
amine (154b, 50 mg, 0.13 mmol), and 1-methylhomopiper-
azine (0.16 mL, 1.3 mmol), the reaction mixture was purified
by column chromatography (0–5% ammonia methanol in
dichloromethane) to yield the title product as a white solid,
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(54 mg, 97%). mp < 30  C; IR (cm 1) 3299, 2938, 2799, 1659, 1582; 1H NMR (400
MHz, CDCl3) 7.35–7.25 (m, 5H), 6.91 (d, J = 6.0 Hz, 1H), 6.75 (d, J = 6.0 Hz, 1H),
4.8 (br s, 1H), 4.11–4.02 (m, 1H), 3.95 (t, J = 4.8 Hz, 2H), 3.85 (t, J = 6.4 Hz, 2H),
3.58 (s, 2H), 2.89 (d, J = 12.0 Hz, 2H), 2.69( t, J = 4.8 Hz, 2H), 2.56 (t, J= 6.4Hz,
2H), 2.37 (s, 3H), 2.19(t, J = 15.6 Hz, 2H), 2.11 (d, J =15.6 Hz, 2H), 2.00 (d, J =
5.2 Hz, 2H), 1.61–1.57 (m, 2H); 13C (100 MHz, CDCl3,  ) 169.7, 159.4, 156.3, 138.4,
129.1 (2C), 128.2 (2C), 127.0, 116.8, 115.5, 108.3, 63.1, 58.7, 57.3, 52.4 (2C), 47.9,
46.7, 46.2, 46.1, 32.3,(2C), 27.7; HRMS (ES) (m/z ) calcd. for C24H33N6S: 437.2487,
found: 437.2487.
Compound 164: 2,6-Dichloropurine [151]
In order to prepare pyrophosphoryl chloride, phosphoryl chloride (50
mL) was added dropwise 10 mL of water. Then the mixture was boil
for 1.5 hours to dispel the hydrogen chloride, cooled and the top layer
decanted from the thick syrup at the bottom. The top layer was used
for the chlorination of xanthine. A mixture of xanthine (3.2 g, 21
mmol) and the prepared pyrophosphoryl chloride was heated in a sealed tube at 165
 C for 2 days. After cooling down, the brown solution was decanted from the solid
residue in the tube and the volatile material was removed under reduced pressure.
The syrupy residue was poured onto the ice-cooled water, a precipitate was removed
and the filtrate was extracted (6 ⇥ 100 mL) portions of diethyl ether. The ethereal
solution was dried and then concentrated under reduced pressure. The title product
was obtained as a yellow solid (1.8 g, 46%). mp >180  C; 1H NMR (400 MHz,
DMSO-d6,  ) 8. 74 (s, 1H), 14.15 (s, 1H). 13C NMR (100 MHz, DMSO-d6,  ) 156.1,
150.8, 148.0, 147.6, 128.55 HRMS (ES) (m/z ) calcd. for C5H3N4Cl2: 188.9735, found:
188.9745 .
Compound 165: N -(1-Benzylpiperidin-4-yl)-2-chloro-7H -purin-6-amine [166]
A solution of the 2,6-dichloropurine (1.3 g, 6.95 mmol) and triethyl-
amine (1.28 mL, 7.64 mmol) in 15 mL of n-butanol was heated
and stirred in a sealed tube overnight. The resulting mixture
was concentrated and dissolved in dichloromethane (25 mL). The
organic layer was washed with water (25 mL⇥3), dried and concen-
trated under reduced pressure. The residue was purified by column
chromatography (0–5% ammonia in methanol) to a↵ord the title product as a white
solid (664 mg, 27%). mp > 180  C; IR (cm 1) 3232, 3028, 2960, 2805, 1626, 1529;
1H NMR (400 MHz, CDCl3 and CH3OD,  ) 7.79 (s, 1H), 7.32–7.22 (m, 5H), 4.12 (s,
2H), 3.31 (m, 1H), 2.85 (m, 2H), 2.24 (t, J = 12 Hz, 2H), 1.65 (dd, J = 12.4 Hz,
2H), 1.67–1.61 (m, 2H); HRMS (ES) (m/z ) calcd. for C17H19ClN6: 343.1438, found:
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343.1431.
Compound 167: N -(1-Benzylpiperidin-4-yl)-2-(piperidin-1-yl)-7H -purin-6-amine
[166]
Following general procedure 3, heating N -(1-benzylpiperidin-
4-yl)-2-chloro-7H -purin-6-amine (159, 80 mg, 0.24 mmol, and
piperidine (0.23 mL, 2.4 mmol), the reaction mixture was pur-
ified by column chromatography (0–5% ammonia methanol in
dichloromethane) to yield the title product as a white solid, (22
mg, 23%). mp 90–93  C; IR (cm 1) 3061, 2930, 2803, 1594,
1481; 1H NMR (400 MHz, CDCl3) 7.56 (s, 1H), 7.31–7.27 (m, 5H), 5.62 (br s, 1H),
4.14 (br s, 1H), 3.80 (t, J = 8 Hz,2H), 3.56 (s, 2H), 2.91–2.87 (m, 2H), 2.28–2.22 (m,
2H), 2.14–2.10 (m, 2H), 1.70–1.64 (m, 8H); 13C (100 MHz, CDCl3,  ) 159.2, 154.0,
151.7, 138.4, 135.0, 129.1 (2C), 128.2 (2C), 127.0, 113.3, 63.2 (2C), 52.3 (2C), 47.5,
45.83 (2C), 32.2, 29.71 (2C), 24.91; MS (ES) (m/z ) [M+H]+ 392.42.
Compound 169: N -(1-Benzylpiperidin-4-yl)-2-(4-methyl-1,4-diazepan-1-yl)-7H -
purin-6-amine [166]
Following general procedure 3, heating N -(1-benzylpiperidin-
4-yl)-2-chloro-7H -purin-6-amine (159, 100 mg, 0.29 mmol),
and 1-methyl homopiperazine (0.36 mL, 2.9 mmol), the reac-
tion mixture was purified by column chromatography (0–5%
ammonia methanol in dichloromethane) to yield the title
product as a white solid, (41 mg, 33%). mp 179–182  C;
IR (cm 1) 3061, 2938, 2800, 1598, 1489; 1H NMR (400 MHz, CDCl3) 7.52 (s, 1H),
7.37-7.27 (m, 5H), 5.59 (br s, 1H), 4.09 (br s, 1H), 4.01-3.98 (m, 2H), 3.86 (t, J =
8 Hz), 3.65 (s, 2H), 2.93-2.88 (m, 2H), 2.79-2.76 (m, 2H), 2.66-2.63 (m, 2H), 2.42
(s, 3H), 2.23-2.21 (m, 2H), 2.10–2.07 (m, 4H), 1.71-1.62 (m, 2H); 13C (100 MHz,
CDCl3,  ) 158.8, 153.8, 138.4, 134.7, 129.2 (2C), 128.3 (2C), 127.1, 113.1, 63.2, 58.6,
57.3, 52.3 (2C), 47,7, 46.7 (2C), 46.3, 32.3 (2C), 27.7 (2C); MS (ES) (m/z ) [M+H]+
421.47.
Compound 172: 2,4-Dichloro-6,7-dimethoxyquinoline
A solution of malonic acid (5.4 g, 65 mmol) in phosphoryl chloride
(60 mL) was stirred, followed by addition of 3,4-dimethoxyaniline
(10 g, 52 mmol). The reaction was heated under reflux for 3 hours.
Then the mixture was allowed to cool down at room temperature and
slowly added into ice-cooled water. The resulting aqueous layer was
extracted with dichloromethane (100 mL X 3). The combined organic layer was
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washed with brine (300 mL), dried, concentrated under reduced pressure. The crude
was purified by column chromatography to provided the title product as a brown
solid (6.8 g, 51%). mp 144–148  C; IR (cm 1) 3428, 3351, 3245, 2825, 1627, 1593,
1232; 1H NMR (400 MHz, CDCl3,  ) 7.51 (s, 1H), 7.37 (s, 1H), 7.31 (s, 1H), 4.04
(s, 3H), 4.03 (s, 3H); 13C (100 MHz, CDCl3,  ) 154.5, 151.1, 146.5, 144.0, 143.2,
120.8, 119.7, 106.4, 101.7, 56.5, 56.3; HRMS (ES) (m/z ) calcd. for C11H10NO2Cl2:
258.0089, found: 258.0099.
Compound 173: 4-Chloro-6,7-dimethoxy-2-(4-methylpiperazin-1-yl)quinoline
The mixture of 2,4-dichloro-6,7-dimethoxyquinoline (172, 1.0 g,
3.87 mmol), 1-methyl piperazine (0.64 mL, 5.81 mmol) and N ,N -
diisopropylethylamine (1.0 mL, 5.81 mM) in 15 mL of dioxane
was stirred and heated in a sealed tube at 140  C for 3.5 days.
After the reaction was cooled down to room temperature, the
reaction mixture was concentrated under reduced pressure and 50 mL of ethyl
acetate was added and the organic layer was washed with water (100 mL ⇥ 3), then
dried, and concentrated under reduced pressure. The crude was purified by column
chromatography (0–5% methanol in dichloromethane) to obtain the title product as
a white solid (90 mg, 7%). mp 162–165  C; IR (cm 1) ; 1H NMR (400 MHz, CDCl3,
 ) 7.28 (s, 1H), 7.13 (s, 1H), 6.96 (s, 1H), 4.02 (s, 6H), 3.72-3.69 (m, 4H), 2.59-2.56
(m, 4H), 2.39 (s, 3H); 13C (100 MHz, CDCl3,  ) 158.8, 153.8, 138.4, 134.7, 129.2
(2C), 128.3 (2C), 127.1, 113.1, 63.2, 58.6, 57.3, 52.3 (2C), 47,7, 46.7 (2C), 46.3, 32.3
(2C), 27.7 (2C); 13C (100 MHz, CDCl3,  );156.6, 153.0, 147.4, 145.1, 141.6, 115.7,
107.2, 106.6, 102.4, 56.1, 56.0, 54.9 (2C), 46.2, 45.2 (2C) HRMS (ES) (m/z ) calcd.
for C16H21N3O2Cl: 322.1313, found: 322.1313.
Compound 174: 4-Chloro-6,7-dimethoxy-2-(4-methyl-1,4-diazepan-1-yl)quinoline
The mixture of 2,4-dichloro-6,7-dimethoxyquinoline (172, 2 g,
7.74 mM), 1-methyl homopiperazine (1.15 mL, 11.62 mM) and
N ,N -diisopropylethylamine (2.02 mL, 11.62 mM) in 15 mL of
dioxane was stirred and heated in a sealed tube at 140  C for 3
days. After the reaction was cooled down to room temperature,
the reaction mixture was concentrated under reduced pressure.
25 mL of water was added, then the suspension was extracted with dichloromethane
(25 mL ⇥ 3). The organic phase was combined, dried with magnesium sulphate,
and concentrated under reduced pressure. The residue was purified by column
chromatography (0–6% 7 M ammonia methanol in dichloromethane) to provide the
title product as a yellow solid (298 mg, 11%). mp 115–119  C; IR (cm 1) 3423, 3352,
3240, 2828, 1591, 1410; 1H NMR (400 MHz, CDCl3,  ) 7.27 (s, 1H), 7.08 (s, 1H),
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6.82 (s, 1H), 4.01 (s, 3H), 3.99 (s, 3H) 3.72–3.94 (m, 2H), 3.76 (t, J = 8 Hz, 2H),
2.89 (t, J = 8 Hz, 2H), 2.66–2.63 (m, 2H), 2.44 (s, 3H), 2.14–2.08 (m, 2H); 13C (100
MHz, CDCl3,  ) 155.7, 152.9, 146.7, 145.5, 141.5, 114.9, 106.5, 106.1, 102.5, 58.5,
57.3, 56.0 (2C), 46.7, 46.5, 46.0, 27.4; HRMS (ES) (m/z ) calcd. for C17H23N3O2Cl:
336.1479, found: 336.1472.
Compound 175: 4,5-Dimethoxy-2-nitrobenzonitrile [166]
3-4 dimethoxybenzonitrile (16.3 g, 0.1 mol) was dissolved in acetic
anhydride (130 mL) at 0  C. Excess of nitric acid (36.5 mL) was
continuously added to the mixture over 15 min. Then, the reaction was
allowed to room temperature and stirred overnight. The mixture was
poured into ice-cooled water (1 L) and the resulting precipitate was
filtered, washed with water and dried under vacuum to a↵ord the title product as a
yellow solid in quantitative yield. mp 77–80  C; IR (cm 1) 3351, 2963, 2226, 1568,
1515; 1H NMR (400 MHz, DMSO-d6,  ) 7.80 (s, 1H), 7.23 (s, 1H), 4.04 (s, 3H), 4.03
(s, 3H) ; 13C (100 MHz, CDCl3,  ) 154.8, 148.8, 140.7, 119.1, 114.4, 99.4, 84.4, 56.6,
56.5; HRMS (ES) (m/z ) calcd. for C9H8N2O4: 208.0489, found: 208.0416.
Compound 176: 2-Amino-4,5-dimethoxybenzonitrile [166]
Tetrabutylammonium bromide (10.40 g, 36.8 mmol) was added toa
solution of 4,5-dimethoxy-2-nitrobenzonitrile (175, 30.5 g, 146 mmol)
in dichloromethane (250 mL), followed by slow addition of a solution of
sodium dithionite (100 g, 576 mmol) in water (250 mL). The mixture
was stirred overnight at room temperature and then basified to pH 9
using 2 N sodium hydroxide. The aqueous layer was extracted with dichloromethane
(250 mL ⇥ 3). The organic layer was concentrated to 100 mL. 4 M HCl in dioxane
then was added slowly until precipitation occurred. The resulting solid was collected
by filtration and re-dissolved in 2 N sodium hydroxide (200 mL). Finally, the aqueous
layer was extracted again with dichloromethane (200 mL ⇥ 3), dried over magnesium
sulphate and concentrated under reduced pressure to a↵ord the title product as a
fine yellow solid (14.5 g, 56%). mp 78–80  C; IR (cm 1) 3328, 3228, 2949, 2211,
1619, 1504; 1H NMR (400 MHz, CDCl3,  ) 6.76 (s, 1H), 6.26 (s, 1H), 4.30 (br s, 2H),
3.85 (s, 3H), 3.78 (s, 3H); 13C (100 MHz, CDCl3,  ) 158.8, 153.8, 138.4, 134.7, 129.2
(2C), 128.3 (2C), 127.1, 113.1, 63.2, 58.6, 57.3, 52.3 (2C), 47,7, 46.7 (2C), 46.3, 32.3
(2C), 27.7 (2C); 13C (100 MHz, CDCl3,  ) 154.5, 146.4, 141.8, 118.3, 113.3, 99.1,
86.0, 56.5, 55.9; MS (ES) (m/z ) [M+H]+ 179.1.
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Compound 177: Ethyl-N -2-cyano-4,5-dimethoxyphenylacetimidate [143]
A solution of 2-amino-4,5-dimethoxybenzonitrile (176, 1.6 g, 9.14
mmol) in triethylorthoacetate (5.4 mL, 28.6 mM) was heated at
150  C under reduced pressure for 6 hours. After the reaction
mixture was cooled down to room temperature, the mixture was
concentrated and left under high-vac for 48 hours to a↵ord a brown
solid (2.16, 96%). mp 58–60  C; IR (cm 1) 2979, 2214, 1663, 1505; 1H NMR (400
MHz, CDCl3,  ) 6.97 (s, 1H), 6.39 (s, 1H), 4.29 (q, J = 8.0 Hz, 2H), 3.90 (s, 3H),
3.88 (s, 3H), 1.90 (s, 3H), 1.37 (t, J = 8.0 Hz, 3H); HRMS (ES) (m/z ) calcd. for
C13H16N2O3: 249.1239, found: 249.1240.
Compound 178a: 4,5-Dimethoxy-2-(1-(4-methylpiperazin-1-yl)ethylideneamino)
benzonitrile [166]
p-Toluenesulfonic acid (15 mg) was added into a solution of the
intermediate ethyl N -2-cyano-4,5- dimethoxyphenylacetimidate
(177, 2.0 g, 8.0 mmol) in 1-methyl piperazine (1.97 mL, 16.0
mmol). The reaction mixture was heated at 100  C for 24 hours.
The reaction was allowed to cool to room temperature and di-
chloromethane (30 mL) was added. The organic layer was extracted with 2 N HCl (30
mL ⇥ 3) and the combined aqueous layer was basified by adding sodium carbonate
powder until pH 8. The aqueous layer was extracted again with dichloromethane
(100 mL ⇥ 3), dried over magnesium sulphate, concentrated under reduced pressure.
The residue was purified by column chromatography (0–4% ammonia methanol in
dichloromethane) to a↵ord the title product as yellow oil (990 mg, 40%). 1H NMR
(400 MHz, CDCl3,  ) ;
13C (100 MHz, CDCl3,  ) 1157.5, 153.4, 151.3, 144.1, 118.8,
113.6, 106.3, 95.5, 56.2, 55.9, 54.9, 54.7 (2C), 46.1(2C), 15.3; HRMS (ES) (m/z )
calcd. for C16H23N4O2: 303.1821, found: 303.1827.
Compound 178d: 4,5-Dimethoxy-2-(1-(4-methyl-1,4-diazepan-1-yl)ethylideneami-
no) benzonitrile [166]
p-Toluenesulfonic acid (20 mg) was added into a solution of the
intermediate ethyl N -2-cyano-4,5- dimethoxyphenylacetimidate
(177, 23.0 g, 12.0 mmol) in 1-methyl-homopiperazine (4.0 mL,
24.0 mmol) The reaction mixture was heated at 100  C for 24
hours. The reaction was allowed to cool to room temperature
and dichloromethane (30 mL) was added. The organic layer was
extracted with 2 N HCl (30 mL ⇥ 3) and the combined aqueous layer was basified by
adding sodium carbonate powder until pH 8. The aqueous layer was extracted again
with dichloromethane (100 mL ⇥ 3), dried over magnesium sulphate, concentrated
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under reduced pressure. The residue was purified by column chromatography (0–4%
ammonia methanol in dichloromethane) to a↵ord the title product as yellow oil (1.5
g, 45%). 1H NMR (400 MHz, CDCl3,  ) 6.93 (s, 1H), 6.34 (s, 1H), 3.89 (s, 3H), 3.86
(s, 3H), 3.80–3.63 (m, 4H), 2.73 (br s, 2H), 2.68–2.65 (m, 2H), 2.43 (s, 3H), 2.01–1.98
(m, 2H), 1.96 (s, 3H); HRMS (ES) (m/z ) calcd. for C17H25N4O2: 317.1978, found:
317.1985.
Compound 179a: 6,7-Dimethoxy-2-(4-methylpiperazin-1-yl)quinolin-4-amine [166]
A solution of 4,5-dimethoxy-2-(1-(4-methylpiperazin-1-yl) ethyl-
ideneamino) benzonitrile (178a, 800 mg, 3.04 mmol) and zinc
chloride (2.48 g, 18.24 mmol) in dimethylacetamide (40 mL) was
heated at reflux for 24 hours. After the reaction was cooled
down to room temperature and diethyl ether (100 mL ⇥ 2) was
added to the mixture and it was stirred for 10 min. The supernatant was discarded
each time. The tar residue was treated with 2 N sodium hydroxide (100 mL) and
the mixture was stirred at room temperature for 10 min. The resulting suspension
was extracted by dichloromethane (100 mL ⇥ 3). The combined organic layer was
dried and concentrated under reduced pressure. The residue was purified by column
chromatography (0–5% ammonia methanol in dichloromethane) to a↵ord the title
compound as a yellow crystalline solid (330 mg, 36%). mp 80–83  C; IR (cm 1) 3355,
3218, 2937, 2801, 1593, 1422; 1H NMR (400 MHz, CH3OD,  ) 7.27 (s, 1H), 7.04 (s,
1H), 6.15 (s, 1H), 3.93 (s, 3H), 3.92 (s, 3H), 3.56 (t, J = 8 Hz, 4H), 2.58 (t, J = 8
Hz, 4H), 2.35 (s, 3H); 13C (100 MHz, CH3OD,  ) 158.8, 153.8, 138.4, 134.7, 129.2
(2C), 128.3 (2C), 127.1, 113.1, 63.2, 58.6, 57.3, 52.3 (2C), 47,7, 46.7 (2C), 46.3, 32.3
(2C), 27.7 (2C); 13C (100 MHz, CDCl3,  ) 158.9, 152.5, 152.2, 145.9, 144.4, 109.2,
105.6, 101.4, 88.1, 55.22, 54.7, 54.5 (2C), 45.4 (2C), 45.1; HRMS (ES) (m/z ) calcd.
for C16H23N4O2: 303.1821, found: 303.1828.
Compound 179d: 6,7-Dimethoxy-2-(4-methyl-1,4-diazepan-1-yl)quinolin-4-amine
[166]
A solution of 4,5-dimethoxy-2-(1-(4-methyl-1,4-diazepan-1-
yl)ethylideneamino)benzonitrile (179d, 1.4 g, 4.43 mmol) and
zinc chloride (3.61 g, 26.58 mmol) in dimethylacetamide (40 mL)
was heated at reflux for 36 hours. The reaction mixture was
cooled down to room temperature and diethyl ether (400 mL x
2) was added to the mixture and it was stirred for 10 min. The
supernatant was discarded each time. The tar residue was treated with 2 N sodium
hydroxide (200 mL) and the mixture was stirred at room temperature for 10 min. The
resulting suspension was extracted by dichloromethane (100 mL ⇥ 3). The combined
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organic layer was dried with magnesium sulphate and concentrated under reduce
pressure. The residue was purified by column chromatography (0–12% ammonia
methanol in dichloromethane) to a↵ord the title compound as a yellow crystalline
solid (456 mg, 33%). mp >180  C; 1H NMR (400 MHz, CDCl3,  ) 7.09 (br s, 1H),
6.85 (s, 1H), 5.99 (s, 1H), 4.33 (br s, 2H), 4.00 (s, 3H), 3.96 (s, 3H), 3.95–3.92 (m,
2H), 3.75 (t, J = 4 Hz, 2H), 2.74 (m, 2H), 2.62–2.58 (m, 2H), 2.40 (s, 3H), 2.17–2.13
(m, 2H); HRMS (ES) (m/z ) calcd. for C17H25N4O2: 317.1978, found: 317.1992.
Compound 180: N -(1-Benzylpiperidin-4-yl)-6,7-dimethoxy-2-(piperidin-1-yl)qui-
nolin-4-amine [166]
A mixture of 6,7-dimethoxy-2-(4-methylpiperazin-1-yl)quinolin-
4-amine (179a, 90 mg, 0.30 mmol), 1- benzyl-4-piperidone (55
µL, 0.30 mmol) and acetic acid (5 µL) in toluene (10 mL) was
refluxed using Dean-Stark apparatus for 4 days. The mixture
then was concentrated under reduced pressure and tetrahydro-
furan (10 mL) and sodium borohydride (67.6 mg, 1.8 mmol)
was added. The resultant reaction mixture was heated at reflux for 1 day. After
the reaction was allowed to cool to room temperature, it was concentrated under
reduced pressure. The residue was suspended in 2 N sodium hydroxide (25 mL) and
the aqueous layer was extracted with dichloromethane. The combined organic layer
was dried over magnesium sulphate and concentrated. The resulting residue was
repeatedly purified by silica column chromatography (0–3% 7 M ammonia methanol
in dichloromethane) to a↵ord the title product as a yellow solid (14 mg, 10%). mp
86–89  C; IR (cm 1) 3275, 2923, 2852, 1593, 1425; 1H NMR (400 MHz, CDCl3,  )
7.34–7.27 (m, 5H), 7.15 (br s, 1H), 6.75 (s, 1H), 5.89 (br s, 1H), 4.34 (br s, 1H), 3.97
(s, 3H), 3.95 (s, 3H), 3.65–3.64 (m, 4H), 3.57 (s, 2H), 3.53–3.49 (m, 1H), 2.90 (d, J
= 12.0 Hz, 2H), 2.56 (t, J = 4.8 Hz, 4H), 2.35 (s, 3H), 2.23 (dt, J = 11.6, 2.4 Hz,
2H), 2.14 (dd, J = 11.6, 4 Hz, 2H), 1.67–1.65 (m, 2H); HRMS (ES) (m/z ) calcd. for
C28H38N5O2: 476.3026, found: 476.3042.
Compound 183: N -(1-Benzylpiperidin-4-yl)-6,7-dimethoxy-2-(4-methyl-1,4-diaze-
pan-1-yl)quinolin-4-amine [166]
A mixture of 6,7-dimethoxy-2-(4-methyl-1,4-diazepan-1-
yl)quinolin-4-amine (183, 166 mg, 0.51 mmol), 1-benzyl-4-
piperidone (94 µL, 0.56 mmol) and acetic acid (15 µL) in
toluene (10 mL) was refluxed using Dean-Stark apparatus for
2 days. The mixture was then concentrated under reduced
pressure and tetrahydrofuran (10 mL) and sodium triacetoxy-
borohydride (215 mg, 1.02 mmol) was added. The reaction
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mixture was heated at reflux for 2 days. After the reaction was allowed to cool to
room temperature, it was concentrated under reduced pressure. The residue was
suspended in 2 N sodium hydroxide (25 mL) and the aqueous layer was extracted with
dichloromethane. The combined organic layer was dried with magnesium sulphate
and concentrated. The resulting residue was purified by silica column chromato-
graphy (0–4% 7 M ammonia methanol in dichloromethane) to give a mixture of
starting material and the title product hat was further purified by preparative TLC
(1% ammonia methanol in dichloromethane, repeated until Rf = 0.5) to a↵ord the
title compound as a white solid (52 mg, 13%). mp 78–81  C; IR (cm 1) 3402.51,
2936, 2800, 1596, 1427; 1H NMR (400 MHz, CDCl3,  ) 7.35–7.28 (m, 5H), 7.11 (br s,
1H), 6.76 (s, 1H), 5.77 (s, 1H), 4.36 (br s, 1H), 3.98 (s, 3H), 3.96 (s, 3H), 3.95–3.93
(m, 2H), 3.58 (t, J = 6 Hz, 2H), 3.58 (s, 2H), 3.52–3.51 (m, 1H), 2.91 (d, J = 12.0
Hz, 2H), 2.75 (t, J = 4.4 Hz, 2H), 2.60 (t, J = 5.2 Hz, 2H), 2.40 (s, 3H), 2.25 (t, J
=10.4 Hz, 2H), 2.16(d, J =12.0 Hz, 2H), 2.05 (m, 2H), 1.70–16.7 (m, 2H); HRMS
(ES) (m/z ) calcd. for C29H40N5O2: 409.32182, found: 490.3186.
4.2 Assay Protocols and Conditions
All biological assays were conducted by our collaborator, including SGC (enzymatic
assay) and Professor Brown’s Group (cell-based assays).
4.2.1 PRC2 Assay (preformed by SGC)
Following the protocol from [113], IC50 values were determined for the compounds in
triplicate at 0.2 µM of peptide H3 (21–44) and 1 µM of 3H-SAM using 20 nM of EZH2
complex (EZH2:EED:SUZ12) and incubating the reaction mixtures for 1hour at 23  C.
To stop the enzymatic reactions, 7.5 M Guanidine hydrochloride was added, followed
by 180 µl of bu↵er (20 mM Tris, pH 8.0), mixed and then transferred to a 96-well
FlashPlate (Cat.# SMP103; Perkin Elmer; www.perkinelmer.com). After mixing,
the reaction mixtures in Flash plate were incubated for 2 h and the CPM counts
were measured using Topcount plate reader ((Perkin Elmer, www.perkinelmer.com).
The CPM counts in the absence of compound for each dataset was defined as 100%
activity. In the absence of the enzyme, the CPM counts in each dataset was defined
as background (0%). The IC50 values were determined using SigmaPlot software and
fixing the top and bottom to 100 and 0 respectively.
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4.2.2 Mechanism of PRC2 Inhibition Assay (MOA) (performed by
SGC)
Following the protocol from [113], inhibition of PRC2 trimeric complex (EZH2 : EED
: SUZ12) by compound 3 (at 0, 50, 100 and 200 µM) at varying concentrations of
(A) SAM: S-adenosyl-L-methionine (from 0.625 to 10 µM) and (B) peptide substrate
(0.3 to 5 µM) were assessed by monitoring the incorporation of tritium-labeled
methyl group to peptide substrate using SAM2©Biotin Capture Membrane from
Promega. Lineweaver-Burk plots for kinetic analysis of the inhibition indicates that
compound 3 is a peptide competitive and SAM non-competitive PRC2 inhibitor.
Peptide concentrations for A and SAM concentration for B were 5 µM and 10 µM
respectively. Assays were performed in triplicate. Data were plotted using SigmaPlot,
Enzyme Kinetics Module).
4.2.3 Selectivity Assay (preformed by SGC)
Following the protocol from [166], e↵ects of our compounds on methyltransferase
activity of G9a, EHMT1, SUV39H2, SUV420H1, SUV420H2, SETD7, SETD8,
SETD2, MLL1 complex, EZH1 complex EZH2 complex, PRMT1, PRMT3, PRMT5-
MEP50 complex, PRMT6, PRMT7, PRMT8, SMYD2, DNMT1, PRDM9, was
assessed by monitoring the incorporation of tritium-labeled methyl group to lysine
or arginine residues of peptide substrates using Scintillation Proximity Assay (SPA)
(PMID: 25032507). Assays were performed in a 10 µl reaction mixture containing
3H-SAM (Cat.# NET155V250UC; Perkin Elmer; www.perkinelmer.com) at substrate
concentrations close to Km values for each enzyme. Three compound concentrations
(1, 10 and 50 µM) were used in all selectivity assays. To stop the enzymatic reactions,
10 µl of 7.5 M Guanidine hydrochloride was added, followed by 180 µl of bu↵er
(20 mM Tris, pH 8.0), mixed and then transferred to a 96-well FlashPlate (Cat.#
SMP103; Perkin Elmer; www.perkinelmer.com). After mixing, the reaction mixtures
in Flash plates were incubated for 1 hour and the CPM were measured using Topcount
plate reader (Perkin Elmer, www.perkinelmer.com). The CPM counts in the absence
of compound for each data set were defined as 100% activity. In the absence of the
enzyme, the CPM counts in each data set were defined as background (0%).
For DNMT1 the dsDNA substrate was prepared by annealing two complementary
strands (biotintlated forward strand: B-GAGCCCGTAAGCCCGTTCAGGTCG and
reverse strand: CGACCTGAACGGGCTTACGGGCTC), synthesized by Eurofins
MWG Operon.
For DOT1L, NSD1, NSD2, and NSD3 a filter-based assay was used. In this
assay, 10 µl of reaction mixtures were incubated at RT for 1 hour, 60 µl of 10% TCA
174
was added, mixed and transferred to filter-plates (Millipore; cat.# MSFBN6B10;
www.millipore.com). Plates were centrifuged at 2000 rpm (Allegra X-15R - Beckman
Coulter, Inc.) for 2 min followed by 2 additional 10% TCA wash and one ethanol
wash (180 µl) followed by centrifugation. Plates were dried and 20 µl MicroO
(MicroScint-O; Cat.# 6013611, Perkin Elmer; www.perkinelmer.com) was added to
each well, centrifuged and removed. 20 µl of MicroO was added again and CPM was
measured using Topcount plate reader.
4.2.4 qRT-PCRMeasurements for Cell-based Screening (preformed
by Professor Brown’s group)
Following the protocol [113], our compound treatment of MDA-MB-231 for 48
hours (in 6-well plates), media was removed and 1.5 ml of TRIzol (Invitrogen) was
added directly to lyse cells and RNA was isolated according to the manufacturers
instructions. Reverse transcription was done using the SuperScript III First-Strand
Synthesis System (Invitrogen) according to the manufacturers instructions. Each
measurement was done in triplicate, For normalisation, we have used GAPDH and
RNA pol II. Experiments were also done with the Fast Sybr Green Cell-to-CTTM-Kit
according to the manufacturers instructions (Applied Biosystem). Fifteen thousand
cells per 96 well were plated, and after 24 hours, treated with compounds at various
concentrations.
4.2.5 MTT Assay (preformed by Professor Brown’s group)
Following the protocol from [113], MTT assay for cell viability of MDA-MB-231
cells after treatment. MDA-MB-231 cells were seeded in 96 well plates. After 24
hours, increasing doses of inhibitors (1, 2.5, 5, 7.5, 10 and 15µM) were added to cells.
Control was media with 0.5% DMSO. Cell viability was measured by MTT assay
after 48 hours treatment and a 24 hr proliferation period.
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